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Chapter 1
Preface
World’s shortest story is a powerful one; ‘For sale: baby shoes, never worn.’ 
Unfortunately, a story that could be told too often in The Netherlands according to the first 
Europeristat reports of 2008 and 2013 1,2. These reports, comparing all European countries 
with data originating from 2004 and 2010 respectively, showed that the Dutch perinatal 
mortality rate was above average. A surprise, considering that the unique Dutch obstetric 
care model long served as an example of well-organized maternity care 3.
In response Europeristat’s reports, the Dutch Health ministry organized a steering committee 
that published recommendations to improve the obstetric healthcare system. These 
recommendations set a base for the Pregnancy and Childbirth research program organized 
by ZonMw, a Dutch governmental organization aimed at innovation and healthcare research 
4. Two of the main pillars of this program were improving the risk selection of pregnant
women and integrating obstetric care. This resulted into the start of two projects in Limburg:
1) Installation of the Limburg Obstetric Consortium (LOC), intended to jointly reorganize
obstetric healthcare in the region and establish an infrastructure for scientific research, and
2) The Expect Study, aimed at improving risk selection during early pregnancy.
Risk selection and prevention of adverse outcomes
In obstetric healthcare, risk selection is the process of quantifying and judging a woman’s 
risk of an adverse pregnancy outcome. The methods used to identify women at increased 
risk of adverse outcomes varies greatly among countries. In the Netherlands, autonomous 
midwives (primary care) or gynecologists (secondary care) monitor pregnant women 3. 
The obstetric indication list (Verloskundige IndicatieLijst, VIL) is used to check whether 
there is a predefined risk factor present (e.g. chronic hypertension, diabetes mellitus), or 
a complication arises (e.g. pregnancy induced hypertension, gestational diabetes mellitus) 
that warrants transfer from primary to secondary care 5. Although this list is a national 
guideline used to judge pregnant women’s risk, it is not an individual risk assessment tool, 
nor does it describe the contents of primary or secondary healthcare. 
The majority of perinatal deaths in the Netherlands are related to either asphyxia (Apgar 
score <7 after 5 minutes), preterm birth (PTB), small-for-gestational-age infancy (SGA), 
or congenital anomalies 6. Hypertensive disorders in pregnancy, such as pre-eclampsia 
(PE), are strongly associated with SGA and PTB 7. On the other hand, gestational diabetes 
mellitus (GDM) increases the risk of large-for-gestational-age infants (LGA) 8,  which in turn 
is associated with birth injuries and asphyxia 9. As a result, PE, GDM, PTB, SGA, and LGA 
are all related to perinatal mortality. Therefore, preventing these adverse outcomes would 
eventually lead to a reduction of perinatal mortality.
Identification of women at increased risk for these adverse events may improve outcomes 
due to increased awareness of both pregnant women as healthcare professionals regarding 
the occurrence of these events. However, risk selection is even more useful if appropriate 
and effective interventions exist. A number of interventions may prevent or reduce the 
risk of adverse pregnancy outcomes, some examples are: low-dose aspirin treatment in 
case of PE 10-12, adequate management of GDM 13,14, and progesterone administration in 
women at risk of spontaneous PTB 15. However, most of these interventions are not suitable 
for all pregnant women, due to either possible adverse effects, patient burden, or costs. 
Algorithms by which it would be possible to predict adverse outcomes such as PE accurately 
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during early pregnancy, would give healthcare professionals the opportunity to apply these 
preventive measures based on women’s individual risk profile.
Often, such algorithms, or prediction models, are logistic regression models. In case of 
prediction, the coefficients of the model parameters are used to estimate the absolute 
probability of a certain outcome instead of just describing the correlation between the 
parameters and the outcome 16. Consequently, such models take the weighted risk of 
multiple factors into account simultaneously and allow for a more fine-tuned estimation of 
the weight of multiple risk factors and possible inter-relations 17. Therefore, these models 
may me be more accurate in identifying women at increased risk then guidelines that 
recommend to merely check whether one of the listed risk factors is present in a woman 
(e.g. BMI >35, age >40, history of PE) 18. 
Development of prediction models for clinical practice
Scientific research aimed at the use of a prediction model in clinical practice can be divided 
in three to four categories 19,20. Each category resembles a crucial step in order to achieve the 
ultimate goal of widespread adoption of the prediction model in clinical practice. 
Model development is the first step. Preferably, candidate predictors are selected with the 
aid of existing literature and an expert opinion panel. Using an observational study design, 
ideally a prospective cohort, the initial model can be trained by using the selected candidate 
predictors to predict the outcome 21. During model development, several variables are 
eventually selected from the candidate predictors to create a final model 22. Predictor 
selection can be a difficult process, with several pitfalls that may affect the reliability of the 
final model. There are several methods to select the predictors, but there is no consensus 
yet regarding the best strategy to achieve a final model 16.
Often, results indicating the predictive performance of a model are overestimated when 
retrieved from the development dataset 20. For this reason, a prediction model always needs 
to be validated after development. During validation the model’s reliability is tested. There 
are roughly two kinds of validation: internal and external validation. Internal validation 
is the validation of the model within the observational study used to develop the model, 
procedures such as bootstrapping can be applied to correct the initial model with an 
shrinkage factor 20. 
For external validation, the model is applied to a new dataset that has not been used 
for its development. This dataset represents another cohort which differs in either time, 
geographical location, or the participants are selected differently 20. Since most models 
have a tendency to show too optimistic results even after the internal validation, external 
validation is strongly recommended before applying the model in clinical practice 23. If 
necessary, the results of the external validation process can be used to update the model to 
improve its accuracy 24.
When a prediction model successfully passes the external validation, the model accurately 
predicts the outcome in the external validation dataset, the next step is analyzing the 
potential impact of the model. In other words, the potential usefulness of adopting the 
model in clinical practice should be studied. Depending on the specific setting and goal of 
the model an impact analysis is performed with respect to clinical outcomes, healthcare 
costs, patient satisfaction, or allocations of healthcare resources 19. When these three phases 
are successfully completed and the prediction model appears to be clinically beneficial (the 
model has the potential to improve current clinical practice) the final step is widespread 
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implementation of the model. 
Impact analysis and implementation of the model are, however, not per se mutually 
exclusive processes. It may be impossible to address several aspects of the impact analysis 
without implementing the model at a certain level due to a lack of specific data, for example 
patient satisfaction related with the use of the model. 
Implementing a prediction model in clinical practice, thus changing the current clinical 
practice, can be a complex process. A multitude of barriers and incentives are often at play 
that may either hinder or facilitate the implementation process. Grol and Wensing describe 
a 10-step model to induce change of professional behavior 25. The evidence regarding the 
most effective  strategies to produce behavioral change, however, remains inconclusive and 
vary greatly depending on the setting and target groups 25. Still, the chance of successful 
implementation increases by using a tailored strategy that identifies and addresses potential 
barriers during the entire process 26,27. 
Impact and implementation studies are an essential step in translating predictive research 
to clinical practice. First, such studies may facilitate the implementation itself, by providing 
an easy accessible format of the prediction model. Second, they may improve our insight 
regarding the effects in daily practice. These effects may differ substantially from the results 
expected from study results, since usage of the prediction tool as well as adherence rates of 
both healthcare professionals as patients contribute to the observed effect in daily practice 
28. Impact and implementation studies will improve our understanding of how a prediction
model is used, whether recommendations correlated to the risks are applied, and whether
the effects suggested from earlier studies is achieved 29.
The Expect Study and the Limburg Obstetric Consortium
The Limburg Obstetric Consortium (LOC) consists of five regions representing the Southeastern 
part of the Netherlands. Every region consists of a hospital providing secondary obstetric care 
(gynecologists and clinical midwives) and a corresponding group of independent midwives 
providing primary obstetric care. The LOC committee consists of two to four representatives 
per region (midwives and gynecologists), representatives of maternity care, representatives 
of Maastricht University, and a manager. With the aid of numerous surveys consulting all 
obstetric healthcare professionals of Limburg they reorganized the obstetric healthcare of 
the province. The main goal was to achieve a uniform set of recommendations that form 
the base of risk-based care pathways. These care pathways would standardize the obstetric 
healthcare of the region and would enable a system of integrated client-centered care.  
Validation Study
The Expect Study was designed to improve risk selection during early pregnancy and to 
provide a starting point for personalized obstetric healthcare. Prediction models may be 
useful tools to achieve an individual assessment of important risks upon adverse pregnancy 
outcomes. Several models trying to predict the risks of PE, GDM, PTB, SGA, and LGA during 
early pregnancy have been published. Unfortunately, most models were not externally 
validated and consequently were not yet ready for usage in clinical practice 30.
The first part of the Expect Study, Expect Study I, aimed to evaluate the validity of published 
prediction models. The Expect Study specifically focused on models that are applicable 
during the first trimester and solely relied on non-invasive predictors: predictors that are 
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collected routinely in Dutch obstetric health care, or are easily to obtain in an outpatient 
midwifery setting. 
For the validation study, 2,614 women were enrolled in a multicenter prospective cohort 
study from 2013 to 2015 throughout Limburg 31. The results of Expect Study I indicated 
that implementing prediction models predicting PE, or GDM may be clinical beneficial and 
have the potential to improve obstetric care. The non-invasive models predicting fetal 
growth (SGA, and LGA) were unable to predict these outcomes accurately enough in order 
to improve current obstetric healthcare. Moreover, the definitions of LGA and SGA also 
include constitutionally larger or smaller infants. Clinical relevant fetal growth deviations, on 
the other hand, are often related to underlying disorders such as gestational diabetes and 
hypertensive disorders. Models predicting the underlying disorders may therefore be more 
specific 8. The results regarding the external validation of models predicting spontaneous 
preterm birth are covered in chapter two of this thesis.
Risk-based care pathways
During the recruitment period of Expect Study I, the LOC developed healthcare pathways 
that are tailored to women’s individual risk profiles. This resulted in pathways consisting 
of basic antenatal care for all women and additional recommendations for women at risk 
for pregnancy related complications. For example, women with an increased PE-risk or 
GDM-risk are recommended to consider a low-dose aspirin prophylaxis or an oral glucose 
tolerance test, respectively. A detailed description of the specific content of the healthcare 
pathways is provided in chapter 4 of this thesis.
Members of the LOC agreed to use the best performing prediction models externally 
validated in Expect Study I to assess women’s risk of PE and GDM. Furthermore, consensus 
was reached regarding suitable cut-off values as risk-threshold. In case women’s risk exceeds 
the selected threshold, it is advised to discuss additional recommendations using a shared 
decisional approach. 
Implementation and impact study
Despite the increasing amount of published prediction models and external validation 
studies, outside the realm of research, such models have rarely been implemented in daily 
obstetric practice 32. The second part of the Expect Study, Expect Study II, was aimed at 
analyzing the impact of the risk-based care paths assigned to women by the aid of the 
validated prediction models. To be able to perform an impact analysis and evaluate the 
effect of risk-based care, Expect Study II also played an important role in facilitating the 
implementation of the prediction models. 
An online prediction tool, the Expect Calculator, embedding externally validated prediction 
models and LOC’s risk-based healthcare pathways, was developed and made available 
to all healthcare professionals of the region. To facilitate the shared decisional approach 
regarding the additional recommendations for women with an increased risk, the results 
of the risk assessment were visualized at a linear scale and provided with corresponding 
patient brochures. 
To evaluate the impact of the prediction tool we used a before-after study design. During 
Expect Study II, a second prospective multicenter cohort was recruited. Besides a smaller 
population size and recruitment being facilitated by the prediction tool, Expect cohort I and 
12   
Chapter 1
II share the same recruitment regimen. Consequently, Expect cohort I represents the former 
care-as-usual approach and Expect cohort II represents the risk-based care approach in this 
before-after analysis.
Aims and outline of this thesis
This thesis consists of two parts: the first part describes the preparations that have been 
performed to facilitate the impact study and its impact analysis, the second part describes 
the results of the implementation and impact study. The main purposes of the studies in the 
first part were to analyze the previous care-as-usual approach. 
The second part of the thesis addresses several aspects of the implementation process 
and focusses on the impact of risk-based care. These studies provide insight to what extent 
the risk-based care approach was implemented and whether discussed interventions were 
applied in case of an increased risk. Moreover, the impact of risk-based care upon perinatal 
health is analyzed and a cost-benefit analysis is performed to evaluate the economic impact 
of risk-based care compared to former care-as-usual.
Part I – Framework of conditions for implementing personalized obstetric care
Chapter two describes the external validation of published models predicting spontaneous 
preterm birth. It evaluates the clinical potential of these models and whether implementation 
of these models may be clinical beneficial. Furthermore, strategies and methods that may 
improve these models are suggested for future research. 
Chapter three analyzes women´s appreciation of the obstetric healthcare services during 
the care-as-usual period (Expect Study I). This chapter specifically focusses on determinants 
that may cause women to be less satisfied regarding the obstetric healthcare system, in 
order to increase our understanding how obstetric healthcare could be improved from a 
client’s perspective. 
Chapter four describes the protocol of the impact study and how the impact analysis will be 
performed. Additionally, the specific content of risk-based care is discussed.
Part II – Implementation and impact of personalized obstetric care
The process of selecting cut-of values that indicate which women have an increased risk of 
PE, is described in chapter five. Furthermore, healthcare professional’s adherence to the 
recommendation to discuss low-dose-aspirin usage with women with an increased PE-risk 
is analyzed as well in this chapter.
The usage of low-dose-aspirin by pregnant women with an increased PE-risk is analyzed in 
chapter six, along with potential reasons for non-use. 
Chapter seven focusses at the recommendation of an oral glucose tolerance test (OGTT), 
indicated for women with an increased GDM-risk. Furthermore, this chapter gives insight 
regarding the burden of the OGTT as experienced by women and we discuss the pro- and 
cons of universal versus selective GDM screening
The economic impact of risk-based care is discussed in chapter eight. The cost-effectiveness 
of risk-based care compared to former obstetric care-as-usual is analyzed as well as its 
impact on perinatal health. 
The final chapter, chapter nine, provides a general discussion of the main findings in this 
dissertation. Along with the results, limitations as well as implications and recommendations 
for future research and clinical practice will be discussed.
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Abstract
Introduction
Prediction models may contribute to personalized risk-based management of women at high 
risk of spontaneous preterm delivery. Although prediction models are published frequently, 
often with promising results, external validation generally is lacking. We performed a 
systematic review of prediction models for the risk of spontaneous preterm birth based on 
routine clinical parameters. Additionally, we externally validated and evaluated the clinical 
potential of the models. 
Methods 
Prediction models based on routinely collected maternal parameters obtainable during first 
16 weeks of gestation were eligible for selection. Risk of bias was assessed according to the 
CHARMS guideline. We validated the selected models in a Dutch multicentre prospective 
cohort study comprising 2,614 unselected pregnant women. Information on predictors 
was obtained by a web-based questionnaire. Predictive performance of the models was 
quantified by the area under the receiver operating characteristic curve and calibration 
plots for the outcomes spontaneous preterm birth <37 weeks and <34 weeks of gestation. 
Clinical value was evaluated by means of decision curve analysis and calculating classification 
accuracy for different risk thresholds.
Results
Four studies describing five prediction models fulfilled the eligibility criteria. Risk of bias 
assessment revealed a moderate to high risk of bias in three studies. The AUROC of the 
models ranged from 0.54 to 0.67 and 0.56 to 0.70 for the outcomes spontaneous preterm 
birth <37 weeks and <34 weeks of gestation, respectively. A subanalysis showed that the 
models discriminated poorly (AUROC 0.51 to 0.56) for nulliparous women. Although we 
recalibrated the models, two models retained evidence of overfitting. The decision curve 
analysis showed low clinical benefit for the best performing models. 
Discussion 
This review revealed several reporting and methodological shortcomings of published 
prediction models for spontaneous preterm birth. Our external validation study indicated 
that none of the models had the ability to adequately predict spontaneous preterm birth in 
our population. Further improvement of prediction models, using recent knowledge about 
both model development and potential risk factors, is necessary in order to provide an 
added value in personalized risk assessment of spontaneous preterm birth.
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Introduction
Preterm birth (PTB), usually defined as birth before 37 weeks of gestation, occurs in 5-10% 
of singleton pregnancies in Europe 1. The majority of preterm deliveries, approximately 70%, 
start spontaneously (sPTB) 2. As both perinatal mortality and morbidity are inversely related 
to gestational age, health benefits may be achieved by increased monitoring and preventive 
interventions resulting in a prolongation of pregnancy 3,4. 
Progesterone treatment has been reported to reduce the risk of sPTB before 34 weeks of 
gestation in women at high risk 5,6. Cervical cerclage or application of a pessary may also 
protect against sPTB 7-9. Evidence whether which of the three interventions is most effective 
is limited 7-9. 
Women with a history of sPTB, cervical surgery or a mid-pregnancy short cervix are 
considered to be at high risk 10. Without routine cervical length screening, the majority 
of nulliparous women are regarded as low risk and thus do not receive any preventive 
treatment. However, universal cervical length screening in women without a history of sPTB 
results in relatively high numbers needed to screen (1147 in low-risk nulliparous women) 
11,12. Universal cervical length screening is not performed in Dutch obstetric care. Besides a 
history of sPTB, other risk factors have been associated with PTB, including socioeconomic 
status, psychological characteristics, family history, height, weight and smoking 13. Early risk 
assessment may be useful in order to identify women at risk who may benefit from effective 
follow-up management strategies. 
In the past, several risk assessment tools for sPTB based on a list of single risk factors 
were developed showing low accuracy rates 14. In the last decade, a number of promising 
prediction models based on multivariable regression analysis for the risk of sPTB have been 
published 15. Prediction models may be more accurate in identifying women at high risk as 
regression allows for a more fine-tuned estimation of the weight of multiple risk factors and 
possible inter-relations 16. A review of all existing models assessing their methodological 
quality is lacking. Moreover, most models have not been externally validated, an essential 
step before implementation in clinical practice 17. In this article, we performed a systematic 
review of all existing models predicting sPTB based on routine clinical parameters obtained 
in first 16 weeks of pregnancy. We externally validated and compared the selected models 
in a Dutch multicenter prospective cohort of pregnant women. 
Methods
Search strategy
This systematic review is reported in accordance with the recently published guidelines for 
systematic reviews and meta-analyses of prediction model performance 18. We systematically 
searched PubMed and EMBASE up to June 26, 2017. Keywords for prediction studies were 
combined with synonyms for the outcome sPTB appearing in the title, abstract, or MeSH 
terms. Reference lists of included studies and related articles (i.e. reviews) were manually 
checked to identify additional eligible articles. The detailed search strategy is provided in 
Supplementary File S2.1.
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Selection criteria
We aimed to identify all published prediction models for the risk of sPTB that are applicable 
in the first 16 weeks of pregnancy and are based on non-invasive predictors (Supplementary 
Table S2.1). Studies were eligible if they met the following criteria: (1) the article presented 
a newly developed prediction model, or a validation or update of a previously developed 
model in pregnant women, (2) the outcome of the model was the risk of sPTB, (3) the model 
contained more than one predictor, (4) predictors were available in Dutch obstetric practice 
(maternal characteristics, anthropometric measures, or blood pressure measurements), 5) 
predictor values were obtainable during first 16 weeks of pregnancy, and (6) these predictor 
values were based on regression coefficients. Authors of the original articles were contacted 
if the model algorithm or definitions of predictors were not available. Studies were excluded 
in a language other than English, German, French, or Dutch, or if it was a non-original 
study (for example review). Two researchers (LM, PvM) screened the retrieved titles and 
abstracts and assessed the eligibility of the full-text papers independently. Discrepancies 
were resolved by discussion. A third reviewer (LS) was available in case no consensus was 
reached. 
Data extraction and critical appraisal
The risk of bias of the included studies was assessed using the CHecklist for critical Appraisal 
and data extraction for systematic Reviews of prediction Modelling Studies (CHARMS) 19. 
The following data were extracted for each included study: source of data, participants, 
outcome(s) to be predicted, candidate predictors, sample size, handling of missing data, 
model development, model performance, model evaluation, model presentation, and 
model interpretation. The risk of bias was critically assessed for eight risk domains: source 
of data, participant selection, predictor assessment, outcome assessment, sample size, 
attrition, analysis, and presentation of the model. Risk of bias was rated as low if bias was 
unlikely, moderate if there were no fatal shortcomings and high if essential errors were 
made. Previously published risk of bias criteria were used and slightly adapted 20. Data 
extraction and critical appraisal was performed independently by two reviewers (LM, PvM). 
Discrepancies were resolved by discussion and a third reviewer (LS) was available in case of 
no consensus. 
Validation cohort
The included prediction models were externally validated in the Expect Study I 21. The 
main purpose of the Expect Study I was to validate published prediction models for several 
obstetric complications in an independent population. A multicentre prospective cohort 
study was performed in 36 midwifery practices (primary care) and six hospitals (secondary 
and tertiary care) in the south-eastern part of the Netherlands between July 1, 2013 and 
January 1, 2015. Follow-up took place until December 31, 2015. All pregnant women up to 
16 weeks of gestation and aged 18 years or older were eligible. Eligible pregnant women 
were asked to complete two web-based questionnaires (a paper version was available 
upon request), one before 16 weeks of gestation and one six weeks after the estimated 
due date. The online questionnaires were accessible via the study website using a unique 
login code provided with the study information. Automatic reminders were sent in case 
of incompleteness or nonresponse. Medical records and discharge letters were requested 
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from caregivers. Pregnancies ending in a miscarriage or termination before 24 weeks of 
gestation, and women lost-to-follow-up, were excluded. For this study, we also excluded 
multiple pregnancies and cases of iatrogenic preterm onset of parturition.
The Medical Ethical Committee of the Maastricht University Medical Centre evaluated the 
study protocol and declared that no ethical approval was necessary (MEC 13-4-053). All 
participating women gave informed consent through the Internet. The study was registered 
at The Netherlands Trial Registry on 21 August 2013 (NTR4143, www.trialregister.nl).
Predictor and outcome assessment
Predictors in the included prediction models were assessed by the pregnancy questionnaire 
completed before 16 weeks of gestation. We used the same definitions as defined in the 
original articles (Supplementary Table S2.2). 
The primary outcome sPTB was defined as a delivery before 37 weeks of gestation with 
spontaneous onset of parturition (primary contractions or preterm premature rupture of 
membranes). Secondly, we defined early sPTB as a spontaneously delivery before 34 weeks 
of gestation. The outcome was obtained from a combination of the medical record and 
postpartum questionnaire. Cause of labour onset (i.e. spontaneous or not) was available in 
both data sources. Duration of pregnancy was also available in both data sources and was 
moreover calculated based on estimated due date and date of birth. Discrepancies between 
the two variables and data sources were checked. In the absence of the postpartum 
questionnaire (n=421 sPTB <37 weeks and n=424 sPTB <34 weeks), the medical record was 
used as reference standard and vice versa (n=16 for both sPTB <37 weeks and sPTB <34 
weeks).
Data analysis
A sample size of 2500 women was expected to provide a minimum of 100 cases and 100 
non-cases, assuming a 4.5% incidence rate of spontaneous preterm birth <37 weeks of 
gestation 22.
We imputed missing data for predictors using stochastic regression imputation with 
predictive mean matching as the imputation model 23. Characteristics of the validation 
cohort were described as an absolute value with percentage for categorical variables and 
as mean ± standard deviation (SD) for continuous variables. We evaluated the relatedness 
of development samples and validation cohort by comparing the distribution of population 
characteristics. 
The original formulas were used to calculate individual predicted probabilities for each 
model (Supplementary Table S2.3). We assessed the predictive performance of each model 
by means of discrimination and calibration for the outcomes sPTB <37 and <34 weeks of 
gestation, as described in the framework reported by Steyerberg et al. 16. Discrimination 
indicates the ability of the model to distinguish between women who will have a sPTB and 
those who will not. For each model, we computed the area under the receiver operating 
characteristic curve (AUROC) with 95%-confidence interval (CI). A subgroup analysis 
was performed among nulliparous women as a history of sPTB is a strong risk factor for 
recurrent sPTB. Calibration refers to the agreement between the actual outcome and 
predicted probabilities by the model. We constructed calibration plots in which women 
were divided into 10 groups with similar predicted risks, and calculated calibration-in-
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the-large and the slope. Calibration-in-the-large (intercept), which compares the mean 
predicted probabilities with mean observed risk, indicates the extent to which predictions 
are systematically too low or too high. The slope refers to the average strength of predictor 
effects. Perfect predictions have an intercept of zero and a slope of one 17. The prediction 
models were recalibrated by adjusting the intercept and slope using the linear predictor as 
the only covariate. Discriminative performance (AUROC) of the models is not affected as 
this recalibration method does not change the ranking of the predicted probabilities 24. A 
discriminative performance below 0.70 is generally considered moderate 16.
Lastly, we performed decision curve analysis to evaluate the potential clinical utility of the 
models. Decision curve analysis assesses the net benefit (proportion of true positives and 
false positives) of the prediction models over a range of risk thresholds compared with 
considering all and no women to be at high risk for sPTB 25. Sensitivity, specificity, and 
positive and negative predictive values at certain risk thresholds were calculated for the 
model with the highest overall net benefit.
Statistical analyses were performed with R version 3.4.1, packages rms, pROC, and 
DecisionCurve.
 
Results
General characteristics of the studies
The search identified 2018 unique articles. After title and abstract screening, full t ext 
assessment was performed for 47 articles. Four articles fulfilled the eligibility criteria26-29. 
Reference cross-checking provided no additional articles. An overview of the systematic 
study selection is shown in Supplementary Figure S2.1.
The four included studies were all development studies describing five models predicting 
the risk for sPTB based on maternal characteristics. The studies were conducted in four 
different countries and published between 2011 and 2014. Two studies used a prospective 
cohort design and the other two were based on registry data. The number of predictors in 
the published prediction models varied between 2 and 16. Common predictors were body 
mass index (BMI), smoking, and previous preterm delivery. The prevalence of sPTB, defined 
as sPTB <34 weeks of gestation by two studies and <37 weeks of gestation by the other 
two studies, ranged from 0.9% to 1.1% for sPTB <34 weeks of gestation and from 3.7% to 
5.7% for sPTB <37 weeks of gestation. Discriminative performance (AUROC) varied from 
0.62 to 0.70. Only one study performed internal validation by bootstrapping and the study 
of Sananes et al. performed an external validation of which the results were not reported. 
The key characteristics of the included studies are shown in Table 2.1. 
Risk of bias
A summary of potential bias per domain is shown in Figure 2.1. Two studies used registry 
data for model development, which may be less effective for research purposes due to the 
likelihood of missing data on promising predictors. Moreover, the outcome was extracted at 
the same time as the predictors which may lead to bias. Nevertheless, sPTB is an objective 
outcome so assessment may be less biased. The domain participants was rated as liable to 
a moderate to high risk of bias due to selective reporting of patient characteristics. Para-
Cordero et al. used criteria which are not available at the intended moment of prediction. 
Besides, women may be treated for spontaneous onset of PTB. Only Alleman et al. explicitly 
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reports exclusion of women undergoing cerclage or tocolysis from their study population. 
Parra-Cordero et al. merely excluded women with a history of cerclage. Sample size was 
scored at moderate risk for the model of Parra-Cordero et al. because the overall number of 
cases was low (n=31) which probably led to the inclusion of only two predictors. The domains 
attrition and analysis had the highest risk of bias for all included models. All studies either 
had incomplete data (loss-to-follow-up or missing predictor values), or did not report any 
information about missing data (Parra-Cordero et al.). The other three studies were scored 
as moderate risk because they had a substantial amount of missing data and performed a 
complete case analysis. Methods of analysis were not reported in enough detail by Parra-
Cordero et al.. All studies selected predictors based on statistical significance and only one 
study performed shrinkage of the regression coefficients. For the models of two studies, only 
odds ratios were available. As the intercept was unavailable, no initial calibration plots could 
be drawn. Alleman et al. reported their final model including serum markers. The algorithm 
consisting only maternal characteristics was provided after contacting the authors. Overall, 
the study of Beta et al. showed the lowest risk of bias. A detailed description of the data 
extraction and risk of bias assessment according to the CHARMS checklist is provided in 
Supplementary Table S2.4 and S2.5. 
Figure 2.1 Risk of bias assessment of the four included studies according to CHARMS checklist 19
Validation cohort
The validation cohort consisted of 2,540 women of which 118 (4.6%) had a sPTB <37 weeks 
of gestation (Figure 2.2). Patient characteristics are shown in Table 2.2. There were ≤1.2% 
missing values per predictor and the cohort was generally similar after imputation of 
incomplete predictor variables. Supplementary Table S2.6 provides an overview of complete 
cases and the imputed validation cohort. The study population for the outcome sPTB <34 
weeks of gestation comprised 2,576 women, since fewer women were excluded because of 
an iatrogenic preterm onset of labour, of which 34 women (1.3%) delivered spontaneously 
before 34 weeks of gestation. 
The distribution of predictors and predictor effects in the original cohorts and our validation 
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cohort are available in Supplementary Table S2.7. In contrast to the original cohorts, 
women in our validation cohort were nearly all of Caucasian origin. Almost all population 
characteristics of Sananes et al. differed considerably compared with the validation cohort. 
Women in the cohort of Alleman et al. had a higher BMI and higher prevalence of pre-
existing diabetes mellitus. The populations of Parra-Cordero et al. and Beta et al. were 
more comparable, but Parra-Cordero et al. had a higher prevalence of smoking during 
pregnancy and women in the cohort of Beta et al. were shorter and had a higher prevalence 
of previous fetal loss. The prevalence of sPTB <37 weeks of gestation was higher in Alleman 
et al. (5.7%) and lower in the overall population of Sananes et al. (3.7%) compared with the 
validation cohort (4.6%). The outcome sPTB <34 weeks of gestation was comparable with 
our prevalence. 
Figure 2.2 Flowchart validation cohort spontaneous preterm birth (sPTB)
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Table 2.2 Baseline characteristics of the validation cohort (Expect Study I)
Characteristics Missing 
values,
n (%)
Observed validation cohort (Expect Study I)a
Overall
(n=2540)
sPTB <37 weeks
(n=118)
No sPTB ≥37 weeks
(n=2422)
Age, years 0 (0.0) 30.2 (3.9) 30.1 (3.8) 30.2 (3.9)
Ethnicity
  Caucasian
  Afro-Caribbean
  South Asian
  East Asian
  Other Asian
  Hispanic
  Mixed
0 (0.0)
2462 (96.9)
3 (0.1)
4 (0.2)
4 (0.2)
11 (0.4)
11 (0.4)
45 (1.8)
115 (97.5)
1 (0.8)
0 (0.0)
1 (0.8)
1 (0.8)
0 (0.0)
0 (0.0)
2347 (96.9)
2 (0.1)
4 (0.2)
3 (0.1)
10 (0.4)
11 (0.5)
45 (1.9)
Tertiary level of education 3 (0.1) 1380 (54.3) 69 (58.5) 1311 (54.1)
Height, cm 3 (0.1) 168.8 (6.4) 167.3 (6.6) 168.9 (6.4)
Weight, kg 5 (0.2) 68.9 (13.0) 65.6 (11.5) 69.0 (13.0)
Body mass index, kg/m2 5 (0.2) 24.1 (4.3) 23.4 (3.8) 24.2 (4.3)
Smoking during pregnancy 1 (0.0) 149 (5.9) 8 (6.8) 141 (5.8)
Diabetes mellitus
  Type 1
  Type 2
  Other
0 (0.0) 10 (0.4)
8 (0.3)
1 (0.0)
1 (0.0)
1 (0.8)
1 (0.8)
0 (0.0)
0 (0.0)
9 (0.4)
7 (0.3)
1 (0.0)
1 (0.0)
History of chronic hypertension 0 (0.0) 24 (0.9) 0 (0.0) 24 (1.0)
Parity
  Nulliparous
  Primiparous
  Multiparous
0 (0.0)
1284 (50.6)
1003 (39.5)
253 (9.9)
77 (65.3)
35 (29.7)
6 (5.0)
1207 (49.8)
968 (40.0)
247 (10.2)
Conception
  Spontaneous
  Ovulation induction
  IVF/ICSI
0 (0.0)
2375 (93.5)
88 (3.5)
77 (3.0)
114 (96.6)
3 (2.5)
1 (0.8)
2261 (93.4)
85 (3.5)
76 (3.1)
History of fetal loss <16 weeks of 
gestation
0 (0.0) 702 (27.6) 24 (20.3) 678 (28.0)
History of recurrent miscarriages 
(≥3)
0 (0.0) 49 (1.9) 1 (0.8) 48 (2.0)
Vaginal bleeding (≥2 days) 0 (0.0) 277 (10.9) 27 (20.3) 250 (10.3)
History of sPTB 
  16-23 weeks of gestation
  24-27 weeks of gestation
  28-30 weeks of gestation
  31-33 weeks of gestation
  34-36 weeks of gestation
30 (1.2) 76 (3.0)
4 (0.2)
7 (0.3)
2 (0.1)
13 (0.5)
52 (2.0)
16 (13.6)
1 (0.8)
1 (0.8)
2 (1.7)
3 (2.5)
9 (7.6)
60 (2.5)
3 (0.1)
6 (0.2)
0 (0.0)
10 (0.4)
43 (1.8)
History of iatrogenic preterm      de-
livery ≥24 weeks of gestation
29 (1.1) 44 (1.7) 0 (0.0) 44 (1.8)
History of term delivery 29 (1.1) 1130 (44.5) 29 (24.6) 1101 (45.5)
History of live birth 18 (0.7) 1221 (48.1) 40 (33.9) 1181 (48.8)
aOriginal data (not imputed) presented as mean (SD) or absolute number (%) ICSI, intracytoplasmic sperm injec-
tion; IVF, in vitro fertilisation; sPTB, spontaneous preterm birth
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Performance of the models
The discriminative performance of the included models is shown in Table 2.3. For the primary 
outcome sPTB <37 weeks of gestation, the AUROC ranged from 0.54 to 0.67. The AUROC of 
the model of Alleman et al. decreased considerably from 0.70 to 0.57 (95% CI 0.52-0.62). 
The model of Sananes et al. had a slightly higher discrimination compared with the original 
cohort. All models performed better for the outcome sPTB <34 weeks of gestation. Model 
2 of Beta et al. yielded the highest discriminative performance (AUROC 0.70, 95% CI 0.61-
0.78). Wide confidence intervals were observed due to the low number of cases for sPTB 
<34 weeks of gestation. The subgroup analysis among nulliparous women showed a drastic 
decrease towards almost no discriminative performance for all models. The ROCs in the 
overall cohort are presented in Supplementary Figure S2.2. 
Calibration plots of the two models that provided a complete algorithm are provided in Figure 
2.3. The model of Alleman et al. underestimated the risk of sPTB and was overfitted (slope 
<1). Besides the difference in baseline risk, Sananes et al. was fitted well to our population 
(slope = 1). Recalibration showed closer fitting to the ideal calibration line (Supplementary 
Figure S2.3). The models of Alleman et al. and Beta et al. retained some overfitting. 
The decision curve analysis of the two best performing models is presented in Figure 2.4. 
The models had a positive net benefit compared with classifying all or no women as high-
risk over a small range of probability thresholds (2.5-10%). However, net benefit remained 
low throughout this range. This low clinical usefulness is also shown in Table 2.4. Choosing 
a high sensitivity leads to a large proportion of women that will be indicated unnecessarily 
as having a high risk of sPTB <37 weeks of gestation. Conversely, a higher specificity leads 
to a minimal amount of true positives. The model performed especially insufficient among 
nulliparous women. The moderate performance is predominantly determined by a history 
of sPTB or term delivery.
Table 2.3 Discrimination of selected prediction models for spontaneous preterm birth
Study, first 
author (year)
AUROC (95% CI)
Original 
publication
AUROC (95% CI)
Validation cohort
sPTB <37 weeks 
(n=2540)
AUROC (95% CI)
Validation cohort
sPTB <34 weeks 
(n=2576)
AUROC (95% CI)
Validation 
cohort, 
nulliparous
sPTB <37 weeks 
(n=1284)
AUROC (95% CI)
Validation cohort, 
nulliparous
sPTB <34 weeks 
(n=1305)
Parra-Cordero 
et al. (2014)
NR 0.54 (0.50,0.57) 0.56 (0.49,0.63) 0.52 (0.50,0.54) 0.51 (0.46,0.55)
Sananes et al. 
(2013)
0.618 
(0.595,0.641)
0.64 (0.60,0.68) 0.68 (0.59,0.76) 0.53 (0.48,0.57) 0.53 (0.43,0.63)
Alleman et al. 
(2013)
0.703 (NR) 0.57 (0.52,0.62) 0.61 (0.51,0.71) 0.55 (0.49,0.60) 0.51 (0.39,0.63)
Beta et al. 
(2011)
Model 1: 0.668 
(0.639,0.698)
Model 2: NR
0.65 (0.60,0.70)
0.67 (0.62,0.72)
0.68 (0.59,0.77)
0.70 (0.61,0.78)
0.51 (0.45,0.57)
0.54 (0.48,0.60)
0.52 (0.39,0.65)
0.56 (0.44,0.68)
AUROC, area under the receiver operating characteristic curve; CI, confidence interval; NR, not reported; sPTB, 
spontaneous preterm birth
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Figure 2.3 ROC curves of externally validated first trimester prediction models for spontaneous preterm birth 
(sPTB) <37 weeks and <34 weeks of gestation
Figure 2.4 Calibration plots of externally validated first trimester prediction models for spontaneous preterm birth 
(sPTB) <37 weeks and <34 weeks of gestation. The grey line is the reference line with intercept = 0 and slope = 1 
(perfect calibration). Triangles correspond to grouped predicted risks with 95% confidence intervals (vertical lines)
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Figure 2.5 Decision curve analysis of three best performing models for the risk of spontaneous preterm birth <37 
weeks of gestation. Decision curve analysis assesses the net benefit (vertical axis; proportion of true positives and 
false positives) of the prediction models over a range of risk thresholds compared to considering all (solid grey line) 
and no women (horizontal solid black line) to be at high risk for sPTB
Discussion
Main findings
In this systematic review we provided an overview of the currently available prediction 
models of sPTB based on routine clinical parameters. We identified four articles describing 
five models fulfilling the eligibility criteria. Assessment of methodological quality revealed 
several shortcomings in reporting of models. Furthermore, there is a moderate to high 
risk of bias in the development of the models according to the CHARMS criteria. External 
validation resulted in a decreased discriminative ability for all models. Model 2 of Beta et al. 
had the highest AUROC (sPTB <37 weeks: 0.67, and sPTB <34 weeks: 0.70) after validation. 
This model was based on age, ethnicity, height, method of conception, nulliparous fetal 
loss, nulliparous late miscarriage, prior PTB (subcategories), prior iatrogenic PTB, prior term 
delivery, and smoking. The model of Sananes et al. showed the best calibration (slope of 
one) for sPTB <37 weeks of gestation.
Interpretation
Our systematic review identified a moderate reporting quality of most studies according 
to the CHARMS criteria. Reporting shortcomings were also noted in a general systematic 
review about obstetric prediction models 15. The recently published transparent reporting of 
a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) statement, 
may lead to improvements in the reporting quality of future studies 30. Risk of bias assessment 
revealed a moderate to high risk of bias in three out of four studies. The main sources of 
bias were in the domains of analysis, attrition and modeling. All studies selected predictors 
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on the basis of statistical significance, which leads to a model that fits the data too closely 
24,31. Next, continuous variables were often dichotomized, in example age and BMI in two of 
our selected models, leading to loss of information 32. Moreover, only one study, Beta et al., 
applied the regression shrinkage technique and only Alleman et al. performed an internal 
validation by bootstrapping. The methodological limitations mentioned could have been 
one of the reasons why the reported model performance was not achieved in our validation 
cohort. 
Only Sananes et al. mentioned that they validated their model in another population, but 
the results were not reported. To our knowledge, no other independent external validation 
study of prediction models for sPTB exists. External validation is recommended to assess the 
generalizability to other ‘related’ populations 24. Our comprehensive independent validation 
study indicated that all models overestimated performance measures. This illustrates the 
need for external validation of models before clinical implementation. 
Nevertheless, performance measures do not indicate whether a model is clinically useful. 
Assessment of the clinical utility of the best discriminating model showed a very high false 
positive rate at acceptable sensitivity rates. These cut-off points result in a major proportion 
of nulliparous women being unnecessarily considered to be at high risk. Furthermore, for 
multiparous women the most important predictors are derived from a previous sPTB. In 
summary, we think that the clinical utility of currently available models is low.
Implications
This systematic review demonstrates shortcomings in the quality and performance of existing 
non-invasive prediction models for sPTB. Improvement of non-invasive models is necessary. 
The currently available prediction models mainly rely on previous PTB as predicting variable. 
However, models mainly relying upon a prior event as the discriminative factor do not add 
much clinical value since caregivers are already aware that these women are at high risk. 
Obstetric care would benefit from valid prediction of sPTB in nulliparous women 11. 
Future research should focus on the variety of published association studies when selecting 
candidate predictors. Another important well-known risk factor is cervical surgery 10,33. 
However, only a minority of women will be identified as high risk by adding this predictor 
11. Other routine clinical parameters that may also contribute to the prediction of sPTB 
in nulliparous women are: socio-economic status, psychological characteristics, family 
history, medical history, and smoking status 10. Predictive performance of a model might 
improve by taking into account biomarkers or ultrasound imaging (i.e. cervical length). A 
few models based on cervical length measurements and biomarkers such as pregnancy-
associated plasma protein A (PAPP-A) or alpha-fetoprotein (AFP) have been published 29,34,35. 
The reported discriminative performance of these models was only slightly better than the 
performance of models using maternal characteristics alone. We focused in this review on 
routine clinical parameters, as these ‘specialized’ tests are not always routinely performed 
or readily available in general care, and may generate substantial additional costs 36. Lastly, 
different modeling methods can be employed as well. In this review, all selected studies 
used a multiple logistic regression model. Other methods that can be used are machine 
learning methods using health records, such as tree-based algorithms or neural networks 
37,38. However, despite all efforts, sPTB may remain a tough outcome to predict due to its 
heterogeneous and often unknown causes 2. 
Nevertheless, a future model with a moderate performance may still be useful. The tradeoff 
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between the benefit of identifying women at high risk and the false positive rate is important. 
Using cervical length screening in all women results in the need to screen relatively high 
numbers of women 11. A non-invasive model combined with a high sensitivity cut-off point 
will be able to identify women at very low risk of sPTB who could be excluded from cervical 
length screening, resulting in the need to screen a smaller number of women. Furthermore, 
such an approach creates the opportunity to identify women at high risk whom may benefit 
from preventive interventions such as progesterone treatment 3-5. 
Strengths and limitations
To our knowledge, this is the first systematic review of studies reporting non-invasive 
prediction models for the risk of sPTB. We had to exclude several published models as three 
models contained predictors which are not available in the first 16 weeks of pregnancy, 
in example fetal gender, since this is crucial for early prediction of sPTB. Moreover, three 
other models did not provide the algorithm, which is essential for independent external 
validation. 
A strength of our study is that we validated all included prediction models in a large 
independent multicentre prospective cohort of unselected pregnant women. The data 
were very complete with a maximum of only 1.2% of missing values. However, although 
our cohort contained a sufficient number of cases for sPTB <37 weeks of gestation, there 
were only 34 cases for the secondary outcome sPTB <34 weeks of gestation. An inadequate 
sample size decreases the precision of external validation measures 22,39.
Our cohort might suffer from treatment bias to a small extent since we did not exclude 
women who had received treatment such as a cerclage or tocolysis. This may have resulted 
into the prevention of sPTB and thus an underestimation of model discrimination and 
calibration 40. One of the selected studies, Alleman et al., explicitly reported exclusion of 
women undergoing cerclage or tocolysis from their study population 27. Parra-Cordero et al. 
only excluded women with a history of cerclage 28.
Conclusion
This review revealed several reporting and methodological shortcomings of published 
prediction models for sPTB. Our external validation indicated that none of the models had 
the ability to adequately predict sPTB in our population. Obstetric care would benefit most 
from models predicting sPTB accurately among nulliparous women since most of these 
women are indicated as low risk in current practice.
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Supplementary File 2.1. Search strategy
PubMed
(“predictive model”[tiab] OR “predictive models”[tiab] OR prediction[tiab] OR “risk 
calculator”[tiab] OR “risk calculators”[tiab] OR “risk model”[tiab] OR “risk models”[tiab] 
OR “risk score”[tiab] OR algorithm*[tiab] OR “risk assessment”[tiab] OR nomogram[tiab] 
OR “prognostic model”[tiab] OR “prognostic models”[tiab] OR “scoring system”[tiab] 
OR “scoring systems”[tiab] OR “screening model”[tiab] OR “screening models”[tiab] OR 
“decision rule”[tiab] OR “decision rules”[tiab]) AND (“preterm labour”[tiab] OR “premature 
labour”[tiab] OR “premature labor”[tiab] OR “premature delivery”[tiab] OR “premature 
deliveries”[tiab] OR “premature parturition”[tiab] OR “premature birth”[tiab] OR 
“preterm labor”[tiab] OR “preterm birth”[tiab] OR “preterm delivery”[tiab] OR “preterm 
deliveries”[tiab] OR “preterm parturition”[tiab] OR “Premature Birth”[Mesh])
Embase
1. predictive model.ab,ti. 19. decision rules.ab,ti.
2. predictive models.ab,ti. 20. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or
       12 or 13 or 14 or 15 or 16 or 17 or 18 or 19
3. prediction.ab,ti. 21. preterm labour.ab,ti.
4. risk calculator.ab,ti. 22. preterm labor.ab,ti.
5. risk calculators.ab,ti. 23. premature labour.ab,ti.
6. risk model.ab,ti. 24. premature labor.ab,ti.
7. risk models.ab,ti. 25. premature delivery.ab,ti.
8. risk score.ab,ti. 26. premature deliveries.ab,ti.
9. algorithm.ab,ti. 27. premature parturition.ab,ti.
10. risk assessment.ab,ti. 28. premature birth.ab,ti.
11. nomogram.ab,ti. 29. preterm birth.ab,ti.
12. prognostic model.ab,ti. 30. preterm delivery.ab,ti.
13. prognostic models.ab,ti. 31. preterm deliveries.ab,ti.
14. scoring system.ab,ti. 32. preterm parturition.ab,ti.
15. scoring systems.ab,ti. 33. 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
or 31 or 32
16. screening model.ab,ti. 34. 20 and 33
17. screening models.ab,ti. 35. remove duplicates from 34
18.decision rule.ab,ti.
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Supplementary Table S2.1 Framework of systematic research aim according to the CHARMS checklist 19
Item Systematic review aim
Type of prediction model Prognostic prediction model
Intended scope of review Reviewing prediction models that may help identifying women who are at high 
risk for spontaneous preterm birth to aid decision-making regarding preventive 
interventions or closer monitoring
Type of prediction modelling 
studies
Model development studies and model validation studies
Target population Overall pregnant population
Outcome to be predicted Probability of spontaneous preterm birth
Time span of prediction First trimester prediction for probability of the outcome in current pregnancy
Intended moment of using the 
model
First trimester of pregnancy
Supplementary Figure S2.1 Flowchart study selection
38   
Chapter 2
Supplementary Table S2.2 (continued) Definition and assessment predictors included prediction models for 
spontaneous preterm birth
Predictor Definition (D)/measurement (M) 
original studies
Definition/measurement validation cohort 
(Expect Study I)
Ethnicity Beta 2011
D: Ethnic origin divided into 
Caucasian, Afro-Caribbean, Indian 
or Pakistani or Bangladeshi (South 
Asian), Chinese or Japanese (East 
Asian) and mixed.
M: Self-reported questionnaire 
11+0-13+6 weeks of gestation.
Self-reported pregnancy questionnaire 1, ethnici-
ty was divided into ten subgroups: Dutch, Turkish/
Kurdish, Moroccan (Moroccan, Algerian, North 
African), African (African, Surinamese/Antillean of 
Negroid origin), Hindustani (Hindustani, Pakistani, 
Indian, Surinamese / Antillean of Hindu origin), 
Middle East (Iran, Iraqi, Afghan), Asian (Chinese, 
Japanese, Indonesian, Albanian, Vietnamese), 
Other Western (European, North American, Aus-
tralian), Other Non-Western (South and Central 
American), and mixed.
Ethnicity was recoded to Caucasian, Asian, Af-
ro-Caribbean, Hispanic, and mixed (combination 
of other categories). Subdivision of Asian ethnicity 
was based on country of birth biological parents.
Beta 2011: we added women with an Asian 
ethnicity other than South Asian or East Asian to 
the category mixed. Hispanics were categorized as 
Caucasians.
Height, cm Beta 2011
D: Continuous in centimetres.
M: Height measured at routine 
assessment at 11+0-13+6 weeks of 
gestation.
Self-reported pregnancy questionnaire 1, height 
in centimetres.
History of fetal loss <16 
weeks of gestation
Beta 2011
D: Previous miscarriage or termina-
tion before 16 weeks.
M: Self-reported questionnaire 
11+0-13+6 weeks of gestation.
Self-reported pregnancy questionnaire 1, previous 
pregnancies (miscarriages and terminations 
<16 weeks of gestation). Obstetric records were 
checked for discrepancies.
History of iatrogenic 
preterm birth
Beta 2011
D: Parous iatrogenic preterm deliv-
ery before 37 weeks.
M: Self-reported questionnaire 
11+0-13+6 weeks of gestation.
Self-reported pregnancy questionnaire 1, previous 
pregnancies (gestational age at delivery and 
spontaneous onset labour). Obstetric records 
were checked for additional information about 
onset of labour.
We defined history of iatrogenic preterm delivery 
as a prior iatrogenic preterm birth ≥24 weeks of 
gestation.
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Supplementary Table S2.2 (continued) Definition and assessment predictors included prediction models for 
spontaneous preterm birth
Predictor Definition (D)/measurement (M) original 
studies
Definition/measurement validation cohort 
(Expect Study I)
History of live birth Alleman 2013
D: Previous live birth.
M: Neonatal birth certificates.
Self-reported pregnancy questionnaire 1, 
previous pregnancies (live birth).
History of preterm 
birth
Parra-Cordero 2014
D: Prior preterm delivery <37 weeks of 
gestation.
M: Interview before the ultrasound scan at 
11+0-13+6 weeks of gestation.
Sananes 2013
D: Previous preterm deliveries categorized 
as 24-27 weeks, 28-33 weeks, and 34-36 
weeks of gestation.
M: Electronic medical records.
Alleman 2013
D: Previous preterm birth.
M: Neonatal birth certificates.
Self-reported pregnancy questionnaire 1, 
previous pregnancies (gestational age at 
delivery) and checked for discrepancies 
by obstetric record. We defined preterm 
birth as a delivery <37 weeks of gestation. 
Categorical variables generated according to 
definition original prediction model.
History of spontaneous 
preterm birth
Sananes 2013
D: History of miscarriage between 16 and 
24 weeks of gestation.
M: Electronic medical records.
Beta 2011
D: Previous spontaneous deliveries ≥24 
weeks of gestation, subdivided into: 24-27+6 
weeks, 28-30+6 weeks, 31-33+6 weeks, and 
34-36+6 weeks of gestation. In a second 
model, the categories were subdivided ac-
cording to the number or previous preterm 
deliveries: one or at least two spontaneous 
deliveries between 16-30+6 weeks of gesta-
tion with and without additional deliveries 
between 31-36+6 weeks or ≥37 weeks of 
gestation, and spontaneous delivery be-
tween 31-36+6 weeks of gestation with and 
without additional deliveries ≥37 weeks of 
gestation.
M: Self-reported questionnaire 11+0-13+6 
weeks of gestation.
Self-reported pregnancy questionnaire 1, 
previous pregnancies (gestational age at 
delivery and spontaneous onset labour). 
Obstetric records were checked for addi-
tional information about onset of labour. 
Categorical variables generated according to 
definition original prediction model.
History of term delivery
Sananes 2013
D: Term delivery ≥37 weeks of gestation.
M: Electronic medical records.
Beta 2011
D: Deliveries at or after 37 weeks.
M: Self-reported questionnaire 11+0-13+6 
weeks of gestation.
Self-reported pregnancy questionnaire 1, 
previous pregnancies (gestational age at 
delivery). We defined term delivery as a 
delivery ≥37 weeks of gestation.
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Supplementary Table S2.2 (continued) Definition and assessment predictors included prediction models for 
spontaneous preterm birth
Predictor Definition (D)/measurement (M) 
original studies
Definition/measurement validation cohort 
(Expect Study I)
Smoking Parra-Cordero 2014
D: Smoking during pregnancy.
M: Interview before the ultra-
sound scan at 11+0-13+6 weeks of 
gestation.
Sananes 2013
D: Smoking status during preg-
nancy.
M: Electronic medical records.
Beta 2011
D: Cigarette smoker.
M: Self-reported questionnaire 
11+0-13+6 weeks of gestation.
Self-reported pregnancy questionnaire 1, cigarette 
smoking status (non-smoker, stopped during preg-
nancy, current smokers) and number of cigarettes 
a day.
Smoking status was recoded to definition original 
prediction model. We defined cigarette smok-
ing as current smoker at completion pregnancy 
questionnaire 1.
Supplementary Table S2.3 Model algorithms for prediction of spontaneous preterm birth
Original study The probability of spontaneous preterm birth was calculated as elp/(1+ elp), where:
Parra-Cordero 
2014
Lp = α + 1.163 (if nulliparous and smoking) + 1.526 (if parous with previous preterm delivery).
Sananes 2013 Lp = -3.3772 + 0,2490 (if age ≤22 or ≥35) + 0,3290 (if BMI ≤19 kg/m2) + 0,2880 (if smoking) + 
0,7722 (if prior late miscarriage 16-23 weeks of gestation) + 1,6249 (if prior preterm delivery 
24-27 weeks of gestation) + 0,6622 (if prior preterm delivery 28-33 weeks of gestation) + 
1,1326 (if prior preterm delivery 34-36 weeks of gestation) - 0,62 (if prior term delivery ≥37 
weeks of gestation). 
Alleman 2013 Lp = -2.6603 – 0.4949 (if maternal education postsecondary degree) + 1.0524 (if diabetes 
mellitus) + 1.5801 (if prior preterm delivery) – 0.3396 (if prior live birth) + 1.4385 (if BMI 
<18.5 kg/m2) + 0.7352 (if BMI >40 kg/m2). 
Beta 2011 Lp = α + 0.025 (age, years) – 0.019 (height, cm) + 0.589 (if Afro-Caribbean) + 0.554 (if South 
Asian) + 0.168 (if East Asian) – 0.4 (if Mixed) + 0.567 (if smoker) + 0.535 (if assisted con-
ception) + 0.239 (if nulliparous, fetal loss <16 weeks of gestation) + 1.976 (if nulliparous, 
miscarriage at 16-23 weeks of gestation) + 1.734 (if parous, preterm delivery 24-27 weeks of 
gestation) + 1.503 (if parous, preterm delivery 28-30 weeks of gestation) + 1.142 (if parous, 
preterm delivery 31-33 weeks of gestation) + 0.907 (if parous, preterm delivery 34-36 weeks 
of gestation) – 0.414 (if parous, term delivery >37 weeks of gestation) + 0.309 (if parous, 
iatrogenic preterm delivery). 
Lp = α + 0.027 (age, years) – 0.019 (height, cm) + 0.568 (if Afro-Caribbean) + 0.554 (if South 
Asian) + 0.149 (if East Asian) – 0.387 (if Mixed) + 0.595 (if smoker) + 0.538 (if assisted concep-
tion) + 1.766 (if delivery at 16-30 weeks of gestation, one event) + 2.93 (if delivery at 16-30 
weeks of gestation, two events) + 1.992 (if delivery at 16-30 weeks of gestation, one event 
plus 31-36 weeks of gestation) + 0.437 (if delivery at 16-30 weeks of gestation, one event plus 
≥37 weeks of gestation) + 2.277 (if delivery at 16-30 weeks of gestation, two events plus ≥37 
weeks of gestation) + 0.846 (if delivery 31-36 weeks of gestation) + 0.627 (if delivery 31-36 
weeks of gestation plus ≥37 weeks) – 0.54 (if delivery ≥37 weeks of gestation).
BMI, body mass index; Lp, linear predictor
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2
Supplementary Table S2.6 Characteristics of pregnancies in the observed and imputed validation cohort
Characteristics Missing 
values,
n (%)
Observed Validation 
cohort
Complete casesa 
(n=2502)
Observed
Validation cohort
Women with missing 
value(s)b (n=38)
Imputed Validation 
cohort
(n=2540)
Age, years 0 (0.0) 30.2 (3.9) 30.9 (4.0) 30.2 (3.9)
Ethnicity
  Caucasian
  Afro-Caribbean
  South Asian
  East Asian
  Other Asian
  Hispanic
  Mixed
0 (0.0)
2426 (97.0)
3 (0.1)
3 (0.1)
4 (0.2)
11 (0.4)
11 (0.4)
44 (1.8)
36 (94.7)
0 (0.0)
1 (2.6)
0 (0.0)
0 (0.0)
0 (0.0)
1 (2.6)
2462 (96.9)
3 (0.1)
4 (0.2)
4 (0.2)
11 (0.4)
11 (0.4)
45 (1.8)
Tertiary level of education 3 (0.1) 1367 (54.6) 13 (34.2) 1380 (54.3)
Height, cm 3 (0.1) 168.8 (6.4) 167.9 (6.7) 168.8 (6.4)
Weight, kg* 5 (0.2) 68.8 (13.0) 71.6 (12.9) 68.9 (13.0)
Body mass index#, kg/m2 5 (0.2) 24.1 (4.3) 25.3 (4.2) 24.1 (4.3)
Smoking during pregnancy 1 (0.0) 145 (5.8) 4 (10.5) 150 (5.9)
Diabetes mellitus
  Type 1
  Type 2
  Other
0 (0.0) 10 (0.4)
8 (0.3)
1 (0.0)
1 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
10 (0.4)
8 (0.3)
1 (0.0)
1 (0.0)
History of chronic hypertension* 0 (0.0) 23 (0.9) 1 (2.6) 24 (0.9)
Parity
  Nulliparous
  Primiparous
  Multiparous
0 (0.0)
1280 (51.2)
977 (39.0)
245 (9.8)
4 (10.5)
26 (68.4)
8 (21.1)
1284 (50.6)
1003 (39.5)
253 (9.9)
Conception
  Spontaneous
  Ovulation induction
  IVF/ICSI
0 (0.0)
2338 (93.4)
88 (3.5)
76 (3.0)
37 (97.4)
0 (0.0)
1 (2.6)
2375 (93.5)
88 (3.5)
77 (3.0)
History of fetal loss <16 weeks of 
gestation
0 (0.0) 686 (27.4) 16 (42.1) 702 (27.6)
History of recurrent miscarriages 
(≥3)*
0 (0.0) 46 (1.8) 3 (7.9) 49 (1.9)
Vaginal bleeding (≥2 days)* 0 (0.0) 275 (11.0) 2 (5.3) 277 (10.9)
History of spontaneous preterm 
delivery 
16-23 weeks of gestation
24-27 weeks of gestation
28-30 weeks of gestation
31-33 weeks of gestation
34-36 weeks of gestation
30 (1.2) 75 (3.0)
3 (0.1)
7 (0.3)
2 (0.1)
13 (0.5)
52 (2.1)
1 (2.6)
1 (2.6)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
77 (3.0)
4 (0.2)
7 (0.3)
2 (0.1)
13 (0.5)
53 (2.1)
History of iatrogenic preterm 
delivery ≥24 weeks of gestation
29 (1.1) 43 (1.7) 1 (2.6) 44 (1.7)
History of term delivery 29 (1.1) 1128 (45.1) 2 (5.3) 1159 (45.6)
History of live birth 18 (0.7) 1206 (48.2) 15 (39.5) 1239 (48.8)
aAll predictor values of the included models were complete; bAt least one missing value for a predictor of the in-
cluded models; *Not a predictor in the included models;  #Recoded/calculated on the basis of (imputed) original 
variables. ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilisation
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Supplementary Figure S2.2 Calibration plots of recalibrated first trimester prediction models for spontaneous 
preterm birth (sPTB) <37 weeks of gestation. The grey line is the reference line with intercept = 0 and slope = 1 
(perfect calibration). Triangles correspond to grouped predicted risks with 95% confidence intervals (vertical lines). 
CF, correction factor
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Supplementary Figure S2.3 Calibration plots of recalibrated first trimester prediction models for spontaneous 
preterm birth (sPTB) <34 weeks of gestation. The grey line is the reference line with intercept = 0 and slope = 1 
(perfect calibration). Triangles correspond to grouped predicted risks with 95% confidence intervals (vertical lines). 
CF, correction factor
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Abstract
Background
Satisfaction of pregnancy and childbirth is an important quality measure of maternity care. 
Satisfaction questionnaires generally result in high scores. However, it has been argued 
that dissatisfaction relies on a different construct. In response to a worldwide call for 
obstetric care that is more woman-centred, we identified and described the contributors to 
suboptimal satisfaction with pregnancy and childbirth.
Methods
A prospective sub cohort of 739 women from a larger cohort (Expect Study I, n= 2,614) 
received a pregnancy and childbirth satisfaction questionnaire. Scores were transformed 
to a binary outcome whereby a score <100 points corresponded with less satisfied women. 
We performed a multiple logistic regression analysis to define independent perinatal factors 
related to suboptimal satisfaction.
Results
Decreased perceived personal wellbeing, antenatal anxiety, and obstetrician-led care 
during labour were all independently associated with suboptimal pregnancy and childbirth 
satisfaction. No difference in satisfaction was found between antenatal care led by a 
midwife or an obstetrician, but midwife-led antenatal care reduced the odds of suboptimal 
satisfaction compared to women who were transferred to an obstetrician in the antenatal 
period. Antenatal anxiety was experienced by 25% of all women and is associated with 
decreased satisfaction scores. 
Discussion
Screening and treatment of women suffering from anxiety might improve pregnancy and 
childbirth satisfaction, but further research is necessary. Women’s birthing experience may 
improve by reducing unnecessary secondary obstetric care.
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Introduction
Satisfaction with care delivered during pregnancy and birth is a topic of increasing interest 
and is an essential component of quality of obstetric care 1. In the Netherlands, one in six 
women has a negative recall of their birth experience 2. The prevalence of posttraumatic 
stress disorders resulting from childbirth is estimated at 2.9% 3. Patient satisfaction and birth 
experience are important factors influencing short- and long-term outcomes of both mother 
and child (e.g. postpartum depression, the ability to breast-feed, and child abuse) 1.
Studies of satisfaction with childbirth care are beset by several problems. The role of the 
healthcare professional is an influential factor shaping a woman’s birthing experience 4. 
Findings regarding the contribution of several other factors to satisfaction with obstetric 
care, such as age and pain, are inconsistent 1,5. Satisfaction questionnaires administered 
shortly after birth generally result in high satisfaction scores. It has been argued that 
women may be unable to assess the perceived maternity care properly because they are 
unaware of other options 6. Additionally, satisfaction and dissatisfaction are considered to 
be different constructs rather than a continuum of each other 7. It may be better to focus on 
determinants associated with women who are not perfectly satisfied with the obstetric care 
services received during pregnancy and birth 8. Focussing on the less satisfied women may 
result into renewed insights that could improve obstetric care. At present, few studies have 
focused on determinants of suboptimal care as perceived as such by pregnant women 5.
Antenatal anxiety is related to several adverse pregnancy outcomes (e.g. spontaneous 
preterm birth, low birth weight 9) and is associated with a negative subsequent birthing 
experience 10. The negative influence of maternal anxiety upon satisfaction levels with 
received obstetric care services has been reported as well, but mostly for specific subgroups 
(i.e. women with fear of birth) 11,12.
Women’s satisfaction regarding pregnancy and labour is also associated with parity. In 
general, multiparous women report higher levels of satisfaction as compared to nulliparous 
women 13,14. Furthermore, it is likely that multiparous women’s expectations concerning 
their current pregnancy is influenced by their previous experiences with pregnancy, giving 
birth, and the obstetric care system 11. These expectations are likely to be more realistic than 
those of nulliparous women (e.g. prior birth mode is an important prognostic factor for the 
subsequent mode of birth 15,16) which expectedly contributes to better satisfaction levels 13.
In this study, we examined the Pregnancy and Childbirth Satisfaction (PCS) of women who 
recently gave birth in a prospective multicentre cohort. Our objective was to identify factors 
independently associated with suboptimal PCS and to evaluate the association of maternal 
anxiety with subsequent PCS in a general population.
Methods
We conducted a cross sectional analysis among a subgroup of a prospective multicentre 
cohort study, the Expect Study I. The recruitment of this cohort has been described in detail 
elsewhere 17. Briefly, women aged 18 years or older were recruited at their first prenatal 
visit (<16 weeks of pregnancy), in the south region of the Netherlands between 2013 and 
2015. Pregnancies ending in a miscarriage (<16 weeks of gestation) or termination before 
24 weeks of gestation and women lost-to-follow-up were excluded from the main cohort. 
Additionally, for this study, we excluded twin pregnancies.
Women were approached for participation in a sub cohort of the Expect Study I after 
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completion of the first survey (Figure 3.1). Participants in this sub cohort received additional 
surveys at 24 and 32 weeks of gestation. Moreover, the post-partum survey of the Expect 
Study, sent 6 weeks after the due date, was extended. The additional questions these 
women received addressed topics of patient satisfaction, anxiety state, and obstetric care 
services used. Women who reported preterm birth during the surveys at 24 or 32 weeks 
were automatically redirected to the post-partum survey. 
The medical ethics committee of Maastricht University Medical Centre (MUMC+) evaluated 
the study protocol and declared that no ethical approval was necessary for this study under 
Dutch law (METC-17-4-057). All participants gave informed consent.
Figure 3.1 Flowchart sub cohort Expect study I
Pregnancy and childbirth satisfaction was measured using the pregnancy and childbirth 
questionnaire (PCQ). The PCQ is a validated questionnaire measuring perceived quality 
of care among post-partum women 18. With 25 questions using a five point Likert scale, 
it addresses topics specifically related to pregnancy and giving birth. Because the PCQ 
contains questions addressing childbirth, the PCQ was incorporated in the post-partum 
questionnaire. PCQ-scores were converted so that higher scores correlates with higher 
levels of satisfaction. Total scores can range from 25 to 125 points (Cronbach’s alpha 0.92). 
We classified women with a total PCQ score of less than 100 points, mean score < 4 out 
of 5, less satisfied regarding their childbirth experience. In this study, we classified these 
women as ‘dissatisfied’. Therefore, we will refer to this group from now on as Pregnancy and 
Childbirth Dissatisfaction (PCD) instead of PCS.
To estimate the strength of the association of independent variables with PCD, we used 
multiple logistic regression analysis. The independent variables of interest were selected 
from the literature and consist of maternal factors, neonatal health outcomes, and 
factors related to the obstetric care received. Additionally, we performed sub-analyses for 
nulliparous and multiparous women. 
Maternal factors included demographic variables such as age, educational degree, and socio-
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economic status. Other factors were; antenatal anxiety, parity (nulliparous or multiparous), 
decrease in perceived personal wellbeing, a neonatal health composite outcome, and a 
maternal health composite outcome. 
Antenatal anxiety levels were measured using the state anxiety items of the State-Trait 
Anxiety Inventory (STAI), completed at 24 weeks of gestation. The STAI is a validated and 
commonly used inventory for the measurement of the general anxiety state. Consisting of 
20 items using a 4 point Likert scale, STAI scores can range from 20-80. Higher STAI scores 
represent a higher state of anxiety 19. We used a threshold of 39 points to identify antenatal 
anxiety as this cut-off has been suggested to detect clinical significant anxiety symptoms 20. 
Socio-economic status was estimated using postal codes and corresponding socio-economic 
status scores provided by the Dutch government 21. 
A decrease in perceived personal wellbeing was defined as a postpartum self-report score 
(scale 0-100) that was at least 10 points lower than the health status reported at enrollment 
(<16 weeks of gestation). Personal wellbeing was measured with the Euroqol Visual 
Analogue Scale 22. 
We defined the maternal health composite outcome, a binary outcome, as an occurrence of 
either pre-eclampsia, gestational diabetes, postpartum haemorrhage (reported blood loss 
>1000ml), or admission to an intensive or high care unit.
The neonatal composite outcome, a binary outcome defined in Expect Study I 17, was
defined as an occurrence of one of the following situations; perinatal death within seven
days after birth, asphyxia (Apgar score <7 after 5 minutes), admission to a neonatal intensive
care unit (NICU) within 28 days after birth, birthweight <2.3 weight percentile, birth before
32 completed weeks of pregnancy. The birthweight percentile was assessed using Dutch
customised birth weight curves which correct for gestational age, ethnicity, gender and
parity 23.
Parity and all items of both the neonatal and maternal composite health outcomes, were
retrieved from discharge letters, medical records, and the questionnaires. In case of
discrepancies, we contacted the corresponding healthcare professional for the final decision.
Independent variables related to the obstetric care services received were: healthcare
professional in lead during antenatal care until at least 34 weeks of gestation (categorical
variable: autonomous midwife in a primary care setting, obstetrician in a secondary care
setting, or both as a result of transfer of care); healthcare professional during labour
(categorical variable: midwife, obstetrician, or both as a result of transfer during labour),
birth mode (categorical variable: spontaneous vaginal birth, instrumental vaginal birth, or
cesarean section), and usage of analgesics (epidural analgesia, intravenous remifentanil)
during labour (yes/ no). The variable ‘transfer of care’ refers to transfer in only one direction,
namely from midwife (primary care) to obstetrician (secondary care). In case of antenatal
or intrapartum transfer of care after 34 weeks of gestation, we considered the healthcare
professional who was in lead until 34 weeks of gestation to be the one in lead during
antenatal care.
Missing data for explanatory variables were imputed using stochastic regression imputation
with predictive mean matching as the imputation model 24. Characteristics of the observed
cohort were described as mean ± standard deviation (SD) for continuous variables.
Categorical variables were expressed as an absolute value with a percentage. We compared
the distribution of characteristics in order to evaluate the relatedness of the imputed cohort
and the observed cohort.
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In the Dutch obstetric system, obstetric care is divided in primary, secondary and tertiary 
care. Autonomous midwives provide care for low-risk pregnant women in primary care 
independently. Women with high-risk pregnancies receive care by obstetricians in a 
secondary care (hospital) setting. If women remain low-risk throughout pregnancy, they 
remain under the supervision of their midwife, including the postpartum period. These 
women have the option of giving birth at home or in a birthing centre supervised by their 
midwife, or in a hospital supervised by an obstetrician. Women with a high-risk pregnancy 
are always supervised by an obstetrician and thus give birth in a hospital. Antenatal, 
intrapartum or postpartum transfer of care, from midwife to obstetrician, is a result of 
either an unexpected finding or a complication during pregnancy or labour. 
Results
In total 2,614 women were included in the Expect cohort of whom 1,548 (59%) gave 
informed consent for receiving the additional questionnaires. Twelve participants were 
excluded because of multiple gestation, which complicates the interpretation of the neonatal 
composite outcome. After providing informed consent, 885 women eventually participated 
in the sub cohort by completing the first additional survey. The PCQ was completed by the 
majority of these women (n=739, 84%), implying a loss to follow-up of 16%. 
Table 3.1 displays the characteristics of participants, illustrating the differences between 
participants lost to follow-up and those who completed the postpartum survey. The 
differences between these groups were minimal. Women lost to follow-up had a slightly 
lower socio-economic status, they tended to have a lower level of education, and were 
more likely to receive analgesics during labour. The postpartum questionnaire is the 
only instrument with questions regarding a decreased perceived personal wellbeing and 
admission to a high care or intensive care unit. As a result, differences with respect to these 
variables between completers and women lost to follow-up cannot be measured. 
Overall, total PCQ-scores were high with a mean score of 109.7 out of 125 points for all 
respondents (SD 12.5). One quarter of all respondents (n= 176) had PCD, with a mean 
PCQ score of 92.6 points (SD 6.8). As shown in Table 3.2, these women scored lower on all 
subscales.
Table 3.2 Pregnancy and Childbirth Questionnaire scores. Data expressed as mean (standard deviation)
Scale
All respondents 
(n=739) 
Satisfied respondents 
(n=563)
Dissatisfied respondents 
(n= 176) 
Total score (25 items) 109.7 (12.5) 115 (8.3) 92.6 (6.8)
Personal treatment during pregnancy (11 items) 49.1 (5.8) 51 (3.9) 41.7 (4.1)
Education information (7 items) 30.3 (4.2) 32 (3.2) 25.3 (3.1)
Personal treatment during labour (7 items) 30.3 (4.5) 32 (3.6) 25.6 (3.9)
In the multivariable logistic regression, several factors were significantly associated with 
PCD. Results were adjusted for all other factors, as shown in Table 3.3. Statistically significant 
maternal factors associated with PCD were decreased perceived personal wellbeing (odds 
ratio: 1.62; 95% CI: 1.09-2.40), and antenatal anxiety (odds ratio: 2.23; 95% CI: 1.50-3.30). 
Age was borderline significant with younger women tending to be more likely to experience 
PCD (odds ratio: 0.95; 95% CI: 0.90-1.00). 
Regarding factors related to obstetric care services, there was a statistically significant 
association between PCD and the healthcare professional in charge of antenatal care and 
during labour. Transfer from primary to secondary care during the antenatal period was 
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associated with increased PCD. Antenatal transfer of care before 34 weeks of gestation, was 
significantly associated with PCD when compared to uninterrupted midwife led care (odds 
ratio: 1.82; 95% CI: 1.10-3.00). Antenatal transfer also increased the odds of PCD (albeit not 
significantly) when compared to uninterrupted obstetrician led care (odds ratio: 1.62; 95% 
CI: 0.93-2.83).
If all labour stages were led by an obstetrician (n = 368), the odds ratio for experiencing PCD 
was 2.33 (95% CI: 1.34-4.08), compared to all labour stages led by a midwife (n = 232). For 
women who were referred by their midwife to an obstetrician during labour (n = 100), the 
odds ratio of PCD was 0.80 (95% CI: 0.37-1.65) compared to those who were assisted by 
their midwife from onset of labour. 
We performed sub-analyses for nulliparous and multiparous women. This did not result 
in material differences except for cesarean section. A cesarean section was significantly 
correlated with PCD in nulliparous women (odds ratio 2.68; 95% CI: 1.30-5.57), but not in 
multiparous women (odds ratio 0.61; 95% CI: 0.25-1.47). 
Table 3.3 Multiple logistic regression of maternal and healthcare factors related to pregnancy and childbirth 
discontent
Determinants Satisfied
(n=563)
Mean (sd) or n (%)
Dissatisfied
(n=176)
Mean (sd) or n (%)
Unadjusted odds 
ratio (95% CI)
Adjusted odds 
ratio (95% CI)
Patient related factors
Age (continuous) 30.8 (3.7) 30.4 (3.7) 0.97 (0.93-1.02) 0.95 (0.90-1.00)
Socio-economic status (continuous) -0.5 (1.1) -0.5 (1.0) 1.02 (0.87-1.19) 1.08 (0.91-1.29)
Primary or secondary level of 
education
197 (35.0) 64 (36.4) 1 [Reference] 1 [Reference]
Tertiary level of education 366 (65.0) 112 (63.6) 0.94 (0.66-1.34) 1.05 (0.71-1.55)
Multiparous 271 (48.1) 85 (48.3) 1 [Reference] 1 [Reference]
Nulliparous 292 (51.9) 91 (51.7) 0.99 (0.71-1.40) 0.98 (0.65-1.48)
No neonatal composite outcome 537 (95.4) 112 (63.6) 1 [Reference] 1 [Reference]
Neonatal composite outcome 26 (4.6) 7 (4.0) 0.86 (0.34-1.90) 0.58 (0.22-1.36)
No maternal composite outcome 557 (98.9) 152 (86.4) 1 [Reference] 1 [Reference]
Maternal composite outcome 6 (1.07) 24 (13.6) 1.21 (0.72-1.97) 0.98 (0.56-1.67)
No decreased perceived personal 
wellbeing
435 (77.3) 118 (67.0) 1 [Reference] 1 [Reference]
Decreased perceived personal 
wellbeing
128 (22.7) 58 (33.0) 1.70 (1.17-2.45)* 1.62 (1.09-2.40)*
No antenatal anxiety 444 (78.9) 139 (79.0) 1 [Reference] 1 [Reference]
Antenatal anxiety 119 (21.0) 37 (21.0) 2.18 (1.51-3.15)* 2.23 (1.50-3.30)*
Healthcare related factors
Healthcare professional care during antenatal care
Antenatal care led by midwife 387 (68.7) 89 (50.6) 1 [Reference] 1 [Reference]
Antenatal care led by obstetrician 103 (18.3) 42 (23.9) 1.77 (1.15-2.71) 1.12 (0.67-1.85)
Transfer during antenatal care 73 (13.0) 45 (25.6) 2.68 (1.73-4.14)* 1.82 (1.10-3.00)*
Healthcare professional during labour
Labour led by midwife 202 (35.9) 37 (21.0) 1 [Reference] 1 [Reference]
Labour led by obstetrician 269 (47.8) 125 (71.0) 2.54 (1.70-3.86)* 2.33 (1.34-4.08)*
Transfer during labour 92 (16.3) 14 (8.0) 0.83 (0.42-1.58) 0.80 (0.37-1.65)
No analgesics used during labour 324 (57.5) 89 (50.6) 1 [Reference] 1 [Reference]
Analgesics used during labour 239 (42.5) 87 (49.4) 1.33 (0.94-1.86) 0.71 (0.43-1.16)
Mode of giving birth
Spontaneous vaginal labour 436 (77.4) 119 (67.6) 1 [Reference] 1 [Reference]
Instrumental vaginal labour 47 (8.3) 16 (9.1) 1.25 (0.66-2.23) 1.19 (0.60-2.30)
Cesarean section 80 (14.2) 41 (23.3) 1.88 (1.22-2.87)* 1.53 (0.88-2.63)
sd, standard deviation
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Discussion
In general, women were highly satisfied with the obstetric care received during their 
pregnancy and childbirth period. Women who experienced PCD scored lower on all 
subscales, indicating that PCD cannot be attributed to one of the PCQ subscales.
Factors statistically significantly and independently related with PCD were antenatal anxiety, 
decreased perceived personal wellbeing, and labour led by an obstetrician. Antenatal 
transfer of care significantly increased the odds upon PCD compared to antenatal care led 
by a midwife, and tends to increase the odds upon PCD compared to antenatal care led by 
an obstetrician. 
The main strengths of our study are the multicentre prospective cohort design, the large 
sample size, and the completeness of data. Using a multicentre prospective design improves 
the probability of collecting a representative sample. Furthermore, it enables optimal 
measurement of outcomes by minimizing recall bias and recording of all independent 
variables before completion of the PCQ. Additionally, the PCQ, used to assess satisfaction, 
has been validated among Dutch women and takes the unique features of the Dutch 
obstetric care system into account 18,25. 
A limitation of this study is that our sub cohort may suffer from some selection bias due to 
non-response rates, particularly since participants were included from a larger cohort 26. 
However, differences between the sub cohort and main cohort were minimal. Moreover, 
the differences between women who agreed to receive additional surveys but never 
responded them and those who did were minimal as well, as shown in Table 3.1. For women 
who started with the first additional survey eventually only 16% did not complete the 
postpartum questionnaire. For women who did complete the postpartum questionnaire we 
had 98% completeness of data. By imputing independent variables containing missing data, 
we limited the possibility of biased results and a loss of statistical precision 27. 
To obtain sufficient numbers of women with PCD in our analysis, we focused on women who 
experienced less than perfect obstetric care, using a total PCQ score of less than 100 points 
as a cut-off. Our study does not have qualitative data regarding the level of satisfaction or 
dissatisfaction related to the obstetric care services. However, the amount of studies using 
the PCQ questionnaire is limited and none of these use dissatisfaction as outcome 18,25. 
In line with previous reports, our results indicate that most post-partum women are highly 
satisfied with obstetric care 6,25,28-30. We found no association between PCD and maternal 
demographic factors including, socio-economic status, educational level, and parity. 
These results correspond with the findings by previous reports 14. We found a borderline 
association between PCD and maternal age, whereby younger women tend to be more 
likely to experience PCD. Results of previous studies are inconsistent regarding the influence 
of maternal age. Some studies report younger women tend to reflect on their childbirth 
experience more negatively, whereas a recent study, focussing on discontent as well, does 
not report any effect of age 5,30,31. Additionally, since age is a non-modifiable factor, its 
relevance in the reduction of PCD is limited; still it could serve as a risk indicator increasing 
awareness among healthcare professionals. 
Interestingly, the neonatal and maternal composite outcomes, measures of the occurrence 
of complications, were not correlated with PCD, but there was a significant association 
between decreased perceived personal wellbeing and PCD. This suggests that it is not 
the presence or absence of complications, but rather perceived wellbeing that affects the 
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experience of pregnancy and birth care. It has been reported that the interaction between a 
woman and her healthcare professional has a greater influence upon women’s perceptions 
of birth than the physical experience of the birth itself 32.
Our analysis discovered antenatal anxiety is highly correlated to PCD. Nearly a quarter of the 
women met the criteria of clinically relevant anxiety. Taken together, this makes antenatal 
anxiety an important factor of interest in order to reduce the number of women who 
experience PCD.
Referral during antenatal care, which results in transfer from primary care to secondary 
care, was associated with increased odds of PCD. Although several studies discuss the 
effects of transfer during labour, studies reporting antenatal transfer are limited. This 
could be due to the unique Dutch setting, which divides obstetric care between primary 
and secondary care. Women generally go to a midwife for their first antenatal visit, and 
in case of a healthy woman with an uncomplicated pregnancy, they receive midwife-led 
care throughout pregnancy, labour and the postpartum period. Due to the nature of this 
system, transfer of care is a result of either an unexpected finding or a complication during 
pregnancy or childbirth. This may increase anxiety. In our analysis we adjusted for clinically 
relevant anxiety, however the increase of anxiety may be more subtle. Another possibility 
explaining the increased odds of PCD, may be the result of feelings of loss of control 2,32.  
We found no association of PCD with either mode of birth or primary (midwife-led) or 
secondary (obstetrician-led) antenatal care. However, we did find a correlation between 
the healthcare professional in charge during labour and PCD. Women assisted by a midwife 
throughout all stages of labour were significantly less likely to experience PCD when 
compared to women assisted by an obstetrician. This accords with previous literature 
showing that women receiving continuity of midwifery care are more likely to be satisfied 
33. In contrast with the findings of previous reports 2,29,32,34, transfer during labour was not
associated with PCD. The odds of PCD did not differ significantly between women who were
transferred during labour and women who continued to receive midwife-led care (adjusted
odds ratio 0.80; 95% CI: 0.37-1.65). Furthermore, the odds of PCD was significantly lower for
women who were transferred during labour compared to women who received obstetrician-
led care during the entire birthing process (adjusted odds ratio 0.34; 95%CI: 0.17-0.66).
Unfortunately, our data do not permit a reliable analysis regarding the reasons for transfer
during labour. A woman may be referred for an emergency with varying degrees of urgency
(and experienced associated stress) or a woman may be referred as a result of her request of
analgesics. In case of a medical emergency, it is reasonable to believe that a woman will feel
a loss of control, which has been strongly associated with a traumatic childbirth experience
32. Because we do not have information on the reasons for transfer of care, we are not able
to analyse this with our data, but it is interesting that women who are transferred have lower
levels of PCD. This may suggest that, overall, the Dutch system of primary and secondary
care works well with respect to women’s birthing experience in relation to transfer during
labour.
Our sub analysis in nulliparous and multiparous women did not yield any material differences
except for cesarean section and level of antenatal care. These two factors increase the odds
of PCD only in nulliparous women. A possible explanation for this discrepancy could be a
difference in expectations between nulliparous and multiparous women. Unmet expectations
have been linked to influence women’s satisfaction with pregnancy and childbirth 13. A
substantial proportion of multiparous women may have received obstetrician-led antenatal
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care, or a cesarean in any of their previous pregnancies. As a result, their expectations 
regarding the course of their current pregnancy may have altered.
Implications
At the moment, the Dutch obstetric system is changing, with a movement towards more 
integrated care 35,36. The Ministry of Health published a report promoting patient-centred 
care combined with integrated care and shared decision making as key concepts of the 
future obstetric care system 37. As a result, there is increased interest in the use of individual 
risk-management systems and decision support aids 17,38. Depending on how it is organized, 
integrated care has the potential to increase positive collaboration between midwives in 
a primary care setting and obstetricians in a secondary care setting. Those who design 
models of integrated care should take note of the positive birthing experiences associated 
with midwives and find ways to insure that features of midwife-led care are not lost in the 
transition 39,40.
Antenatal anxiety was the most important factor related to a negative childbirth experience. 
It is already known that maternal anxiety is related to adverse outcomes, but this study 
shows that it is an independent factor for the way women experience their childbirth 9. 
Current guidelines on anxiety in pregnancy are mostly focused on anxiety or mood disorders 
and the effects of medication 41,42. However, they offer little help for women or healthcare 
professionals who are dealing with the less severe cases. Our study found that almost 25% 
of women had an anxiety score that was clinically relevant. Post-partum interventions in 
women with poor mental health have shown to be cost effective 43. Our work underscores 
the need for further research on the effects of screening and treatment for anxiety in 
pregnancy. Similar to somatic diseases like diabetes and hypertension, pregnancy might be 
a stress test for women’s mental health and early identification and treatment is likely to 
result in an improved birthing experience 44,45. Decision support aids are reported to reduce 
anxiety scores and may be effective tools to imply in order to reduce PCD 46. 
Conclusions
Decreased perceived personal wellbeing, increased anxiety, transfer of care antenatal, and 
obstetrician-led birth, were all independently associated with PCD. One in four women 
experienced general antenatal anxiety. Women’s birthing experience may improve by 
increased awareness regarding women’s antenatal anxiety state and reducing the proportion 
of women unnecessarily receiving obstetric care in a secondary care setting.
64   
Chapter 3
References
1. Goodman, P., Mackey, M.C., et al., Factors related to childbirth satisfaction. Journal of advanced 
nursing, 2004. 46(2): p. 212-219.
2. Rijnders, M., Baston, H., et al., Perinatal factors related to negative or positive recall of birth expe-
rience in women 3 years postpartum in the Netherlands. Birth, 2008. 35(2): p. 107-116.
3. Grekin, R. and O’Hara, M.W., Prevalence and risk factors of postpartum posttraumatic stress dis-
order: a meta-analysis. Clinical Psychology Review, 2014. 34(5): p. 389-401.
4. Larkin, P., Begley, C.M., et al., Women’s experiences of labour and birth: an evolutionary concept 
analysis. Midwifery, 2009. 25(2): p. e49-e59.
5. Baas, C.I., Wiegers, T.A., et al., Client-Related Factors Associated with a “Less than Good” Experi-
ence of Midwifery Care during Childbirth in the Netherlands. Birth, 2017. 44(1): p. 58-67.
6. Teijlingen, E.R., Hundley, V., et al., Maternity satisfaction studies and their limitations:“What is, 
must still be best”. Birth, 2003. 30(2): p. 75-82.
7. Lee, A.V., Moriarty, J.P., et al., What can we learn from patient dissatisfaction? An analysis of dis-
satisfying events at an academic medical center. J Hosp Med, 2010. 5(9): p. 514-20.
8. Redshaw, M., Women as consumers of maternity care: measuring “satisfaction” or “dissatisfac-
tion”? . Birth, 2008. 35(1): p. 73-76.
9. Grigoriadis, S., Graves, L., et al., Maternal Anxiety During Pregnancy and the Association With 
Adverse Perinatal Outcomes: Systematic Review and Meta-Analysis. J Clin Psychiatry, 2018. 79(5).
10. Munstedt, K., von Georgi, R., et al., Wishes and expectations of pregnant women and their part-
ners concerning delivery. J Perinat Med, 2000. 28(6): p. 482-90.
11. Tschudin, S., Alder, J., et al., Previous birth experience and birth anxiety: predictors of caesarean 
section on demand? J Psychosom Obstet Gynaecol, 2009. 30(3): p. 175-80.
12. Spice, K., Jones, S.L., et al., Prenatal fear of childbirth and anxiety sensitivity. J Psychosom Obstet 
Gynaecol, 2009. 30(3): p. 168-74.
13. Christiaens, W. and Bracke, P., Assessment of social psychological determinants of satisfaction 
with childbirth in a cross-national perspective. BMC Pregnancy and childbirth, 2007. 7(1): p. 26.
14. Britton, J.R., The assessment of satisfaction with care in the perinatal period. J Psychosom Obstet 
Gynaecol, 2012. 33(2): p. 37-44.
15. Verhoeven, C.J., Nuij, C., et al., Predictors for failure of vacuum-assisted vaginal delivery: a 
case-control study. Eur J Obstet Gynecol Reprod Biol, 2016. 200: p. 29-34.
16. Schoen, C. and Navathe, R., Failed induction of labor. Semin Perinatol, 2015. 39(6): p. 483-7.
17. Meertens, L.J.E., Scheepers, H.C., et al., External Validation Study of First Trimester Obstetric Pre-
diction Models (Expect Study I): Research Protocol and Population Characteristics. JMIR Res Pro-
toc, 2017. 6(10): p. e203.
18. Truijens, S.E., Pommer, A.M., et al., Development of the Pregnancy and Childbirth Questionnaire 
(PCQ): evaluating quality of care as perceived by women who recently gave birth. European Jour-
nal of Obstetrics & Gynecology and Reproductive Biology, 2014. 174: p. 35-40.
19. Ploeg, H.M., Defares, P.B., et al., Handleiding bij de Zelf-Beoordelings Vragenlijst ZBV: een ned-
erlandstalige bewerking van de Spielberger State- Trait Anxiety Inventory STAI-DY. 1980: Swets & 
Zeitlinger.
20. Julian, L.J., Measures of Anxiety. Arthritis care & research, 2011. 63(0 11): p. 10.1002/acr.20561.
21. SCP. SCP Statusscores. 2017  [cited 2017 24-08]; Available from: http://www.scp.nl/Formulieren/
Statusscores_opvragen.
22. EuroQol-Group, EuroQol-a new facility for the measurement of health-related quality of life. 
Health Policy, 1990. 16(3): p. 199-208.
23. Visser, G.H., Eilers, P.H., et al., New Dutch reference curves for birthweight by gestational age. 
Early Hum Dev, 2009. 85(12): p. 737-44.
24. Van Buuren, S., Flexible imputation of missing data. 2012: CRC press.
25. Truijens, S.E., Banga, F.R., et al., The Effect of Multiprofessional Simulation-Based Obstetric Team 
65   
Satisfaction of pregnancy and childbirth
3
Training on Patient-Reported Quality of Care: A Pilot Study. Simul Healthc, 2015. 10(4): p. 210-6.
26. Berman, D.M., Tan, L.L., et al., Surveys and Response Rates. Pediatr Rev, 2015. 36(8): p. 364-6.
27. Sterne, J.A.C., White, I.R., et al., Multiple imputation for missing data in epidemiological and clin-
ical research: potential and pitfalls. The BMJ, 2009. 338: p. b2393.
28. Karlström, A., Nystedt, A., et al., The meaning of a very positive birth experience: focus groups
discussions with women. BMC Pregnancy and Childbirth, 2015. 15: p. 251.
29. Hitzert, M., Hermus, M.A., et al., Experiences of women who planned birth in a birth centre com-
pared to alternative planned places of birth. Results of the Dutch Birth Centre Study. Midwifery,
2016. 40: p. 70-8.
30. Jenkinson, C., Coulter, A., et al., Patients’ experiences and satisfaction with health care: results of
a questionnaire study of specific aspects of care. Quality and safety in health care, 2002. 11(4): p.
335-339.
31. Borjesson, B., Paperin, C., et al., Maternal support during the first year of infancy. J Adv Nurs,
2004. 45(6): p. 588-94.
32. Hollander, M.H., van Hastenberg, E., et al., Preventing traumatic childbirth experiences: 2192
women’s perceptions and views. Archives of Women’s Mental Health, 2017. 20(4): p. 515-523.
33. Sandall, J., Soltani, H., et al., Midwife-led continuity models versus other models of care for child-
bearing women. Cochrane Database Syst Rev, 2015(9): p. Cd004667.
34. Geerts, C.C., van Dillen, J., et al., Satisfaction with caregivers during labour among low risk women
in the Netherlands: the association with planned place of birth and transfer of care during labour.
BMC Pregnancy and Childbirth, 2017. 17: p. 229.
35. Visser, G.H.A., Obstetric care in the Netherlands: relic or example? J Obstet Gynaecol Can, 2012.
34(10): p. 971-975.
36. Boesveld, I.C., Valentijn, P.P., et al., An Approach to measuring Integrated Care within a Maternity
Care System: Experiences from the Maternity Care Network Study and the Dutch Birth Centre
Study. International Journal of Integrated Care, 2017. 17(2): p. 6.
37. Geboortezorg, E.Z.I., Zorgstandaard Integrale Geboortezorg, 2016, College Perinatale Zorg:
Utrecht.
38. Schoorel, E.N., Vankan, E., et al., Involving women in personalised decision-making on mode of
delivery after caesarean section: the development and pilot testing of a patient decision aid. Bjog,
2014. 121(2): p. 202-9.
39. Perdok, H., Jans, S., et al., Opinions of maternity care professionals and other stakeholders about
integration of maternity care: a qualitative study in the Netherlands. BMC Pregnancy and Child-
birth, 2016. 16: p. 188.
40. Hodnett, E.D., Continuity of Caregivers for Care During Pregnancy and Childbirth. Birth, 2000.
27(3): p. 218-218.
41. Yonkers, K.A., Wisner, K.L., et al., The management of depression during pregnancy: a report from
the American Psychiatric Association and the American College of Obstetricians and Gynecolo-
gists. Obstet Gynecol, 2009. 114(3): p. 703-13.
42. National Collaborating Centre for Mental, H., National Institute for Health and Clinical Excellence:
Guidance, in Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance:
Updated edition. 2014, British Psychological Society: Leicester (UK).
43. Chojenta, C., William, J., et al., The impact of a history of poor mental health on health care costs
in the perinatal period. Arch Womens Ment Health, 2018.
44. Hermes, W., Tamsma, J.T., et al., Cardiovascular risk estimation in women with a history of hyper-
tensive pregnancy disorders at term: a longitudinal follow-up study. BMC Pregnancy Childbirth,
2013. 13: p. 126.
45. Kramer, C.K., Swaminathan, B., et al., Each degree of glucose intolerance in pregnancy predicts
distinct trajectories of beta-cell function, insulin sensitivity, and glycemia in the first 3 years post-
partum. Diabetes Care, 2014. 37(12): p. 3262-9.
66   
Chapter 3
46. Tucker Edmonds, B., Shared decision-making and decision support: their role in obstetrics and
gynecology. Curr Opin Obstet Gynecol, 2014. 26(6): p. 523-30.
Chapter 4
Implementation and effects of risk-dependent obstetric 
care in the Netherlands (Expect Study II): Protocol for an 
impact study 
Pim van Montfort, Jessica P.M.M. Willemse, Carmen D. Dirksen, 
Ivo M.A. van Dooren, Linda J.E. Meertens, Marc E.A. Spaanderman, 
Maartje Zelis, Iris M. Zwaan, Hubertina C.J. Scheepers, Luc J.M. Smits
JMIR Research Protocols, 2018
68   
Chapter 4
Abstract
Background
Recently, validated risk models predicting adverse obstetric outcomes combined with risk-
dependent care paths have been made available for early antenatal care in the southeastern 
part of the Netherlands. This study will evaluate implementation progress and impact of the 
new approach in obstetric care.
Objective
The objective of this paper is to describe the design of a study evaluating the impact 
of implementing risk-dependent care. Validated first-trimester prediction models are 
embedded in daily clinical practice and combined with risk-dependent obstetric care paths. 
Methods
A multicentre prospective cohort study consisting of women who receive risk-dependent care 
is being performed from April 2017 to April 2018 (Expect Study II). Obstetric risk profiles will 
be calculated using a Web-based tool, the Expect prediction tool. The primary outcomes are 
the adherence of healthcare professionals and compliance of women. Secondary outcomes 
are patient satisfaction and cost-effectiveness. Outcome measures will be established using 
Web-based questionnaires. The secondary outcomes of the risk-dependent care cohort 
(Expect II) will be compared with the outcomes of a similar prospective cohort (Expect I). 
Women of this similar cohort received former care-as-usual and were prospectively included 
between July 1, 2013 and December 31, 2015 (Expect I).
Results
Currently women are being recruited for the Expect Study II and a total of 300 women are 
enrolled.
Conclusions
This study will provide information about the implementation and impact of a new approach 
in obstetric care using prediction models and risk-dependent obstetric care paths.
Trial Registration
Netherlands Trial Registry (NTR): NTR4143 
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Introduction
Perinatal mortality plays a pivotal role in the quality assessment of perinatal care 1. In 
developed countries the main causes of perinatal mortality are small-for-gestational-age 
infancy (SGA), preterm birth (PTB), and asphyxia 2,3. Pre-eclampsia (PE) is an important cause 
for both SGA and induced PTB 4. Risks of asphyxia and birth injuries are increased among 
infants that are large-for-gestational-age (LGA) 5, which in turn is strongly associated with 
gestational diabetes mellitus (GDM) 6. Thus, PE, GDM, PTB, SGA, and LGA are all directly or 
indirectly related to perinatal mortality. 
A number of interventions have shown to be effective in the prevention of adverse pregnancy 
outcomes, such as low-dose aspirin treatment in case of PE 7-9, adequate management of 
GDM 10,11, and progesterone administration in women at risk of spontaneous PTB 12. Besides 
calcium supplementation, most of these interventions are not suitable for all pregnant 
women, because of either possible adverse effects, patient burden, or costs. Early prediction 
of obstetric risks may therefore help healthcare professionals in designing intervention 
strategies based on women’s individual risks.
Recently, we performed an external validation study of first trimester prediction models 
predicting the risk of PE, GDM, PTB, SGA and LGA (the Expect Study I) 13,14. The Expect 
Study I identified clinically useful prediction models for PE and GDM. The Limburg Obstetric 
Consortium (LOC), midwives and gynecologists of the southeastern part of the Netherlands 
developed care pathways, i.e., basic antenatal care for women at low risk and additional 
risk-dependent care for women with elevated risks of PE, GDM, PTB, SGA, or LGA. The LOC 
agreed to implement the risk models predicting PE and GDM, in order to identify women at 
increased risk of these outcomes, and to offer these women risk-dependent care. 
The current protocol describes the design of a multicentre prospective cohort study (Expect 
Study II) evaluating the implementation progress of using these prediction models combined 
with tailored care paths for PE and GDM.
The primary aims of the Expect Study II are to measure adherence to the new risk-dependent 
care guidelines by healthcare professionals and compliance of pregnant women who 
received recommendations. The secondary aims are to evaluate its impact upon patient 
satisfaction and cost-effectiveness. Secondary aims will be studied by comparing these 
outcomes of the Expect II cohort with the Expect I cohort.
Methods
Study Design and Recruitment
In April 2017, the Expect prediction tool was introduced. The Expect prediction tool was 
developed to enable individual risk assessment during early pregnancy regarding the risks of 
PE, GDM, PTB, SGA, and LGA. Validated models selected by the LOC to predict PE and GDM 
have been incorporated into this tool (study submitted by Meertens et al). Risk assessment 
of spontaneous PTB, SGA and LGA is achieved using the revised LOC guidelines 15. For 
nulliparous women, the prediction tool comprises 14 variables concerning anthropometric 
data, relevant medical history, and family history. For multiparous women the tool enquires 
six more variables, all concerning the women’s obstetric history.
The Expect prediction tool is a Web-based form, which calculates the estimated risk profiles. 
This tool was made available for healthcare professionals via the Expect study website 
70   
Chapter 4
(https://www.zwangerinlimburg.nl) for implementation in daily obstetric care. Besides the 
estimated risks of adverse pregnancy outcomes, the tool provides recommendations for 
tailored antenatal care based on personalized risks (i.e., risk-dependent care). In addition, 
patient information brochures relevant to the patient’s risk profile will be automatically 
generated. The health care professionals can use this tool during one of the pregnant 
woman’s antenatal visits before 16 weeks of pregnancy. Using a shared decision approach, 
the appropriate risk-dependent care path with corresponding preventive measures and 
check-ups will be selected.
In order to implement risk-dependent care successfully, midwives and gynecologists are 
encouraged to use the Expect prediction tool by representatives of the LOC. The Expect 
prediction tool is introduced by email to all obstetric healthcare professionals in the region. 
Furthermore, oral presentations will be given at every hospital and at local midwifery 
meetings. Additionally, the hospitals and midwifery practices are contacted regularly by 
phone and in person to evaluate the Expect prediction tool.
The midwives and gynecologists play a central role in enrolling pregnant women into 
the Expect Study II, by asking women whether they are interested in receiving further 
information about participating in the Expect Study II. Almost every pregnant woman is 
eligible for our study. The exclusion criteria are (1) maternal age <18 years, (2) documented 
multiple pregnancy, and (3) ≥16 weeks of gestation at intake. The eligibility criteria are 
identical to those of the Expect Study I cohort 13. Eligible women agreeing to participate 
are asked to give informed consent and to complete 4 Web-based surveys at enrolment, 24 
weeks and 34 weeks of gestation, and 6 weeks after due date. 
A personal link to the first online survey will be sent immediately after enrolment. If the 
survey was not accessed or incomplete, two automatic reminders will be sent by email at 
3-day intervals for surveys one to three and at 6-day intervals for the postpartum survey. In
case of non-response, women will be contacted by phone (provided that a correct phone
number is available). If women report PTB at the beginning of survey two or three, they will
automatically be redirected to the postpartum survey.
The medical ethical committee of Maastricht University Medical Centre (MUMC+) evaluated
the study protocol and declared that the study did not fall within the scope of the Dutch
Medical Research Involving Human Subjects Act (WMO) (METC-17-4-057).
Tailored-Care Paths
The LOC consists of midwives (n=9), gynecologists (n=9), professionals in maternity care 
(n=2), researchers (n=3), and an independent chairperson. They meet four to five times 
annually and represent the University medical school, midwifery academy, all hospitals, and 
roughly 80% (n=90) of the midwives of the province. The midwives and gynecologists of 
the LOC revised the content of obstetric care. We will briefly describe the most important 
changes regarding antenatal care compared to former care-as-usual, which has been 
observed during Expect Study I. All women will receive basic antenatal care. In the new 
tailored care paths, recommendations about calcium and vitamin D supplementation are 
emphasized for all women and an additional ultrasound for foetal growth assessment at 32 
weeks of pregnancy is introduced as part of basic antenatal care.
An overview of the care pathways is provided in Table 4.1. Additional risk-dependent care 
for women with a mildly elevated risk of PE comprises the recommendation of preventive 
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aspirin treatment, 80-100 mg aspirin daily from 12 weeks up to 36 weeks of pregnancy. 
Obstetric care for women with a substantial risk of PE additionally comprises of extended 
blood tests, blood pressure measurements every 2 weeks from 14 weeks up to 40 weeks of 
gestation, and 2 additional ultrasounds for foetal growth measurements. 
Women with a history of GDM are advised to have an oral glucose tolerance test (OGTT) 
at 16 and 26 weeks of pregnancy. Women with a mildly elevated risk are advised to have 
an OGTT at 24 weeks of pregnancy. Furthermore, in both cases, women will receive two 
additional ultrasounds for foetal growth measurements in addition to basic antenatal care.
Outcome Measures and Measurement
The primary outcomes are healthcare professionals’ adherence to key recommendations 
and compliance of the women involved in the study. Adherence is defined as the proportion 
of women that actually received the key recommendations they should have received from 
their healthcare professional according to the LOC guidelines. Adherence will be analysed 
regarding recommendations of adequate vitamin D (yes or no) and calcium intake (yes or 
no) for all women, preventive aspirin treatment (yes or no) for women with elevated PE 
risks, and OGTT (yes or no) for women with elevated GDM risks. 
Compliance is defined as the proportion of women whom comply with the LOC 
recommendations they have received (yes, no or partially). Compliance will be analysed 
regarding: adequate vitamin D (10 microgram per day) and calcium (1,000 milligram per 
day) intake, preventive aspirin treatment, and OGTT.
The secondary outcomes are patient satisfaction and cost-effectiveness. These secondary 
outcomes of Expect Study II will be compared to the outcomes of Expect Study I.
Patient satisfaction will be measured by validated patient satisfaction questionnaires. The 
Patient Satisfaction Questionnaire Short Form (PSQ-18) will be incorporated in antepartum 
surveys two and three. In the postpartum survey, patient satisfaction will be assessed by the 
Pregnancy and Childbirth Questionnaire (PCQ) 16. The PCQ is validated for Dutch women who 
recently gave birth and addresses three topics: women’s satisfaction with the healthcare 
professional during pregnancy, health education, and satisfaction with the healthcare 
professional during labour. Furthermore, Truijens et al showed the PCQ is sensitive to pick 
up effects regarding patient satisfaction due to simulation-based obstetric team training 17.
In order to perform cost-effectiveness calculations, we will calculate two incremental cost-
effectiveness ratios (ICERs). The first ICER expresses the healthcare costs per one neonatal 
composite outcome prevented. The neonatal composite outcome is defined as perinatal 
death within seven days after birth, asphyxia (Apgar score <7 after 5 minutes), admission to 
a neonatal intensive care unit (NICU) within 28 days after birth, SGA (birthweight <2.3 weight 
percentile), and very preterm birth (birth before 32 completed weeks of pregnancy) 13. The 
second ICER will express the healthcare cost per one maternal gained Quality Adjusted Life 
Year (QALY).
Data Collection
For the primary outcomes, we will use the data collected for the Expect Study II. For the 
secondary outcomes, when comparing the effects of risk-dependent care with former 
care-as-usual, the outcomes of the Expect Study II will be compared with the outcomes 
of the Expect Study I. For this reason, the survey intervals and the questions regarding the 
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secondary outcomes are similar between the two studies. 
In the Expect Study II, data will be collected using the Expect prediction tool, comprising 
women’s personal risk profile, and Web-based patient surveys. A structured overview of 
patient enrolment and data collection for the Expect Study II is shown in Figure 4.1. 
The first survey addresses the following topics: (1) recommendations and information 
given by health healthcare professionals, (2) women’s intention to comply with these 
recommendations, (3) dietary intake of calcium and vitamin D sunlight exposure, and (4) 
vitamin and mineral supplement usage.
The second and third surveys are comparable to each other and will address the following 
topics: (1) patient satisfaction, (2) women’s state anxiety, (3) maternal quality of life, (4) 
changes in vitamin and mineral supplement usage, and (5) healthcare resource use. 
In order to document the nature and volume of healthcare resource used, women will be 
asked to record all visits to midwives, hospitals, and other care institutions. Furthermore, 
questions related to medication use, hospital admission, diagnostic and medical procedures, 
and the delivery will be asked. To minimize patient recall problems, information regarding 
the usage of health care resources will be requested at three intervals (surveys two, three 
and four) during the study period.
Survey four, the postpartum survey, addresses obstetric outcomes, compliance of healthcare 
recommendations, and the topics mentioned in survey two and three. Furthermore, this 
survey also contains questions regarding the healthcare consumption related to the neonate.
Sample size
According to the results of the validation study (Expect I), we expect approximately 30% of 
women to have an elevated estimated risk of PE, the obstetric complication with the lowest 
incidence (article submitted by Meertens et al). Furthermore, an adherence of 70% and a 
compliance of approximately 40% is expected for the recommended aspirin treatment. This 
will result in approximately 21% and 12% respectively of the general population having an 
elevated risk of PE. In order to estimate these percentages with a precision of approximately 
4% the required sample size is estimated at 400 participants 18. 
Statistical Analysis
Missing values will be handled by imputation. Stochastic regression imputation with 
predictive mean matching as the imputation model will be used to prevent biased results 
based on complete case analysis only 19.
Adherence will be calculated by the proportion of women who reported to have received 
the LOC recommendations regarding adequate vitamin D and calcium intake, preventive 
aspirin treatment, and OGTT. Answers of participants will be linked to their estimated risk 
profile based on the Expect prediction tool.
Compliance will be analysed by calculating the proportion of women who complied with the 
recommendations received from their healthcare professional regarding aspirin treatment, 
OGTT, vitamin D, and calcium intake. Vitamin D is analysed based on supplement intake and 
sunlight exposure. Calcium intake is determined by calculating the daily intake from diet 
and supplement use. Dietary intake will be estimated using answers from a selection of 
questions from the Dutch National Food Frequency Questionnaire tool 20. These questions 
address food products that cumulatively cover >80% of the variance in calcium intake 
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21. Total intake of both nutrients will be compared with the recommended intake by the
LOC (1000 milligram calcium per day and 10 microgram of vitamin D per day) in order to
determine compliance to these recommendations.
The secondary outcomes, patient satisfaction and cost-effectiveness, will be analysed by
comparing Expect Study II with the outcomes of former care-as-usual (Expect Study I).
Patient satisfaction scores will be analysed using multiple linear regression.
For the economic evaluation, we will use a health care perspective according to the Dutch
guidelines for cost calculations 22. A time horizon of approximately eleven months, from
onset of pregnancy up to six weeks post-partum, will be applied. Maternal quality of life
will be evaluated using the Euroqol EQ-5D-3L and EQ VAS (Euroqol Visual Analogue Scale)
questions, which are incorporated, in the surveys. The EQ-5D-3L and EQ VAS are standardized
questionnaires used worldwide to assess quality of life. Maternal QALYs will be calculated
using the corresponding utility scores based on the Dutch population 23,24. All costs will be
expressed as 2017 Euros and if necessary cost prices will be transformed to 2017 Euros
using the Dutch Consumer Price Index 25. Bootstrap- and standard sensitivity analyses will be
performed to quantify the uncertainty regarding the cost-effectiveness outcomes.
Results
Currently, women are being recruited for the Expect Study II and a total of 300 women 
are enrolled. We expect to achieve our goal of 400 participants during April 2018 and 
postpartum data collection will be finished by March 2019. As a result, first study results are 
expected in 2019. 
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Figure 4.1 Flowchart of participant enrolment and data collection of the Expect Study II. Whether or not a woman 
participates to the Expect Study II does not affect the health care women receive during their pregnancy
Discussion
This paper describes the protocol of an impact study regarding the implementation of 
externally validated prediction models combined with risk-based care pathways in obstetric 
care. Prediction models are becoming increasingly popular in medicine 26. Although the 
number of prediction models being published has increased tremendously in recent years, 
the number of external validation studies remains small 26. Furthermore, performances of 
models predicting adverse pregnancy outcomes and the efficacy of preventive interventions 
for these outcomes are generally documented separately 8,27,28. Impact studies, describing the 
effect of using prediction models in daily practice combined with preventive interventions 
relevant to the estimated risk are nearly non-existent 26. To the best of our knowledge, no 
impact studies using prediction models in general obstetric practice have been published. 
The strengths of our design are the multicentre prospective data collection and the 
similarity of both cohorts. Recruitment in multiple centres, hospitals and midwife clinics, 
improves the probability of collecting a representative sample of the obstetric population. 
This is essential in the Netherlands, since most pregnant women receive antenatal care 
by midwives at outpatient clinics 29. Furthermore, optimal measurement of the outcomes 
is achieved by prospective data collection 30. Finally, because the two cohorts are kept as 
similar as possible, we are able to accurately compare the former care-as-usual with the 
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new risk-dependent care. 
Some limitations of the design must also be noted. First, since the comparison of secondary 
outcomes of Expect II with those of Expect I is essentially a before-and-after comparison, 
time trends in the outcomes can theoretically influence results. In the interpretation of 
the results, we will take such trends into account, e.g., by looking at trends in the studied 
outcomes from other regions in the Netherlands.
A second possible limitation of our study is that several outcomes will solely be based on 
participant questionnaires. Potential recall bias, however, is limited due to the prospective 
design and the usage of four questionnaires at limited intervals. Additionally, questionnaires 
have been shown to be a valid method of data collection regarding perinatal outcomes and 
medication exposure during pregnancy 31,32. In the questionnaires we urge respondents to 
answer honestly and emphasize that all answers will be treated confidentially and will not 
influence the care provided by their obstetric health care professional. Furthermore, the 
additional procedures recommended in the risk-dependent care path are all subject to a 
shared decision-making process between woman and healthcare professional. As a result, we 
expect there is currently no taboo regarding the compliance with given recommendations. 
We hypothesize that risk-dependent care results in early detection or prevention of obstetric 
adverse events and can thus reduce prevalence of neonatal adverse events. However, due 
to low prevalence rates of approximately 5%, large cohorts (approximately two times 6,800 
participants) are necessary in order to achieve sufficient power to detect a reduction of 
at least 20% 18. Therefore, the influence of risk-dependent care on the incidence of the 
neonatal composite outcome will be analysed using registry data of the region. Moreover, 
to achieve the desired effects of risk-dependent care, it first needs to be implemented 
successfully. Thus, implementation should first lead to behavioural changes for both health 
care professionals and pregnant women.
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Abstract
Background
Despite improved management, pre-eclampsia remains an important cause of maternal and 
neonatal mortality and morbidity. Low-dose aspirin (LDA) lowers the risk of pre-eclampsia. 
Although several guidelines recommend LDA prophylaxis in women at increased risk, they 
disagree about the definition of high-risk. Recently, an externally validated prediction model 
for pre-eclampsia was implemented in a Dutch region combined with risk-based obstetric 
care paths.
Objectives
To demonstrate the selection of a risk threshold and to evaluate the adherence of obstetric 
healthcare professionals to the prediction tool.
Study Design
Using a survey (n=136) and structured meetings among healthcare professionals, possible 
cut-off values at which LDA should be discussed were proposed. The prediction model, with 
chosen cut-off and corresponding risk-based care paths, was embedded in an online tool. 
Subsequently, a prospective multicenter cohort study (n=850) was performed to analyze the 
adherence of healthcare professionals. Patient questionnaires, linked to the individual risk 
profiles calculated by the online tool, were used to evaluate adherence. 
Results: Healthcare professionals agreed upon employing a tool with a high detection rate 
(cut-off: 3.0%; sensitivity 75%, specificity 64%) followed by shared decision between patient 
and healthcare professional on LDA prophylaxis. Of the 850 enrolled women, 364 women 
had an increased risk of pre-eclampsia. LDA was discussed with 273 of these women, 
resulting in an 81% adherence rate. 
Conclusion
Consensus regarding a suitable risk cut-off threshold was reached. The adherence to this 
recommendation was 81%, indicating adequate implementation.
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Introduction
Pre-eclampsia (PE) is an important cause of mortality and morbidity for both the mother 
and the fetus. Although management of PE has improved, a cure that would preserve 
the pregnancy remains unavailable. Therefore, preventive measures play a pivotal role in 
decreasing the burden of the disease 1.
In addition to adequate calcium intake, diet, and lifestyle interventions, aspirin treatment 
receives an increasing amount of attention as a preventive measure 1,2. Low-dose aspirin 
(LDA) prophylaxis, in a dosage of 80-150mg daily, has been proven to reduce the risk of 
pre-eclampsia 3. Therefore, several professional authorities such as the American College 
of Obstetricians and Gynecologists (ACOG), the US Preventive Services Task Force, and the 
National Institute for Health and Clinical Excellence (NICE) recommend LDA prophylaxis in 
women at increased risk of PE 4-6.
These authorities all recommend LDA to women at increased risk by using a list of separate 
risk factors (e.g. a history of PE, or chronic hypertension). They however differ in their 
selection of risk factors and thus their definition of women at increased risk. Universal 
recommendation for all pregnant women has been proposed as well since LDA is inexpensive, 
widely available, and appears to be safe in pregnancy beyond the first trimester 7. However, 
this view is controversial due to a lack of understanding in the preventive mechanism of 
LDA, and a lack of proven benefits for women at low risk 7. 
Multivariable prediction models estimating the risk of PE weigh several risk factors 
simultaneously and can assist healthcare professionals in identifying women with increased 
risk. The results of a recent study comparing several PE prediction models simultaneously 
in one cohort 8 indicated that some of these models are more efficient compared to a list 
of single risk factors. For a prediction model to serve as a decision tool, a cut-off has to be 
determined for the discrimination of low and increased risk.
Recently, the recommendation of LDA prophylaxis was adopted in the regional guidelines in 
the Southeastern part of The Netherlands 9. Women with an elevated PE risk are identified 
using a prediction model. However, dissemination of guidelines or stating recommendations 
does not automatically result in adherence by healthcare professionals. Implementation 
of effective preventive interventions often suffers from low adherence rates 10-12. Despite 
the increased attention of the role of LDA in the prevention of pre-eclampsia, a recent 
conference report showed that up to 42% of women considered as high risk according to 
the NICE guidelines had not been offered LDA 13.
This paper reports on 1) the selection of a cut-off value by healthcare professionals for the 
identification of women at risk of PE using a prediction model, and 2) results of healthcare 
professional’s adherence to LDA recommendations in the local guidelines.
Methods
Definition of women at risk of pre-eclampsia
The Limburg Obstetric Consortium (LOC) is a committee representing all obstetric health 
care professionals in the Southeastern part of the Netherlands, which consists of five 
regions. Every region consists of a hospital providing secondary obstetric care (gynecologists 
and clinical midwives) and outpatient midwifery practices (autonomous midwives providing 
primary obstetric care)). Each region provides two to four obstetric healthcare professionals 
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as LOC representatives. In total, the LOC consists of independent midwives (n= 11), 
gynecologists (n= 10), maternity care nurses (n=2), and researchers (n=3).
The LOC developed risk-based care pathways that were implemented in 2017. These pathways 
consist of basic antenatal care for the low-risk group and additional recommendations for 
women at risk for several pregnancy related complications including PE. The methods of 
formulating these pathways and their content are reported elsewhere 14,15.
For women at risk of PE additional risk-based care includes the recommendation of LDA 
prophylaxis (80-100mg) from 12 up to 36 weeks of pregnancy. The LOC agreed to use the 
prediction model of Syngelaki 2011, externally validated and recalibrated for their specific 
region by Meertens et al. 8,16. This model was selected because it was the model with the 
highest discriminative performance and its predictors are routinely collected in Dutch 
obstetric practice. Predictors included in the prediction model are age, body mass index, 
ethnicity, parity, assisted conception treatment, smoking during pregnancy, family history 
of PE, and medical history (regarding chronic hypertension, PE, and diabetes mellitus). The 
algorithm of the calibrated model, along with its discriminative performance, is provided in 
supplementary file 1.
Consensus regarding the PE risk-threshold, the cut-off value at which healthcare professionals 
discuss the recommendation of LDA, was reached using a three-step procedure. First, all 
obstetric healthcare professionals of the LOC region received a survey with statements 
regarding the implementation of a PE prediction model and possible risk-thresholds. Second, 
using the results of the survey, the preferences of healthcare professionals were discussed 
in regional meetings with the midwives and gynecologists of the region. Third, the results of 
both the survey and the regional meetings were discussed with the LOC committee. During 
a final meeting the decision was made whether the prediction model should be adopted 
and which risk-threshold was preferred. 
In the survey, three possible risk-thresholds were suggested; 1) a threshold with a high 
sensitivity and low specificity similar to the specificity of the ACOG guideline 4 (risk-threshold 
2.85%, sensitivity 79%, specificity 60%); 2) a threshold resulting in a relative risk of 2.0 
upon PE for positive results (risk-threshold 3.90%, sensitivity 57%, specificity 80%); and 3) 
a threshold with a low sensitivity and high specificity similar to the specificity of the NICE 
guideline 6 (risk-threshold 5.20%, sensitivity 30%, specificity 90%). Each suggested threshold 
was provided with additional information: sensitivity, specificity, as well as total number of 
test positives, test negatives, true positives, false positives, true negatives, false negatives, 
and numbers needed to treat. Data of the external validation study were used to calculate 
these test characteristics per risk-threshold 8.
Healthcare professionals were asked to answer the statement ‘I agree using this cut-off 
value as threshold determining an elevated PE risk’, using a ten-point Likert scale (1 totally 
disagree – 10 fully agree). 
The PE prediction model with corresponding threshold was embedded in the Expect 
prediction tool, which is available online for healthcare professionals. The LOC strongly 
encourages midwives and gynecologists to use the Expect prediction tool during the first 
antenatal visits. This was achieved by oral presentations, e-mails, regular phone calls, and 
in person evaluations 14.
Data collection of pregnant women
When consensus regarding the threshold was reached, the Expect prediction tool was 
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implemented. Participants, pregnant women, were enrolled in a multicenter prospective 
cohort study in the Southeastern part of The Netherlands from April 2017 to August 2018 
(Expect Study II). A more detailed description of the study design has been published 
elsewhere 14. Briefly, women were recruited at their first prenatal visit (<16 weeks of 
pregnancy) if their healthcare professional used the Expect prediction tool. In Dutch 
obstetric care, pregnant women visit either an autonomous midwife (outpatient clinic) or 
a gynecologist (hospital), both midwives and gynecologists recruited women for the Expect 
Study. 
Women of at least 18 years with a singleton pregnancy were eligible for inclusion. 
Questionnaires and study information were provided in Dutch only. Eligible women were 
asked whether they agreed to provide their e-mail address in order to receive information 
regarding the Expect Study. When women agreed to participate and completed an online 
informed consent form, they received a personal link by e-mail to the web-based surveys. 
The first survey, collecting the data used for the analyses in this study, was disseminated 
at enrolment. Two automatic reminders were sent using 3-day intervals. Women were 
contacted by phone if no response was received. The survey embedded questions regarding 
the healthcare services women received from their midwife or gynecologist during the first 
visits. Women were specifically questioned whether their PE risk was discussed with them 
(yes, I have an increased risk/ yes, I have an average risk/ yes, I have a low risk/ no, it was 
not discussed/ I do not recall whether this was discussed). Furthermore, women were asked 
whether the option of LDA was discussed with them (yes/ no/ I do not recall). 
Statistical analysis
We cross-tabulated the proportions of women whom reported to have discussed their 
PE risk and the option of LDA with respect to the predicted PE risk (low risk / increased 
risk). Furthermore, we plotted these proportions with respect to the predicted PE risk by 
categorizing PE risk predictions (≤1.0% to >6.0% using a binwidth of 0.5 percentage points). 
To analyze possible differences in healthcare professionals’ adherence rates to the risk-
based recommendations, we plotted LDA discussion rates reported by women using the 
study duration as a continuous variable. A nonparametric local weighted regression (loess 
regression) was applied to fit the curves. We analyzed the correlation between the discussion 
rates and the predicted PE risk for women with a risk exceeding 3.0% by use of logistic 
regression with predicted PE risk as an independent variable (continuous, percentage). 
All statistical analyses were performed using R statistical software version 3.6.0 along with 
the packages “foreign”, “dplyr”, “tidyr”,, and “ggplot2” 17.
Ethical approval and funding
The Medical Ethical Committee of the Maastricht University Medical Centre evaluated the 
study protocol and declared that the Expect Study does not fall under the Medical Research 
Involving Human Subjects Act (METC-17-4-057). All participants gave informed consent.
Financial support for this study was provided entirely by a grant from ZonMw (The 
Netherlands Organization for Health Research and Development; federal funding). The 
funding agreement ensured the authors’ independence in designing the study, interpreting 
the data, writing, and publishing the report. 
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Results
The survey regarding the risk-threshold preference was sent to 136 healthcare professionals. 
(53 midwives, 32 gynecologists, and 51 residents). In total, 43 (32%) healthcare professionals 
completed the questions regarding the PE risk-threshold. Response rates per type of 
healthcare professional were similar: midwives 30% (n=16), gynecologists 31% (n=10), and 
residents 33% (n=17). The boxplots, displayed in Figure 5.1, indicate that none of the risk-
thresholds were clearly rejected, but that there was no evident preference for a certain 
risk-threshold either.
Figure 5.1 Boxplots of preferences of healthcare professionals for given risk-thresholds. 
Likert scale: 1 totally disagree – 10 fully agree; Se, sensitivity; Sp, specificity; ACOG, the 
American College of Obstetricians and Gynecologists; RR, relative risk; NICE, the National 
Institute for Health and Clinical Excellence
During the regional discussions healthcare professionals unanimously stressed that they 
preferred a prediction tool suitable for shared decision-making. In their opinion, in the case 
of predicted risk exceeding the chosen cut-off value, the first step should be discussing the 
LDA recommendation with the pregnant woman. Furthermore, the prediction tool should 
provide relevant information and insight for both healthcare professional and pregnant 
woman regarding the predicted risk. When these conditions are met, using the prediction 
tool as a first step to start the discussion regarding LDA prophylaxis, a threshold with a high 
sensitivity (high detection rate) was preferred over one with a high specificity (low false 
positive rate). However, regardless of the detection rate, specificity should be kept at an 
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acceptable level. 
The majority preferred either a threshold of 2.85% or 3.90%. At the same time, healthcare 
professionals strongly in favor of 5.20% threshold did not agree with 2.85%. It was felt 
that the number of test positives should not exceed roughly a third of the population. On 
the other hand, healthcare professionals in favor of the 2.85% threshold stressed that at 
least everyone with an increased risk should be counselled. The observed incidence rate in 
external validation study was 2.9% 8. Thus, it was decided that every woman with a PE risk 
above the population average should be informed regarding the option of LDA.
During the final LOC meeting, taking all considerations into account, it was decided to that 
a threshold should be employed and that LDA treatment was to be discussed with the 
pregnant woman if estimated PE risk was greater than 3.0%. In the external validation study, 
this threshold corresponded with a sensitivity and specificity of 75% and 64%, respectively 8. 
To facilitate the shared decisional approach, the results of the prediction were visualized at 
a linear scale and provided together with relevant patient brochures.
Table 5.1 Baseline characteristics of the Expect II study cohort (data expressed as mean +/- standard deviation, 
median (interquartile range), or n (%)
Characteristics Expect II cohort n=850
Age, years 30.7 +/- 4.0
University, or higher vocational education, n (%) 500 (58.8)
Body mass index, kg/m2 24.8 +/- 4.8
Smoking during pregnancy, n (%) 38 (4.5)
History of chronic hypertension, n (%) 17 (2.0)
Family history of pre-eclampsia 
(biological mother), n (%)
42 (4.9)
Nulliparous, n (%) 415 (48.8)
Spontaneous conception, n (%) 772 (90.8)
History of pre-eclampsia, n (%) 50 (5.9)
Estimated pre-eclampsia risk percentage, median 
(interquartile range)
2.7 (1.1-4.3)
Estimated pre-eclampsia risk >3.0%, n (%) 364 (42.8)
In total 866 women provided informed consent, of these 850 (98%) completed the 
questionnaire at enrolment. Table 5.1 shows the characteristics of the women at 
enrolment of the Expect Study II, a flow-chart of study enrolment is provided in Figure 5.2, 
supplementary Figure S5.1 shows the distribution of predicted PE risks of this population. 
Table 5.2 shows the results of the answers regarding the questions whether PE risk prediction 
and LDA treatment were discussed during the prenatal visits. A total of 522 women (61%) 
stated that the results of their estimated PE risk were discussed during the antenatal visits. 
Estimated risks were not discussed with 265 women (31%), and 63 women (7%) could not 
recall whether it was discussed.
Table 5.2 Reported rates of discussing pre-eclampsia risk and low-dose aspirin prophylaxis
Low pre-eclampsia risk n (%) Increased pre-eclampsia risk n (%) All women n (%)
Total 486 (100.0) 364 (100.0) 850 (100.0)
Pre-eclampsia risk discussed
Yes 249 (51.2) 273 (75.0) 522 (61.4)
No 199 (40.9) 66 (18.1) 265 (31.2)
Uncertain 38 (7.8) 25 (6.9) 63 (7.4)
Low-dose aspirin discussed
Yes 71 (14.6) 294 (80.8) 365 (42.9)
No 400 (82.3) 63 (17.3) 463 (54.4)
Uncertain 15 (3.1) 7 (1.9) 22 (2.6)
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Figure 5.2 Flowchart participant enrollment Expect Study II
An estimated risk exceeding 3.0% was adopted as threshold for discussing LDA. In this 
subgroup of 364 women with an increased risk, PE risk and LDA prophylaxis were discussed 
with 273 (75%) and 294 (81%) women, respectively. Figure 5.3 shows the percentages of 
women who stated their healthcare professionals discussed the PE risk and LDA prophylaxis 
per risk category. This graph indicates a positive correlation between the predicted PE 
risk and discussion rates of both PE risk and LDA by healthcare professionals. For women 
identified with a risk exceeding 3.0%, predicted PE risk was a strong positive determinant 
of discussing PE risk (odds ratio per percent increase 1.34; 95%CI 1.18-1.56; p<0.01), and of 
discussing LDA prophylaxis (odds ratio per percent increase 1.28; 95%CI 1.18-1.40; p<0.01). 
Thus, healthcare professionals are significantly more likely to discuss both the predicted PE 
risk and LDA recommendation at increased PE risk estimates.
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Figure 5.3 Adherence rates of discussing pre-eclampsia risk and low-dose aspirin prophylaxis per estimated 
risk category
Figure 5.4 shows healthcare professionals’ adherence rate throughout the study period. 
Therefore, we plotted LDA discussion rates reported by women using the study duration as a 
continuous variable. At the start of our implementation study, adherence rates ranged from 
45 to 65% but eventually rose to approximately 85% and remained constant throughout the 
study period.
Figure 5.4 Adherence rates of discussing low-dose aspirin prophylaxis during the study period
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Discussion
Although, there is an enormous rise in models being published and an increasing amount 
is externally validated, only a few studies report the implementation of a prediction model 
18,19. To our knowledge, also reported by Kleinrouweler et al. 20, this is the first study to 
describe the implementation and usage of a prediction model predicting absolute risks for 
preventive strategies in daily obstetric practice.
Strengths and limitations
Before a prediction model can be used as a basis for clinical decision making, ideally, 
thresholds should be selected that indicate which risks are considered as an increased risk 
21,22. Although, the publication of prediction models increases rapidly, the amount of models 
applied in daily practice is still limited. As a result, most healthcare professionals may not be 
used to interpreting risk estimates. This may explain the low response rate and the lack of 
consensus in the survey regarding the threshold selection.
In this study, a three-step process was used in order to select suitable risk-thresholds. Reilly 
et al report the feelings of diminished autonomy by the healthcare professional as one of 
the potential barriers when applying a decision rule 21. In the final LOC meeting the shared 
decisional approach was strongly stressed which may have diminished this potential barrier. 
A strength of our study is its prospective multicenter design. Particularly in The Netherlands, 
recruitment in multiple centers is essential, because most pregnant women receive antenatal 
care at outpatient midwifery clinics 23. Furthermore, by using our prediction tool as an 
inclusion method, we were able to link the received healthcare services to the estimated 
risk profiles of pregnant women.
The Expect Study II focused on analyzing the impact and results of risk-based care. As a 
result, only women for whom the prediction tool was used were eligible for inclusion. Usage 
of our prediction tool as inclusion method enabled us to link the questionnaires completed 
by women to their individual PE risk prediction. The prediction tool was developed for usage 
in the general population and was promoted as such 14. Furthermore, all obstetric healthcare 
professionals of our region committed themselves to use the prediction tool. Nevertheless, 
this may have introduced some selection, since pro-active healthcare professionals may be 
over-represented among the professionals who use our prediction tool. The intensive usage 
of the prediction tool throughout the region and the multitude of collaborating centers 
diminishes the amount of selection.
Recommendation of LDA treatment should preferably be based on the PE risk prediction by 
using a shared decision-making approach. However, for most risk categories more women 
reported that they discussed LDA prophylaxis than that they discussed their PE risk. Thus, 
either their PE risk was not discussed or they did not recall the primary reason of discussing 
LDA prophylaxis. Our data do not allow analyzing possible reasons for this discrepancy. One 
possibility could be differences in women´s ability to recall both topics since aspirin is an easy, 
well-known word among non-professionals whereas pre-eclampsia is not. This hypothesis 
may be supported by the fact that the proportion of women not recalling whether their PE 
risk was discussed (7.4%) is greater than the proportion of women not recalling whether 
aspirin was discussed (2.6%). 
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Interpretation
Discussion of LDA treatment was reported by 81% of women with an elevated PE risk. 
Compared to previous studies in obstetrics regarding protocol and guideline adherence, this 
percentage is relatively high 10,12,13. Additionally, a significant correlation was found between 
discussing LDA prophylaxis and the predicted PE risk. LDA prophylaxis was discussed more 
frequently with women having higher PE risk estimates, these women potentially have the 
highest individual benefit from LDA treatment.
As can be observed in Figure 5.4, the adherence rates tended to increase during the study 
period. At the start of the implementation of our prediction tool along with the selected 
threshold, LDA recommendation was at best mediocre and comparable to adherence rates 
previously reported 13. However, roughly after nine months of implementation, adherence 
rates rose up to 85% and remained consistent during the study period. 
Recent research emphasized the potential benefit of LDA treatment in women at high risk 
of PE. The ASPRE trial, a randomized clinical trial towards the effect of LDA treatment in 
preventing pre-eclampsia, used a prediction model as well to identify the high-risk group 
19. Compared to the model used by the LOC, the ASPRE model has a similar sensitivity but 
outperforms in specificity. However, the ASPRE model does not solely rely on routinely 
available predictors and uses biochemical markers as well as the uterine-artery pulsatility 
index. The addition of these predictors mainly reduces the false positive rate 8. However, 
LDA prophylaxis from 12 weeks of gestation is inexpensive and does not result in adverse 
fetal effects, which reduces the disadvantages of a high false positive rate. As a result, it is 
arguable whether the costs associated with these additional predictors are proportional to 
their benefits 24.
Currently, there is no consensus about the best screening method for identifying women at 
risk of PE. The advantage of a prediction model over a list of risk factors is that it provides 
both the healthcare professional and the pregnant women with the insight of the absolute 
risk. Moreover, prediction models weigh several risk factors and their possible inter-
relations simultaneously allowing for a more personalized estimation of the absolute risk 
25. This information enables healthcare professionals to use a shared decisional approach. 
As a result, pregnant women have the opportunity to participate actively in the choices of 
additional healthcare services aimed at the prevention of PE.
Future research should focus on barriers that hampers the usage of a risk prediction tool by 
healthcare professionals. Moreover, reasons of non-adherence regarding recommendations 
provided by the prediction tool should be addressed. Additionally, more insight is needed 
about the shared decisional approach regarding the choice of LDA prophylaxis. The 
contradictory results between reporting rates whether PE risk was discussed and whether 
LDA prophylaxis was discussed (Figure 5.3), suggests that a substantial group of women may 
not correctly recall or understand the reasons of LDA prophylaxis. In that case, these women 
are unlikely to be able to make an informed choice.
Conclusion
Consensus regarding a suitable risk cut-off threshold to identify women at risk of PE was 
reached. Healthcare professionals agreed upon employing a tool with a high detection 
rate (cut-off: 3.0%, sensitivity 75%, specificity 64%) followed by shared decision between 
pregnant woman and healthcare professional on LDA prophylaxis. The adherence to this 
recommendation was 81%, indicating adequate implementation.
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Supplementary file 1
Model algorithm, discriminative performance, and predicted probabilities
Original study External 
validation study
Model algorithm after recalibration AUC (95% CI)
Syngelaki 2011 Meertens 2018 Lp = -5.773 + 0.075 (BMI, kg/m2) + 0.022 (age, years) + 
1.125 (if Afro-Caribbean) + 0.804 (if South Asian) + 0.526 (if 
East Asian) + 0.379 (if Mixed) + 0.289 (if ovulation drugs) + 
0.598 (if IVF) - 0.233 (if smoker) + 1.519 (if history of chronic 
hypertension) + 0.643 (if type 1 diabetes mellitus) - 0.332 
(if type 2 diabetes mellitus) - 1.329 (if parous, no history of 
pre-eclampsia) + 0.743 (if parous, history of pre-eclampsia) 
+ 0.580 (if woman’s mother had pre-eclampsia).
0.77 (0.72-0.81)9
AUC, area under the curve; CI, confidence interval; Lp, linear predictor; BMI, body mass index; IVF, in vitro 
fertilization
Figure S5.1 Density plot of predicted pre-eclampsia risks
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Abstract
Background
Low-dose aspirin (LDA) prophylaxis has been shown to reduce women’s pre-eclampsia risk. 
Evidence regarding LDA adherence rates of pregnant women is almost exclusively based on 
clinical trials, giving a potentially biased picture. Moreover, these studies do not report on 
determinants of adherence. Since 2017, obstetric healthcare professionals in a Dutch region 
assess women’s pre-eclampsia risk by means of a prediction tool and counsel those with an 
above population average risk on LDA as a prophylactic measure.
Objective
To assess the rates and determinants LDA usage among women with an increased pre-
eclampsia risk in daily practice. 
Methods
From 2017 to 2018, 865 women were recruited in multiple centers and prospectively 
followed using web-based surveys (Expect Study II). Results were compared to findings in 
a similar cohort from a care-as-usual setting lacking risk-based counseling (Expect Study I, 
n=2,614).
Results
In total, 306 women had a predicted increased pre-eclampsia risk. LDA usage was higher 
for women receiving risk-based care as compared to care-as-usual (29.4% vs. 1.5%, RR 19.1; 
95%CI 11.2-32.5). Daily LDA usage was positively correlated with both predicted risk and 
women’s concerns regarding pre-eclampsia. Most reported reasons for non- or incomplete 
use were unawareness of LDA as a preventive intervention, concerns of potential adverse 
effects, and doubts regarding the benefits.
Conclusion
Risk-based counseling was associated with a higher prevalence of LDA usage, but general 
usage rates were low. Future research regarding potential factors improving the usage of 
LDA during pregnancy is necessary.
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Introduction
Pre-eclampsia (PE) is an important cause of serious maternal and fetal complications. 
Despite improved management, curative options preserving the pregnancy remain absent. 
Preventive measures reducing the risk of PE are therefore an essential part of strategies 
aimed at decreasing the burden of PE 1.
Besides lifestyle interventions and adequate calcium intake, low-dose aspirin (LDA) 
treatment is currently one of the key interventions for the prevention of PE 2-4. Reduction 
of PE risk has been shown at aspirin dosages between 80 and 150 milligrams per day 5. The 
majority of publications on LDA with respect to PE focus on its effectiveness. They mainly 
differ regarding dosing, gestational window, or target group 2,5. Published LDA adherence 
rates are fairly high (66-90%), but mostly measured within clinical trials 2,6. It is unlikely that 
women who would not opt for LDA during their pregnancy would be willing to participate 
in a trial involving LDA usage. Thus, trial-based adherence rates may be seriously biased 
upwards. Relatively little is known regarding the daily LDL usage rates among pregnant 
women in daily practice 7.
Several obstetric authorities recommend LDA for women with an increased PE risk, including 
the American College of Obstetricians and Gynecologists (ACOG), the US Preventive Services 
Task Force, and the National Institute for Health and Clinical Excellence (NICE, United 
Kingdom) 8-10. Nevertheless, ‘increased risk of PE’ has been defined in different ways and no 
consensus has yet been achieved. Assessment of PE risk can be performed by using either 
unweighted or weighted combinations of multiple risk factors. The latter method (i.e., 
prediction models) has been shown to outperform the use of unweighted risk factors (i.e. 
NICE criteria) in terms of predictive ability 11,12.
Recently, healthcare professionals in the Southeastern part of the Netherlands implemented 
an externally validated prediction tool to assess, during the first trimester of pregnancy, the 
risk of developing PE 11,13,14. In case of an increased risk, the option of LDA prophylaxis is 
discussed using a shared-decisional approach. In such an approach, healthcare professionals 
share the best available evidence with the women in order to make an informed decision 
together 15. This observational study reports on LDA usage rates by women with an increased 
PE risk, as well as on determinants and reasons given for use and non-use.
Methods
Identifying women at increased risk of pre-eclampsia
In 2017, members of the Limburg Obstetric Consortium (located in the Southeastern part of 
the Netherlands) started to assess women’s PE risk during the first antenatal visits by means 
of a prediction tool. This tool embedded Syngelaki’s prediction model, externally validated 
and recalibrated by Meertens et al 11,16. This model is based on maternal characteristics (age, 
BMI, ethnicity, mode of conception, family history, medical history, and obstetric history) 
and was made available for all healthcare professionals of the region.
A detailed description of the content of risk-based care is reported elsewhere (van Montfort 
et. al, accepted, 13). In short, women with a PE risk exceeding the population average risk 
(>3.0%; sensitivity 75%, specificity 64%) should be counseled regarding the option of LDA-
prophylaxis (80-100 milligrams daily) in a shared-decisional approach. 
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Data collection
All women ≥18 years old with a singleton pregnancy were eligible for inclusion. Women 
were recruited from 2017 to 2018 at their first prenatal visit (<16 weeks of pregnancy), 
when their healthcare professional used the prediction tool. Women were recruited from 
multiple centers; five hospitals and 26 autonomous midwifery practices, all belonging to the 
geographical area of the LOC. 
Figure 6.1 Flowchart of participant enrollment of Expect Study II
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For the analyses in this paper, women with incomplete data regarding LDA usage, or a 
contraindication for LDA usage were excluded. A detailed study protocol has been published 
previously 13. Briefly, after providing informed consent, the results of the risk assessment 
were automatically logged. Enrolled women received four online surveys at intervals (at 
enrolment, at 24 weeks of pregnancy, at 34 weeks of pregnancy, and 6 weeks after the due 
date). In case of preterm birth, women were automatically redirected to the postpartum 
questionnaire when completing the questionnaire sent at 24 or 34 weeks of pregnancy. In 
addition, medical records and discharge letters were retrieved.
The first survey contained questions related to the first antenatal visits. Women were 
asked whether they were informed regarding LDA and whether they intended to use LDA. 
Additionally, women were questioned how often they worried about complications related 
to PE, such as PE itself, small-for-gestational-age (SGA) infancy, and preterm birth (PTB). 
They could choose from the options not at all, sometimes, regularly, and often. Answers 
were transformed to a four-point scale (0, not at all; 1, sometimes; 2, regularly; 3, often). 
The postpartum survey included questions related to LDA usage throughout the pregnancy. 
Women who stated to have used LDA received additional questions regarding the gestational 
window of LDA usage and whether they took it daily. Women stating they did not use LDA 
received additional questions with respect to their most decisive reason of non-use. Women 
were able to choose out of predefined options, but were also able to provide a different 
reason and leave additional remarks.
Statistical analysis
Usage of LDA was analyzed with respect to women’s estimated PE risk. Any LDA usage was 
defined as LDA usage regardless of the numbers of pills taken, duration, or frequency. Per 
protocol LDA usage was defined as the usage as described in the risk-based care pathways: 
daily LDA usage from <16+0 weeks of gestation up to 36 weeks of gestation or, in case of 
preterm birth, up to one week before birth. We cross tabulated the proportions of women 
whom reported to have discussed the option of LDA, any LDA usage, and per protocol LDA 
usage with respect to the estimated PE risk (low risk/ increased risk). 
Data of the Expect Study I (n = 2,614), a similar multicenter prospective cohort study 
conducted in the same region from 2013 to 2015, were used to represent the care-as-usual 
approach lacking risk-based recommendations 11,17. For Expect Study I, a paper and pencil 
questionnaire was available on request. However, the vast majority of women completed the 
web-based version of the questionnaires. The data contained information on usage of LDA, 
but not whether LDA was used in accordance with the risk-based care recommendations. As 
a result, only the proportions of any LDA usage could be compared between risk-based care 
and former care-as-usual. 
Proportions of any LDA usage by women who received care-as-usual and women who 
received risk-based care were plotted using the estimated risk as a continuous variable. A 
nonparametric local weighted regression (loess regression) was applied to fit the curves 18.
For analysis of determinants correlated with per protocol LDA usage, a multiple logistic 
regression was performed. This analysis was restricted to women with an increased risk 
whom were informed by their healthcare professional regarding LDA, since only these 
women are able to make an informed decision. Factors taken into account were estimated 
PE risk (continuous); reported educational level (tertiary yes/ no); concerns regarding 
developing PE (continuous); concerns regarding developing complications related to PE 
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(SGA, continuous; PTB, continuous); and type of healthcare professional responsible for LDA 
counseling (midwife/ gynecologist). For the continuous determinants, we verified whether 
assumptions of linearity were not violated using frequency plots. All statistical analyses 
were performed using R statistical software version 3.6.0 19.
Ethical approval
The Medical Ethical Committee of the Maastricht University Medical Centre evaluated both 
Expect Study protocols I and II and declared that both observational studies do not fall under 
the Medical Research Involving Human Subjects Act (METC-13-4-053 and METC-17-4-057, 
respectively). Online informed consent was obtained from all participants.
Results
Figure 6.1 displays a flowchart of study enrolment. Informed consent was provided by 865 
women. Of these, 30 women were excluded from the study cohort for various reasons. 
Additionally, 121 women were excluded from the current analysis because of either 
incomplete data (n=104), or a contraindication for LDA usage (n=17). In total 714 women 
were available for the analyses. Those excluded (n=121) were more likely to have a primary/ 
secondary educational level (57.7%) than those included (n=714) in the study (38.2%). 
Otherwise no differences in characteristics were observed for parity, body mass index, age, 
ethnicity, unassisted conception, and estimated PE risk (data not presented).
Table 6.1 Baseline characteristics of the Expect Study cohorts I and II
Baseline characteristics <16 weeks of gestation Expect Study I 
care-as-usual cohort 
(n=2,614)
Expect Study II 
risk-based care  cohort 
(n=714)
Age, years; mean +/- sd 30.2 +/- 3.9 30.8 +/- 4.0
Ethnicity
 Caucasian; n (%) 2533 (96.9) 698 (97.8)
 Other; n (%) 81 (3.1) 16 (2.2)
Educational level
 Primary or secondary; n (%) 1194 (45.7) 273 (38.2)
 Tertiary level of education; n (%) 1420 (54.3) 441 (61.8)
Body mass index, kg/m2; mean +/- sd 24.2 +/- 4.3 24.8 +/- 4.6
Smoking during pregnancy
 Yes 319 (12.2) 32 (4.5)
 No 2137 (81.8) 682 (95.5)
Chronic hypertension 28 (1.1) 16 (2.2)
Conception
 Natural; n (%) 2440 (93.3) 644 (90.2)
 Ovulation induction; n (%) 93 (3.6) 35 (4.9)
 In vitro fertilization; n (%) 81 (3.1) 35 (4.9)
Obstetric history
 Nulliparous; n (%) 1326 (50.7) 360 (50.4)
 Prior PE; n (%) 72 (2.8) 38 (5.3)
 No prior PE; n (%) 1216 (46.5) 316 (44.3)
Family history of PE; n (%) 131 (5.0) 36 (5.0)
Counselling of PE risk
 by midwife; n (%) NA 523 (73.2)
 by obstetrician; n (%) NA 191 (26.8)
Estimated PE risk %; median (IQR) 2.5 (1.0-3.6) 2.7 (1.1-4.2)
Increased PE risk; n (%) 974 (37.2) 306 (42.9)
 Estimated PE risk % for women identified 
 with an increased risk; median (IQR)
4.2 (3.4-5.8) 4.7 (3.6-6.8)
PE, pre-eclampsia; sd, standard deviation; IQR, interquartile range; NA, not available
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An overview of baseline characteristics for women enrolled in Expect Study I or II (women 
received care-as-usual and risk-based care respectively) is given in Table 6.1. At baseline, 
the characteristics of women enrolled for both studies do not substantially differ. However, 
for Expect Study II relatively more women had a history of PE. As a result the percentage of 
women identified with an increased PE risk was slightly higher (37.2% vs. 42.9%).
Recommendations of aspirin usage
According to the recommendations of the regional consortium, in risk-based care, women 
identified with an increased PE risk (risk >3.0%) should be informed regarding LDA usage 
for the prevention of PE. A large majority of the women (79%, n = 241) reported having 
discussed LDA with their healthcare provider, indicating a high, but not optimal, adherence 
rate to regional recommendations by healthcare professionals. Of these women, 94 (39%) 
intended to use LDA throughout the pregnancy of which 52 eventually used LDA according 
to protocol resulting in a per protocol usage rate of 22% (Figure 6.2).
Low-dose aspirin usage rates
Postpartum, of all enrolled women 113 (15.8%) reported having used LDA during their 
pregnancy and 87 (12.2%) used it according to protocol (Table 6.2). Among women with an 
increased PE risk (>3%), this results in an average usage rate of 29.4% and a per protocol 
usage rate of 24.8%. Furthermore, a small amount of women (n= 11), used LDA throughout 
the pregnancy despite not being identified with an increased PE risk.
Table 6.2 Proportions of counseling and usage of low-dose aspirin in relation to predicted pre-eclampsia risk
All women (n=714) PE risk ≤3% (n=408) PE risk >3% (n=306)
Total 714 (100) 408 (100) 306 (100)
Aspirin prophylaxis discussed
 Yes 295 (41.3) 54 (13.2) 241 (78.8)
 No 419 (58.7) 354 (86.8) 65 (21.2)
 Uncertain 19 (2.7) 13 (3.2) 6 (2.0)
Aspirin used
 Yes 113 (15.8) 23 (5.6) 90 (29.4)
    According to protocol 87 (12.2) 11 (2.7) 76 (24.8)
 No 601 (84.2) 385 (94.4) 216 (70.6)
PE, pre-eclampsia
The majority of women who started using LDA during their pregnancy in risk-based care, 
used it according to protocol. Of the 26 women who used LDA, but not according to protocol, 
three stopped due to complaints they attributed to LDA (diarrhea n=1, nose bleeding n=2). 
Two women reported they forgot to continue the LDA prophylaxis, and eleven women 
ended LDA usage at the beginning of their third trimester. Additionally, we could not asses 
per protocol usage for nine women who did not recall the date they stopped using LDA.
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For the care-as-usual approach (Expect Study I, 2013-2015), LDA usage was nearly non-
existent with only 23 out of 2,614 women reporting to have used LDA (0.9%). We 
retrospectively calculated the PE risk of these women, resulting in 974 women being 
classified with an increased PE risk of which 15 (1.5%) used LDA. In risk-based care, women 
with an increased PE risk estimation were more likely to use LDA (odds ratio 19.1; 95%CI 
11.2-32.5). This disparity even rises for higher PE risk estimations.
Supplementary figure S6.1 provides an overview of the distribution of observed PE risk 
estimates. Figure 6.3 displays the proportions of any LDA usage by estimated PE risk for both 
risk-based care and the care-as-usual approach. We limited the graph to PE risk estimates 
of ≤15%, which comprises 99% of the observations. Furthermore, per protocol LDA usage 
rates are also shown for the for the risk-based care cohort. This graph indicates a positive 
correlation between estimated PE risk and LDA usage in women receiving risk-based care.
Figure 6.3 Estimated pre-eclampsia risks and low-dose aspirin usage rates by women receiving care-as-usual 
or risk-based care
Determinants of low-dose aspirin usage
The type of healthcare professional (midwife or obstetrician) informing women about LDA, 
was significantly correlated with per protocol LDA usage (odds ratio 2.34, indicating higher 
usage under obstetric-gynecological care; 95%CI 1.32-4.18). However, this association was 
no longer apparent when correcting for the estimated PE risk (adjusted odds ratio 1.32; 
95%CI 0.66-2.60). In the adjusted analysis, Table 6.3, only the degree of women’s concerns 
regarding a pregnancy complicated by PE was statistically significantly associated with per 
protocol LDA usage when controlling for the estimated PE-risk (adjusted odds ratio 1.99; 
95%CI 1.35-2.98).
106  
Chapter 6
Table 6.3 Multiple logistic regression of potential determinants of per protocol low-dose aspirin usage among 
women with an increased risk with whom aspirin usage was discussed
Determinant
No. of participants No. with per protocol 
aspirin usage 
n (%; 95%CI)
Unadjusted odds 
ratio (95% CI)
Adjusted odds ratio* 
(95% CI)
All 241 71 (29; 24-36) - -
Estimated PE risk 1.23 (1.14-1.35) 1.18 (1.09-1.30)
Educational level
 Primary or secondary 106 30 (28; 21-38) 1 [Reference] 1 [Reference]
 Tertiary 135 41 (30; 23-39) 1.10 (0.63-1.94) 1.36 (0.72-2.62)
Concerns regarding PE 2.23 (1.64-3.09) 1.99 (1.35-2.98)
Concerns regarding SGA 1.20 (0.87-1.66) 0.98 (0.65-1.46)
Concerns regarding PTB 1.31 (0.97-1.77) 0.79 (0.52-1.19)
Counselling of PE risk
 by midwife 162 38 (23; 18-31) 1 [Reference] 1 [Reference]
 by obstetrician 79 33 (42; 32-53) 2.34 (1.32-4.18) 1.32 (0.66-2.60)
*Odds ratios adjusted for variables listed in left column. PE, pre-eclampsia; SGA, small-for-gestational-age infan-
cy; PTB, preterm birth; CI, confidence interval
Using a semi-qualitative approach, we analyzed women’s reasons for not using LDA during 
the pregnancy. A list of mentioned reasons for not using LDA and their frequencies is shown 
in Table 6.4. Surprisingly, despite having an increased PE-risk, 92 out of 216 women (43%) 
reported that they believed that the LDA recommendations were not applicable to their 
situation. This proportion was similar in subgroups with higher PE risk estimates. This 
questions whether these women received and understood the information regarding LDA 
usage. Indeed, 39 of these 92 women reported during the first survey that they were not 
informed regarding LDA.
Other frequently mentioned reasons for not using LDA were that women felt that either 
the potential benefit of LDA was too low (n=64; 30%), or that they did not want to use 
(preventive) medication during their pregnancy (n=27; 13%). In the remarks section, 
concerns regarding potential adverse effects of LDA and medicalization of the pregnancy 
were frequently expressed as important reasons for not using LDA. Interestingly, these 
proportions were not much different among women with high PE risk estimates, or among 
women with a history of PE.
Table 6.4 Reported reasons for not using low-dose aspirin during pregnancy
Specified reason PE risk >3% n (%) PE risk >5% n (%)
It was not applicable to my situation 92 (43.2) 27 (39.1)
It was not recommended by my healthcare professional 14 (6.6) 6 (8.7)
The potential benefit is too low for my situation 64 (30) 17 (24.6)
Because aspirin is a drug 27 (12.7) 8 (11.6)
No clear reason (e.g. forgotten) 8 (3.8) 5 (7.2)
Miscellaneous 5 (2.3) 3 (4.3)
Unknown 6 (2.8) 3 (4.3)
Total 216 (100) 69 (100)
PE, pre-eclampsia
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Discussion
Main results
Our prediction tool identified 306 women (43%) with an increased PE risk. The majority of 
these women (n=241; 79%) reported that their healthcare professional discussed the option 
of LDA prophylaxis with them, suggesting adequate adherence of healthcare professionals 
to the risk-based care recommendations. Usage rates of LDA increased as compared to 
care-as-usual (29.4% vs. 1.5%, RR 19.1; 95%CI 11.2-32.5). Daily aspirin usage was positively 
correlated with both predicted risk and the degree of women’s concerns regarding PE. 
Most reported reasons for non- or incomplete use were unawareness of LDA as preventive 
intervention, concerns of potential adverse effects, and doubts regarding the benefits.
Strengths and limitations
This is a large observational study to investigate LDA usage rates by women with an increased 
PE risk, as well as on determinants and reasons given for use and non-use. Another strength 
is the multicenter study design. Combined with the broad inclusion criteria this should have 
ensured an unselected population as possible. Nevertheless, women of Caucasian origin 
in our cohort are overrepresented and the majority of women are well educated. Since 
impaired health literacy is correlated with nonadherence 20, usage rates in our study may be 
somewhat overestimated.
A potential limitation in this paper is that LDA usage was based upon self-report. We were 
unable to reliably verify LDA usage with medical records or pharmacy registries because LDA 
is available over-the-counter in the Netherlands. However, there is no clear gold standard 
available to assess medication use in large-scale studies 21. It could be possible women 
answered in a socially acceptable manner resulting in an overestimation of the usage rate 
22. On the other hand, in risk-dependent care, counselling of LDA had the form of a shared 
decisional process. Usage of medication during pregnancy is not generally perceived as 
‘good’ or ‘bad’ since women are aware medication may cause adverse effects, but could 
be beneficial for their health as well 20,23. Moreover, women were informed that survey 
results would be processed anonymously and would not be shared with their healthcare 
professional. The researchers who distributed the web-based surveys were not involved 
in the care of participants. Therefore, the potential overestimation with respect to the 
adherence rate due to self-report is probably limited. 
Besides socially acceptable answers, self-report of medication usage is also prone to recall 
biases. However, women reporting non-usage are likely to be telling the truth 22. Furthermore, 
underreporting for pregnancy-related medications as well as medication prescribed for a 
longer period is limited in prospective studies 24.
Interpretation
Women’s adherence regarding medication during pregnancy has been studied for several 
drugs, such as anti-diabetics, medicines for chronic airway conditions, or anti-inflammatory 
drugs, with varying adherence rates from 40% to 80% 20,23. However, these drugs are 
prescribed because of an apparent (chronic) medical condition such as diabetes, asthma, 
or inflammatory bowel disease. Therefore, these situations likely differ compared to LDA, 
which is recommended to prevent pre-eclampsia. Most women with an increased PE risk do 
not have any medical complaints warranting LDA usage, which probably leads to different 
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risk-benefit evaluations. 
Studies of pregnant women’s adherence regarding LDA in particular are limited and mostly 
result from clinical trials 2,6. These trials indicate high adherence rates (66-90%). However, 
trial-based adherence rates may be seriously biased upwards, as women who do not want 
to use any drugs (i.e. LDA), are unlikely to be willing to participate in such a trial. We found 
one observational study indicating a lower adherence rate (54%) as well, but within a small 
cohort (n = 42) and restricted to women with high-risk pregnancies 7. Another observational 
study, conducted among high-risk women in Iran, did not provide absolute adherence rates 
25. Compared to these reports, the rate of LDA usage of 25% in our cohort is low, but is 
probably a more realistic estimation of LDA usage in daily practice. 
Most guidelines recommend LDA prophylaxis to women with an increased PE risk, but there 
is no consensus yet as how to identify women with an increased PE risk 8,9,26. In our study, 
an externally validated prediction model was used to estimate women’s PE risk during the 
first antenatal visits. Since the risk assessment was used as starting point of the shared 
decisional process regarding LDA usage, a risk threshold with a relatively high detection rate 
was used (van Montfort et al., accepted). As a result, women identified with an increased 
PE risk in our study may have had a lower PE risk on average as compared to other studies. 
This may have attributed to the lower usage rate. Furthermore, LDA-usage was strongly 
correlated with the predicted PE risk resulting in high usage rates among women with the 
highest risks, similar to the rates previously reported. 
Despite the lower usage rates in general, LDA usage still improved strongly with an absolute 
increase of 27.9%. However, during enrollment of the care-as-usual cohort (2013 to 2015) 
there was no uniform Dutch guideline recommending LDA prophylaxis. Although, many 
obstetric healthcare professionals were familiar with the NICE guideline for hypertensive 
disorders 26, especially gynecologists, LDA recommendation depended mainly on the intention 
of individual healthcare professionals. As a result, the increase of LDA usage may mainly 
reflect adequate implementation of risk-based-care and uptake of its recommendations by 
healthcare professionals. 
To the best of our knowledge, no studies have yet reported on determinants of LDA usage 
as well as women’s reasons for non-usage of LDA in particular. In the unadjusted analysis, 
the LDA usage rate was associated with the type of healthcare professional responsible 
for LDA counselling. However, low-risk women remain primarily under the supervision of 
autonomous midwives in the Dutch maternity care system. As a result, women’s risk should 
be taken into account. Indeed, when correcting for PE risk at baseline, this effect was no 
longer apparent. The degree of concern about possible complications related to PE (SGA 
infancy and PTB) were not significantly linked to the usage rate in the adjusted analysis. 
However, women may be unaware that PE may result into SGA infancy or (iatrogenic) PTB. 
The adjusted analysis also indicates that both the estimated PE risk as well as the level of 
concern regarding PE are positively correlated with LDA usage. This is in line with previous 
research, which suggests that women’s beliefs about medication and its effectiveness are 
a crucial factor in determining their adherence 20,23. This also fits with our finding that most 
frequent reasons of non-use were concerns regarding potential adverse effects of LDA and 
doubts regarding the potential benefits resulting from LDA prophylaxis. Moreover, the 
finding that most women who started using LDA, used it according to protocol suggests 
those women were conscious about their choice. 
Informing women about the low prevalence of effects of LDA, which are also mild, 27-29 may 
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be a central factor to improve adherence rates. Furthermore, a substantial proportion of 
women stating that LDA was not applicable to their situation reported LDA had not been 
discussed with them. Our data do not allow distinguishing whether LDA was not discussed 
by the healthcare professional, or whether these women could not recall that LDA was 
discussed. Clear communication of PE risk and adequate counselling regarding potential 
benefits and harms of LDA may positively influence women’s decision regarding LDA usage 
during pregnancy. Future qualitative research, for example with the aid of focus groups 
among both healthcare professionals as well as pregnant women, may improve our insight 
and understanding regarding the key elements at play in the decisional process regarding 
preventive LDA usage. 
Conclusion
Implementation of risk-based care improved LDA usage by pregnant women with an 
increased PE risk, especially among high-risk women. Nevertheless, general usage rates 
were relatively low. To improve LDA usage rates, more insight in this decisional process 
is necessary, which underlines the importance of future (qualitative) research regarding 
preventive LDA usage by pregnant women. 
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Abstract
Background
Obstetric healthcare relies on an adequate antepartum risk selection. Most guidelines used 
for risk stratification, however, do not assess absolute risks. In 2017, a prediction tool was 
implemented in a Dutch region. This tool combines first trimester prediction models with 
obstetric care paths tailored to the individual risk profile, enabling risk-based care (RBC). 
Objective
To assess impact and cost-effectiveness of RBC compared to care-as-usual (CAU) in a general 
population. 
Methods
A before-after study was conducted using two multicenter prospective cohorts. The first 
cohort (2013-2015) received CAU, the second cohort (2017-2018) received RBC. Health 
outcomes were 1) a composite of adverse perinatal outcomes and 2) maternal quality 
adjusted life years (QALYs). Costs were estimated using a healthcare perspective from 
conception to six weeks after the due date. Mean costs per woman, cost differences between 
the two groups, as well as incremental cost effectiveness ratios were calculated. Sensitivity 
analyses were performed to evaluate the robustness of the findings.
Results
In total 3,425 women were included. In nulliparous women there was a significant reduction 
of perinatal adverse outcomes among the RBC group (aOR 0.56; 95%CI 0.32-0.94), but not 
in multiparous women. Mean costs per pregnant woman were significantly lower for RBC 
(mean difference -€2,766, 95%CI -€3,700 – -€1,825). No differences in maternal quality of 
life, adjusted for baseline health, were observed. 
Conclusion
In the Netherlands, RBC in nulliparous women was associated with improved perinatal 
outcomes as compared to CAU. Furthermore, RBC was cost-effective compared to CAU and 
resulted in lower healthcare costs.
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Introduction
In most developed countries, criteria lists are used to identify women with an increased risk 
of common adverse pregnancy outcomes (e.g. pre-eclampsia, gestational diabetes mellitus) 
1-4. In the Netherlands an obstetric indication checklist is used to allocate women to either 
primary care (autonomous midwives) or secondary care (obstetricians) 1. However, like 
many other guidelines 2-4, this list is composed of a collection of single risk factors. It does 
not assess an individual woman’s absolute risk and neither does it take a combination of 
factors into account. Moreover, this guideline does not describe the content of care, but 
merely indicates the recommended level of healthcare. 
Prediction models, weighing several risk factors simultaneously, improve risk assessment 
of pre-eclampsia (PE) and gestational diabetes mellitus (GDM) (Meertens et al, in press; 
5). If these models are combined with care paths adjusted to the risk profile, obstetric care 
may transform to a more individual, risk-based approach. The Expect Study was designed 
to improve risk assessment in pregnant women and to implement clinically beneficial 
prediction models in daily obstetric practice 6,7. A prediction tool was developed to facilitate 
implementation of risk-based care (RBC). This tool assesses women’s risks during the first 
trimester upon PE, (GDM), fetal growth deviation, and spontaneous preterm birth (sPTB). 
The results of the risk assessment were combined with care paths tailored to the individual 
risks 7. 
RBC comprises basic antenatal care for every woman and specific additional recommendations 
for women with an increased risk. Due to the different organizational model of RBC, healthcare 
resources are reallocated. Moreover, RBC is focused at early detection and prevention of 
pregnancy related complications, which could result in a reduction of complications. For 
example, in RBC, all women are recommended to assure an adequate calcium intake, which 
is correlated with a reduction of PE 8. Furthermore, in case of an increased PE risk, women 
are counseled regarding low-dose aspirin (van Montfort et al, submitted). Aspirin may 
improve perinatal outcomes since it is correlated with a reduction of PE, SGA infancy, and 
sPTB in women at risk of PE 9,11. Furthermore, screening and diagnosis of GDM improved in 
RBC (van Montfort et al, submitted), which is also correlated with a reduction of adverse 
perinatal outcomes 12,13. 
Although, studies developing or validating prediction models may result in potentially useful 
prediction models, clinical impact of a prediction tool in daily practice may vastly differ from 
the results suggested by these studies. This could be due to, for example, differences in 
application, or due to an interplay of both healthcare professionals’ and women’s adherence 
to the recommendations provided 14. 
This is one of the few studies implementing a prediction tool for obstetric care in daily 
clinical practice 15. The aim of this study was to investigate the impact of RBC as compared to 
care-as-usual (CAU) on perinatal health and its cost-effectiveness. A before after analysis has 
been performed by comparing perinatal outcomes and costs of two successive multicenter 
prospective cohorts.
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Methods
Recruitment and study design
To evaluate the impact of RBC we used a before-after design comprising two successive 
multiple prospective cohorts. Women enrolled in the validation study (Expect Study I, 2013-
2015) received CAU. A subgroup of these women received additional questions related to 
the cost-effectiveness outcomes. All women enrolled in the implementation study (Expect 
Study II, 2017-2018) received RBC. All women participating in Expect Study II received the 
cost questionnaires. 
A detailed study protocol for both cohorts has been published previously 6,7. In short, for 
both cohorts all women ≥18 years old, with their first prenatal visit before sixteen weeks of 
pregnancy, were eligible for inclusion. Due to the small number of twin pregnancies (n=4) in 
the cost-effectiveness cohort of Expect Study I, inclusion for Expect Study II was limited to 
singleton pregnancies. Furthermore, to assure that all participants received RBC enrollment 
for Expect Study II was effectuated via the prediction tool (i.e. recruitment was only possible 
if the prediction tool was used). All hospitals of the region and the majority of autonomous 
midwifery practices recruited women for both cohorts.
Data collection
Data collection was similar for both cohorts. Women received four online surveys: at 
enrolment (1), at 24 weeks of pregnancy (2), at 34 weeks of pregnancy (3), and 6 weeks after 
the due date (4). Additionally, medical records and letters of discharge were retrieved and 
entered into a predesigned datasheet. For Expect Study II data retrieved by the prediction 
tool were logged as well. 
Surveys two to four embedded the cost questionnaires. The recall periods in the cost 
questionnaires were approximately 24 weeks (conception – survey two), 10 weeks (survey 
two – survey three), and 12 weeks (survey three – postpartum survey). The questions 
covered every possible type of healthcare professional (e.g. general practitioner, midwife, 
and physiotherapist). A category ‘other’ was provided in case women felt their particular 
healthcare professional was not listed. Additional questions were asked to specify the type 
of contact (e.g. consult, phone call) along with corresponding frequencies. 
Questions related to perinatal outcomes were incorporated in the post-partum survey. 
In case of discrepancies with the medical record, we contacted corresponding healthcare 
professionals for final decision. With respect to maternal QALYs, the EQ-5D-3L questionnaire 
was embedded in each survey allowing four time points for the QALY calculation 16.
Risk-based care
The Limburg Obstetric Consortium (LOC), responsible for the maternity care in the 
Southeastern part of the Netherlands, developed healthcare paths. These paths describe the 
content of obstetric care in detail for all women (basic care) and additional recommendations 
for those with an increased risk. The exact content of these care paths is listed in the Expect 
Study II protocol 7 and is summarized in supplementary Figure S8.1.
To implement RBC, an online prediction tool was developed and made available for all 
healthcare professionals of the region. The algorithms of the prediction models are provided 
in supplementary Table S8.1. This tool assesses the risks of PE, GDM, sPTB, and small- 
and large-for-gestational-age (SGA and LGA) infancy. It embeds the prediction models of 
131  
Impact of risk-based obstetric care
8
Syngelaki and Van Leeuwen for the risk assessment of PE and GDM respectively, externally 
validated and recalibrated by our group 5. Risks of sPTB, SGA, and LGA were assessed with 
regional guidelines.
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Ethical approval
The Medical Ethical Committee of the Maastricht University Medical Centre declared that 
no ethical approval was necessary for Expect Study I and II (MEC-13-4-053 and MEC-17-4-
057, respectively). All participating women gave informed consent. 
Costs
Unit costs of healthcare resources were obtained from the Dutch manual for costing in health 
economic evaluations 17. In case unit costs were unavailable, they were retrieved from the 
Dutch Healthcare Authority Tariffs, or a recently published Dutch cost-effectiveness study 
in obstetrics 18,19. Costs of medication were retrieved from the Dutch Pharmacotherapeutic 
Register 20. Using the Dutch Consumer Price Index all costs were expressed in Euros (2017 
value) 21.
Perinatal health
To assess perinatal health, we prospectively defined a composite outcome 7. The composite 
outcome consists of at least one of the following situations: stillbirth or neonatal death 
within seven days after birth, asphyxia (Apgar score <7 after 5 minutes), admission to a 
neonatal intensive care unit (NICU) within 28 days after birth, birthweight <2.3 weight 
percentile, and birth before 32 completed weeks of pregnancy. Birthweight percentiles 
were calculated using Dutch reference curves, corrected for gestational age, parity, fetal 
sex, and ethnicity 22. Only the first survey (or, in case of RBC, data of the prediction tool) 
combined with either the postpartum survey or medical record were necessary to evaluate 
this outcome. For this reason, we used the data of all participants of both cohorts to assess 
the impact upon perinatal health.
Statistical analysis
The organization of maternity care (CAU vs. RBC) was used as independent variable in the 
logistic regression. To account for differences at baseline, we also performed a multiple 
logistic regression adjusting for: maternal baseline health utility (continuous), PE risk 
(continuous), GDM risk (continuous), obstetric history (nulliparous, multiparous with prior 
sPTB <34 weeks or with prior SGA infancy <10th percentile, multiparous without prior sPTB 
<34 weeks and without prior SGA infancy <10th percentile), level of healthcare received at 
recruitment (primary care vs. secondary care).
For the economic evaluation we used a healthcare perspective, comprising all healthcare 
services received by the woman or her child, over a time horizon of approximately eleven 
months (conception – six weeks after the due date). Women who did not complete any of 
the cost questionnaires (surveys 2-4), were excluded from the cost-effectiveness analysis. 
Missing data were imputed using stochastic regression imputation with predictive mean 
matching (average amount of missing data per variable was 5%) 23. We compared the 
observed cohort and the imputed cohort by comparing the distribution of imputed variables.
Two incremental cost-effectiveness ratios (ICERs) were calculated. The first ICER expresses 
the incremental costs per perinatal composite outcome prevented. Since the nature of 
the perinatal composite outcome is strongly correlated with neonatal admission, costs 
of neonatal admission are not taken into account for this ICER. For cost-effectiveness 
calculations, outcomes are usually coded so that the highest score represents the best 
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health outcome. Therefore, for this ICER, we converted the perinatal composite score: 1 
corresponds with non-occurrence and 0 with occurrence of the outcome. 
The second ICER expresses the incremental costs per incremental maternal Quality Adjusted 
Life Year (QALY). Health-related quality of life was evaluated by means of the standardized 
Euroqol EQ-5D-3L questionnaire using corresponding health utility scores based on the 
Dutch population 16,24. 
To determine the 95% confidence interval (CI), we applied non-parametric bootstrapping 
using 10,000 replications with replacement from the original data and calculated the 
mean costs, effects and ICERs. Confidence intervals were obtained by calculating the bias-
corrected and accelerated (BCa) bootstrap interval 25. Uncertainty regarding these results was 
visualized by plotting the cost-effectiveness plane and the cost-effectiveness acceptability 
curve. All statistical analyses were performed using R statistical software version 3.6.0 26.
Sensitivity analysis and subgroup analysis. 
To analyze the influence of parity and level of healthcare at recruitment on both costs 
and health outcomes, we performed a subgroup analysis for nulliparous and multiparous 
women, and for women recruited in primary care and women recruited in secondary care. 
For the first sensitivity analysis we used the Hoftiezer birthweight percentile curves. These 
new curves describe birthweight more accurately 27, but lack a 2.3rd percentile. Therefore, 
we used the 3rd percentile and adapted our perinatal composite for this analysis. 
To examine the influence of differences between healthcare professionals recruiting women 
for the two cohorts, we performed a sensitivity analysis with data restricted to women 
enrolled by obstetric centers that recruited women for both cohorts. 
To account for possible trends over time we applied a linear and a logistic regression to the 
CAU cohort for healthcare costs and the perinatal composite outcome, respectively. The 
duration of Expect Study I (days, continuous) was used as an independent variable while 
correcting for the same baseline characteristics as in our primary analysis.
Results
Data of 3,425 women were available for the analysis of the adverse perinatal outcome; 2590 
women received CAU and 835 received RBC. For the economic evaluation, data of 1,693 
women were available: 884 and 809 women receiving CAU and RBC, respectively. Figure 8.1 
provides a flowchart of the participant enrollment. Baseline characteristics of both cohorts, 
as well as the cost-effectiveness sub-cohorts are tabulated in Table 8.1. 
The cohorts did not substantially differ for the distributions of age, BMI, as well as the 
proportion of nulli- and multiparous women. The RBC cohort, however, contains a slightly 
larger proportion of women recruited in secondary care, compared to the CAU cohort. 
Additionally, women of the RBC cohort had a slightly lower health utility score at baseline, 
and relatively less often conceived naturally.
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Table 8.1 Baseline characteristics of Expect Study cohort I and II
Baseline characteristics <16+0 
weeks of gestation
CAU, 
all participants; 
n=2,590
CAU, available for 
cost-effectiveness 
analysis; n=884
RBC, 
all participants; 
n=835 
RBC, available for 
cost-effectiveness 
analysis; n=809 
Age, years; mean +/- sd 30.2 +/- 3.9 30.6 +/- 3.7 30.7 +/- 4.0 30.7 +/- 4.0
Ethnicity
 Caucasian; n (%) 2,509 (96.9) 872 (98.6) 817 (97.8) 791 (97.8)
 Other; n (%) 81 (3.1) 12 (1.4) 18 (2.2) 18 (2.2)
Educational level
 Primary or secondary; n (%) 1,183 (45.7) 339 (38.3) 337 (40.8) 324 (40.4)
 Tertiary level of education; n (%) 1,407 (54.3) 545 (61.7) 488 (59.2) 478 (59.6)
Body mass index, kg/m2; 
mean +/- sd
24.2 +/- 4.3 24.1 +/- 4.2 24.8 +/- 4.7 24.8 +/- 4.7
Smoking during pregnancy
 Yes 314 (12.1) 81 (9.2) 38 (4.6) 37 (4.6)
 No 2,276 (87.9) 803 (90.8) 797 (95.4) 772 (95.4)
Medical history
 Pre-existent hypertension 27 (1.0) 18 (2.0) 16 (1.9) 16 (2.0)
 Pre-existent diabetes mellitus 12 (0.5) 7 (0.8) 10 (1.2) 9 (1.1)
Health utility score; mean +/- sd 0.93 +/- 0.13 0.94 +/- 0.12 0.91 +/- 0.13 0.91 +/- 0.13
Conception
 Natural; n (%) 2,419 (93.4) 810 (91.6) 759 (90.9) 734 (90.7)
 Ovulation induction; n (%) 92 (3.6) 41 (4.6) 36 (4.3) 36 (4.4)
 In vitro fertilization; n (%) 79 (3.1) 33 (3.7) 40 (4.8) 39 (4.8)
Obstetric history
 Nulliparous; n (%) 1,315 (50.8) 448 (50.7) 421 (50.4) 409 (50.6)
 Multiparous; n (%) 1,275 (49.2) 436 (49.3) 414 (49.6) 400 (49.4)
  Prior PE; n (%) 72 (2.8) 31 (3.5) 50 (6.0) 48 (5.9)
  Prior GDM; n (%) 14 (0.5) 5 (0.6) 19 (2.3) 19 (2.3)
  Prior SGA; n (%) 110 (4.2) 42 (4.8) 44 (5.3) 43 (5.3)
  Prior LGA; n (%) 168 (6.5) 59 (6.7) 44 (5.3) 42 (5.2)
  Prior sPTB <34 weeks; n (%) 29 (1.1) 11 (1.2) 11 (1.3) 11 (1.4)
Risk assessment
 Increased PE risk; n (%) 965 (37.3) 349 (39.5) 359 (43.0) 350 (43.3)
 Increased GDM risk; n (%) 1,394 (53.8) 478 (54.1) 408 (48.9) 400 (49.4)
Recruited in
 Primary care (midwife); n (%) 2,113 (81.6) 680 (76.9) 616 (73.8) 593 (73.3)
 Secondary care (obstetrician); n (%) 477 (18.4) 204 (23.1) 219 (26.2) 216 (26.7)
CAU, care-as-usual; RBC, risk-based-care; sd, standard deviation; PE, pre-eclampsia; GDM, gestational diabetes 
mellitus; SGA, small-for-gestational-age infancy (<10th percentile); LGA, large-for-gestational-age infancy (>90th 
percentile); sPTB, spontaneous preterm birth; IQR, inter quartile range
Perinatal and maternal health outcomes
Table 8.2 displays the perinatal and maternal health outcomes. No statistically significant 
difference was observed regarding the adverse perinatal composite outcome between 
the RBC and CAU group (4.3% vs. 5.2% respectively). Taking differences at baseline into 
account, the adjusted odds ratio (aOR) was 0.76 (95%CI 0.51-1.11; Table 8.3). Subgroup 
analysis regarding parity, Table 8.4, revealed that for nulliparous women in RBC the risk of 
adverse perinatal outcomes was strongly and statistically significantly reduced (aOR 0.56; 
95%CI 0.32-0.94), while no meaningful association showed in multiparous women (aOR 
1.15; 95%CI 0.64-1.97). 
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Table 8.2 Health outcomes
Health outcomes CAU, 
all participants; 
n=2,590
CAU, available for 
cost-effectiveness 
analysis; n=884
RBC, 
all participants; 
n=835 
RBC, available for 
cost-effectiveness 
analysis; n=809 
Neonatal
Perinatal composite outcome 135 (5.2) 42 (4.8) 36 (4.3) 32 (4.0)
 Birth <32 weeks 26 (1.0) 7 (0.8) 11 (1.3) 8 (1.0)
 NICU admission 54 (2.1) 20 (2.3) 12 (1.4) 11 (1.4)
 Birth percentile <2.3 48 (1.9) 9 (1.0) 11 (1.3) 11 (1.4)
 APGAR <7 after 5 minutes 43 (1.7) 15 (1.7) 12 (1.4) 11 (1.4)
 Stillbirth or neonatal death <7 days 14 (0.5) 4 (0.5) 7 (0.8) 4 (0.5)
Maternal
Maternal QALYs - 0.89 +/- 0.11 0.87 +/- 0.12 0.87 +/- 0.12
 Health utility at baseline 0.93 +/- 0.13 0.94 +/- 0.12 0.91 +/- 0.13 0.91 +/- 0.13
 Health utility at 24 weeks - 0.85 +/- 0.17 - 0.84 +/- 0.16
 Health utility at 34 weeks - 0.81 +/- 0.18 - 0.79 +/- 0.18
 Health utility postpartum 0.94 +/- 0.12 0.94 +/- 0.12 0.91 +/- 0.14 0.91 +/- 0.14
Data expressed as n (%) or mean +/- standard deviation. CAU, care-as-usual; RBC, risk-based-care; NICU, neonatal 
intensive care unit; QALY, quality adjusted life year
Table 8.3 Analysis of perinatal composite score
No. of participants No. with perinatal 
composite outcome 
n (%; 95%CI)
Odds ratio (95% CI) P-value
All 3,425 171 (5.0; 4.3-5.8) - -
Unadjusted analysis
Risk-based-care
No (CAU) 2,590 135 (5.2; 4.4-6.1) 1 [Reference]
Yes (RBC) 835 36 (4.3; 3.1-5.9) 0.82 (0.55-1.18) 0.30
Adjusted analysis
Risk-based-care
No (CAU) 2,590 135 (5.2; 4.4-6.1) 1 [Reference]
Yes (RBC) 835 36 (4.3; 3.1-5.9) 0.76 (0.51-1.11) 0.17
Baseline health utility 0.99 (0.98-1.00) 0.09
Estimated PE risk 1.00 (0.95-1.04) 0.92
Estimated GDM risk 1.01 (0.98-1.03) 0.64
Obstetric history
Nulliparous 1,736 105 (6.0; 5.0-7.3) 1 [Reference]
Prior sPTB <34 weeks or SGA infancy 186 18 (9.7; 6.2-14.8) 1.50 (0.85-2.51) 0.14
No prior sPTB <34 weeks or SGA infancy 1503 48 (3.2; 2.4-4.2) 0.52 (0.36-0.74) 0.00
Recruited in
 Primary care (midwife) 2,729 120 (4.4; 3.7-5.2) 1 [Reference]
 Secondary care (obstetrician) 696 51 (7.3; 5.6-9.5) 1.61 (1.12-2.29) 0.01
CAU, care-as-usual; RBC, risk-based-care; PE, pre-eclampsia; GDM, gestational diabetes mellitus; 
sPTB, spontaneous preterm birth; SGA, small-for-gestational-age; CI, confidence interval
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Maternal health utility scores at enrolment were high in both groups and declined slightly 
during pregnancy (Figure 8.2). A small, but statistically significant difference in maternal 
QALYs was observed. However, the difference was largely attributable to a lower health 
utility at baseline in the RBC group and effectively disappeared after adjustment for baseline 
health utility (adjusted β = -0.002, 95%CI -0.008; 0.004, p=0.54) 28.
Figure 8.2 Health utility scores in care-as-usual and risk-based-care cohort. Area under curve represents the 
quality-adjusted-life-years
Costs and cost-effectiveness
Table 8.5 provides an overview of mean observed costs as well as the mean cost differences 
between RBC and CAU. Mean costs per pregnant woman were lower for RBC (mean 
difference -€2766; 95% BCa –€3703; –€1794). This difference was mainly driven by the 
difference in costs generated by maternal hospitalization and secondary care (healthcare 
services provided by obstetricians). With the exception of costs attributable to labour or 
alternative healthcare services, costs of all components were lower in RBC.
Results of bootstrapped data were plotted in a cost-effectiveness plane (Figure 8.4). Figure 
8.3 shows the cost-effectiveness acceptability curve. Regarding the perinatal composite 
outcome, the ICER indicates that RBC dominates CAU, as costs are lower and perinatal 
outcomes are better for RBC. Regarding maternal QALYs, the ICER point estimate was 
€170,390. Furthermore, 95% of the bootstrapped QALY ICERs are in the quadrant where 
RBC is less costly but also slightly less effective. The probability that RBC was cost-effective 
compared to CAU ranged from 97-100%, assuming an ICER ceiling ratio from €10,000-
€80,000 per QALY in accordance with the Dutch Health Insurance Board 29. 
The subgroup analysis with respect to parity, supplementary Table S8.2, showed a 
discrepancy between nulli- and multiparous women regarding the ICER of the perinatal 
composite outcome. In nulliparous women the ICER indicates that RBC dominates CAU for 
nulliparous women, as costs and perinatal outcomes are better for RBC. For multiparous 
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women, the ICER was €203,402, since most bootstrapped ICERS are in the quadrant where 
RBC is less costly but also slightly less effective (see Figure 8.5 and supplementary Table 
S8.3).
Table 8.5 Costs per pregnant woman
Costs° CAU; mean +/- sd RBC; mean +/- sd Mean difference* 
(CAU – RBC)
Total [95%CI]** 11,478 +/- 10,994 8,712 +/- 8,811 -2766 [-3700 – -1825]
Total, without neonatal 
admission [95%CI]**
8,969 +/- 8,687 6,562 +/- 7,290 -2406 [-3233 – -1719]
Primary care 835 +/- 481 813 +/- 459 -22
 Midwifery 579 +/- 320 578 +/- 325 -1
Secondary care 1,176 +/- 1,507 658 +/- 919 -517
 Gynecology 1,070 +/- 1,420 584 +/- 836 -486
Delivery 1,273 +/- 462 1,347 +/- 445 74
Hospitalization 2,828 +/- 5,447 1,468 +/- 2,980 -1360
Miscellaneous 746 +/- 435 562 +/- 333 -185
 Diagnostics 659 +/- 310 517 +/- 292 -142
 Medication 64 +/- 207 16 +/- 106 -48
 Alternative healthcare 23 +/- 70 28 +/- 79 5
Maternity care 2,135 +/- 1,128 2,008 +/- 629 -127
Neonatal care 2,486 +/- 7,214 1,856 +/- 7,344 -630
 Hospitalization 2,054 +/- 7,110 1,662 +/- 7,315 -392
CAU, care-as-usual; RBC, risk-based-care. All costs are expressed in 2017 Euro’s.
*Costs of CAU cohort (n) minus costs of RBC cohort (n)
**For the mean difference, confidence interval based on bias-corrected and accelerated (BCa) bootstrap interval.
°Supplementary Table S8.2 provides a full overview of unit costs used for the economic evaluation
Figure 8.3 Cost-effectiveness acceptability curve for the incremental costs gained from a healthcare perspective 
per incremental maternal QALY or per incremental adverse perinatal composite outcome. QALY, quality-adjusted 
lifer year. ICER, incremental cost-effectiveness ratio
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Figure 8.4 Cost-effectiveness density plane showing the incremental costs from a healthcare perspective 
(y-axis) and incremental effects (x-axis; maternal QALYs or prevented adverse perinatal composite outcome, 
top and bottom figure, respectively). Each data point represents one bootstrapped estimate of incremental 
costs and effects. QALY, quality-adjusted life year
Figure 8.5 Cost-effectiveness density plane showing the incremental costs from a healthcare perspective 
(y-axis) and incremental effects (x-axis; prevented adverse perinatal composite outcome) in nulliparous (A) 
and multiparous (B) subgroups. Each data point represents one bootstrapped estimate of incremental costs 
and effects
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Discussion
Main findings
For the population as a whole, the risk of an adverse perinatal outcome did not decrease 
statistically significant in RBC as compared to CAU. However, a statistically significant 
reduction of perinatal adverse outcomes was observed in nulliparous women (reduction: 
44%; 95%CI 6%-68%), whereas in multiparous women no clear difference was observed. 
A small difference in QALYs was observed between women receiving RBC and women 
receiving CAU. This difference in maternal QALYs was no longer apparent when adjusting for 
health utility at enrolment. Furthermore, RBC resulted in lower costs and the ICERs indicate 
RBC was cost-effective as compared to CAU. 
Strengths and limitations
Strengths of this study were its large sample size and its prospective, multicenter design. 
The use of multiple web-based surveys, a user-friendly method of data collection, provided 
high data quality by reducing potential recall biases and the numbers of missing data 30-32. 
Furthermore, the diversity of participating midwifery centers, as well as hospitals, combined 
with the broad inclusion criteria, results in a low probability of selection bias. Nevertheless, 
the majority of enrolled women have a tertiary level of education and are of Caucasian 
(native) origin, which may have resulted in generally healthy women with above average 
health literacy skills 33.
Next to our primary outcome (a perinatal composite score) we used maternal QALYs as a 
secondary outcome. Ideally, the QALY calculation would take both maternal and perinatal 
outcomes into account. Yet, combining QALYs is challenging and literature describing how 
to achieve this is limited 34,35. Furthermore, long-term outcomes should preferably be taken 
into account as well, but our study design only allowed for follow-up up to six weeks after 
the due date. 
To ensure women received RBC, inclusion of the RBC cohort was achieved by our prediction 
tool. The prediction tool was developed for usage in the general population and was 
promoted as such 7. All obstetric healthcare professionals of our region of interest committed 
themselves to provide RBC. Nevertheless, it could have been the case that for the RBC cohort 
women in particular were recruited by enthusiastic, above-averagely adherent healthcare 
professionals. On the other hand, the widespread use of our prediction tool, as well as 
the fact that most women receive obstetric care from multiple professionals during their 
pregnancy, minimize the possibility of this effect. Additionally, inclusion criteria for both 
cohorts were identical. Nevertheless, subtle differences are apparent at baseline between 
both cohorts. Per characteristic, differences were small, but together they yielded a less 
favorable risk profile among women in RBC as compared to CAU (e.g. lower health utility 
at baseline, a higher proportion recruited in secondary care, and a more often complicated 
obstetric history). 
Although we adjusted for prognostic important baseline characteristics, residual confounding 
remains possible. Residual confounding may still result in women having a more untoward 
risk profile in the RBC group compared to the CAU group. However, this would rather result 
in an underestimation than an overestimation of the positive effects correlated with RBC. 
Moreover, we performed a sensitivity-analysis restricted to data of women enrolled by 
obstetric centers that recruited women for both cohorts. This did not yield substantially 
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different results and neither did the subgroup analysis to level of care received by women at 
enrolment (primary/ secondary care). This reduces the likelihood that our results are solely 
attributable to a difference in involved healthcare professionals (supplementary Table 8.2).
In essence, our study design used to assess the impact of RBC compared to CAU, is a ‘before-
after-analysis’. Theoretically, despite both cohorts succeeding each other in a relatively 
short time-span (~1.5 years), outcomes may have been affected by external trends over 
time (e.g. reduction of neonatal deaths due to improved healthcare, or a reduction in 
healthcare expenditures). However, the analyses taking into account the study period were 
not suggestive of a decreasing trend regarding the adverse perinatal composite outcome 
during the CAU cohort (aOR 1.02 95%CI 0.98-1.05). Neither did we find an association 
between the study period and the costs (adjusted β -2.0, 95%CI -8.0; 4.0, p=0.51). Moreover, 
nationwide statistics of Dutch health expenditures per capita suggest an increase rather 
than a decrease over time 36. Therefore, we conclude that the cost reduction and improved 
perinatal outcomes in the RBC group are unlikely to be solely attributable to trends over 
time. 
Interpretation
This is one of the few studies implementing a prediction tool for obstetric care in daily clinical 
practice 15. To our knowledge, there are no other studies reporting an economic evaluation 
of obstetric care based on risk assessments provided by a prediction tool. 
We found no differences in maternal QALYs between women receiving RBC and women 
receiving CAU after adjusting for health utility at enrolment. Overall, the measured health 
utilities of both groups were high and close to the perfect health state of ‘1’. This could be due 
to the fact that both cohorts represent a general, young population, with low proportions of 
women suffering from complications.
Our study indicates RBC is associated with a considerable cost reduction without a negative 
impact on maternal QALYs and improved perinatal outcomes in nulliparous women. In 
observational studies, like ours, interpretation of possible causal relationships should be 
done with caution. Moreover, in RBC usage of several preventive measurements improved 
(e.g. low-dose aspirin usage, GDM screening, (van Montfort et.al, submitted)). All these 
factors may have attributed to the improved outcomes in nulliparous women. 
From a larger perspective, differences between RBC and CAU can be summarized by a 
different strategy assessing obstetric risks, combined with specific recommendations in case 
of an increased risk. Both the cost reduction as well as the improved perinatal outcomes 
may be attributable to the availability of clear instructions and standardizing care. Protocols, 
checklists, and triggers are known to improve health outcomes and efficiency 37-39. The 
prediction tool may merely have worked as a triggering system regardless whether the risk 
assessment and usage of preventive measurements actually improved.
We found a significant reduction of adverse perinatal outcomes in nulliparous women. 
Interestingly, we did not find a similar beneficial effect in multiparous women. We 
hypothesize that the differences between RBC and CAU primarily affect obstetric care 
of nulliparous women due to differences in risk assessment. Prediction models take into 
account the weighted risk of multiple factors and possible inter-relations between them, 
allowing for a more personalized estimation of the absolute risk. However, in multiparous 
women, irrespective of the method to assess risks, risk assessment is strongly influenced 
by the obstetric history. In case of a complicated obstetric history (e.g. prior PE, prior GDM, 
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prior sPTB) healthcare professionals and pregnant women are probably already aware of 
any increased risks and their corresponding recommendations. For nulliparous women, 
the risk assessment may be less straightforward, as less information is available. Therefore, 
the improved risk assessment in RBC may be more pronounced in nulliparous women. This 
could have resulted that nulliparous women who would not have been identified with an 
increased risk with CAU, were identified as such with RBC. As a result, these nulliparous 
women may have received additional recommendations and (preventive) interventions 
relatively more often in RBC. Furthermore, both healthcare professionals’ and pregnant 
women’s awareness towards clinical symptoms of possible complications may be improved 
for these nulliparous women. This would particularly explain the reduction of the perinatal 
adverse composite outcome in nulliparous women. 
Conclusion
RBC, as compared to CAU, resulted in a significant reduction of perinatal adverse outcomes 
in nulliparous women, but not in multiparous women. Apparently, in nulliparous women, 
transparent personalized risk estimations followed by tailored care may increase awareness 
amongst all involved. Moreover, RBC was cost-effective and resulted in lower costs without 
a negative impact on maternal health outcomes when adjusted for baseline health utility.
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Table S8.1 Algorithms of prediction models applied in risk-based care
Outcome Original 
study
External 
validation study
Model algorithm after recalibration AUC (95% CI)
Pre-eclamspia 
risk
Syngelaki 
2011
Meertens 2018 Lp = -5.773 + 0.075 (BMI, kg/m2) + 0.022 (age, 
years) + 1.125 (if Afro-Caribbean) + 0.804 (if South 
Asian) + 0.526 (if East Asian) + 0.379 (if Mixed) + 
0.289 (if ovulation drugs) + 0.598 (if IVF) - 0.233 (if 
smoker) + 1.519 (if history of chronic hypertension) 
+ 0.643 (if type 1 diabetes mellitus) - 0.332 (if type 
2 diabetes mellitus) - 1.329 (if parous, no history 
of pre-eclampsia) + 0.743 (if parous, history of 
pre-eclampsia) + 0.580 (if woman’s mother had 
pre-eclampsia)
0.77
(0.72-0.81)
Gestational 
diabetes 
mellitus risk
Van Leeuwen 
2010
Meertens 2018 
(in press)
Lp = -6.28 + 0.83 (if non-Caucasian ethnicity) + 0.57 
(if positive family history of DM ) – 0.67 (if multipara 
without history of GDM) + 0.5 (if multipara with 
history of GDM) + 0.13 (BMI, kg/m2)
0.74
(0.70 0.79) 
AUC, area under the curve; CI, confidence interval; Lp, linear predictor; BMI, body mass index; IVF, in vitro 
fertilization
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Supplementary Table S8.3 Unit costs of healthcare resources
Item Costs per unit (2017 €) Source
Primary care
Consultation (regular) 33.67 Dutch costing guideline 16
Consultation (out of hours) 79.02 Dutch Health Authority Tariff 17
Home visit (regular) 51.01 Dutch costing guideline 16
Home visit (out of hours) 118.52 Dutch Health Authority Tariff 17
Phone call (regular) 17.34 Dutch costing guideline 16
Phone call (out of hours) 25.34 Dutch costing guideline 16
Secondary care
Consultation (regular) 92.85 Dutch costing guideline 16
Consultation (out of hours) 264.25 Dutch costing guideline 16
Phone call 17.34 Dutch costing guideline 16
Maternity care
Intake 65.78 Dutch costing guideline 16
Maternity care (hour) 47.60 Dutch Health Authority Tariff 17
Diagnostics
Ultrasound (fetal dating) 44.37 Dutch Health Authority Tariff 17
Counselling of screening for fetal 
abnormalities
44.22 Dutch Health Authority Tariff 17
Ultrasound (fetal abnormalities screen) 167.17 Dutch Health Authority Tariff 17
Ultrasound (fetal biometry) 36.99 Dutch Health Authority Tariff 17
Oral glucose tolerance test 25.87 Van Leeuwen 40
Laboratory testing, high-risk cases of pre-
eclampsia°*
41.56 Dutch costing guideline, Dutch Health 
Authority Tariff 16,17
Laboratory testing, pre-eclampsia diagnosed* 83.12 Dutch costing guideline, Dutch Health 
Authority Tariff 16,17
Hospitalization
Maternal
General ward (day) 485.65 Dutch costing guideline 16
Intensive care (day) 2,055.87 Dutch costing guideline 16
Neonatal
General ward (day) 639.72 Dutch costing guideline 16
Neonatal intensive care unit (day) 1,664.30 Apostel I 18
Delivery
Home (vaginal, spontaneous) 536.76 Dutch Health Authority Tariff 17
Birthing center (vaginal, spontaneous) 1,093.57 Dutch Health Authority Tariff 17
Hospital (vaginal, spontaneous) 1,212,14 Dutch Health Authority Tariff 17
Hospital (vaginal, instrumental) 1,431.85 Apostel I 18
Hospital (cesarean) 2,137.69 Apostel I 18
Medication**
Tocolysis (treatment)* 55.33 Dutch Pharmacotherapeutic Register 19
Corticosteroids (treatment) 25.73 Dutch Pharmacotherapeutic Register 19
Magnesium sulfate (treatment) 16.01 Dutch Pharmacotherapeutic Register 19
°For baseline values for women receiving RBC with an estimated pre-eclampsia risk ≥ 5.1%
*The mean of several methods is presented
**Costs of miscellaneous medication (e.g. antibiotics, antimycotics, anti-hypertensive drugs, antidepressants, 
antiemetics) are not shown
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General discussion
Obstetric healthcare relies on an adequate antepartum risk selection. Risk selection 
in obstetric care is the process of quantifying and judging a woman’s risk of an adverse 
pregnancy outcome. The methods used to identify women at increased risk of adverse 
outcomes varies greatly among countries. The common aim of the Expect Study and the 
Limburg Obstetric Consortium is to improve obstetric healthcare. In order to achieve this 
goal, the Expect Study focused at improving the risk selection of pregnant women, whereas 
the consortium focused at standardizing obstetric care and the development of healthcare 
pathways tailored to individual risk assessments. By combining prediction models with the 
risk-based care (RBC) pathways, healthcare professionals became able to perform individual 
risk assessments and discuss risk-based recommendations using a shared-decisional 
approach.
The Expect Study consists of two parts: a validation study (Expect Study I); and an 
implementation and impact study (Expect Study II). The validation study evaluated external 
validity of models for the prediction of pre-eclampsia (PE) 1, gestational diabetes mellitus 
(GDM) (Meertens et al., in press), fetal growth deviations 2, and spontaneous preterm birth 
(sPTB) during the first trimester 3. To make implementation of any models feasible and suitable 
for the general population, the study was restricted to models using predictors that were 
non-invasive and easily obtained in Dutch obstetric practice (i.e. maternal characteristics, 
medical history). Expect Study II evaluated the implementation of risk-based care (RBC) and 
its impact on perinatal health outcomes, maternal quality of life, and healthcare costs. 
The first part of this thesis reports on preparatory studies necessary to implement RBC 
and to facilitate the study of its impact. The second part reports on studies evaluating 
implementation and impact of a prediction tool in obstetric care, the Expect Calculator. 
The current chapter gives an overview of the main findings, followed by a number of 
methodological considerations, clinical implications, and recommendations for future 
research. 
Framework conditions for implementing risk-based obstetric healthcare
Prediction of spontaneous preterm birth 
Our systematic search identified 2,018 articles, which resulted in five models predicting sPTB 
risks based on maternal characteristics. After excluding women with multiple pregnancies 
or iatrogenic preterm birth, data of 2,540 women were available for the external validation. 
In the general population, external validation showed poor to average discriminative 
performance of the models (area under curve 0.54 to 0.70). A subgroup analysis showed 
that the models discriminated poorly among nulliparous women (area under curve 0.51-
0.56). Additionally, decision curve analyses indicated low clinical benefit, even for the 
best performing model. These results indicated that the prediction models were unable 
to adequately predict sPTB, or are at least unable to improve current clinical practice. 
Therefore, the Limburg Obstetric consortium decided that in the Expect Calculator, sPTB 
risk-assessment should not be performed by a prediction model, but remains to be based 
on a list of single risk factors 4. 
Perinatal factors related to pregnancy and childbirth satisfaction
Most women receiving care-as-usual (CAU) were highly satisfied with the obstetric healthcare 
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services they received. However, satisfaction questionnaires generally result in high scores 
and some investigators have argued that dissatisfaction relies on a different construct 5,6. 
For this reason, we focused on the less satisfied women to retrieve new insights that could 
improve obstetric care.
Our analyses indicated that antenatal anxiety, obstetrician-led care during labor and a 
decrease in perceived personal wellbeing were independently associated with satisfaction 
scores. No difference in satisfaction scores was found between antepartum care led by 
either a midwife or an obstetrician, but midwife-led antepartum care reduced the odds of 
reduced satisfaction compared to transfer of antenatal care.
The Expect Calculator
If a prediction model is to be used as a basis for clinical decision making, thresholds should 
be selected that indicate which risks are considered as increased 7. Risk thresholds for the 
Expect calculator were determined by use of the ACCORD methodology 8. Recommendations 
provided by the Expect Calculator are not normative, but are meant to trigger a process 
of counselling and shared-decision making. The Expect Calculator was introduced to all 
obstetric healthcare professionals of the region in 2017.
Implementation and impact of risk-based care
In total, 865 women were recruited for Expect Study II. Using multiple web-based surveys, 
these women were questioned regarding the shared decision making with their healthcare 
professional and the services they eventually received. Outcomes considered for the 
implementation and impact study were guideline adherence by caregivers, uptake of risk-
based recommendations by pregnant women, as well as maternal quality of life, perinatal 
health outcomes and healthcare costs.
Adherence to guidelines and uptake of risk-based recommendations
Pre-eclampsia
Low-dose aspirin (LDA) was discussed with 81% of women with an increased PE risk, 
indicating adequate implementation by healthcare professionals. This rate tended to further 
increase over time during the study period. As compared to CAU, LDA usage vastly increased 
in RBC (RR 19.1; 95%CI 11.2-32.5). Yet, just 25% of the women with an increased PE risk in 
the RBC group reported daily LDA usage. Aspirin usage was positively correlated with both 
the predicted PE risk and women’s concerns regarding development of PE. As a result, the 
LDA usage rate increased to a more acceptable level in high-risk women. Most important 
reasons for non-use were unawareness of LDA as preventive intervention, concerns of 
adverse effects, and doubts regarding the benefits.
Gestational diabetes mellitus 
The majority of women (78%) reported their healthcare professional discussed their 
GDM-risk. Furthermore, an oral glucose tolerance test (OGTT) was performed within the 
recommended gestational window in 59% of women with an increased GDM risk estimation. 
Predicted GDM risks were positively correlated with the probability of performing an OGTT, 
resulting in high adherence rates among high-risk women. The majority of women who did 
not have an OGTT within the gestational window reported never having discussed an OGTT 
with their healthcare professional. Notably, a quarter of the women experienced discomfort 
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from the OGTT (Likert score 6-10, with 10 being extremely unpleasant). 
Health outcomes and healthcare costs
To evaluate the impact on health outcomes and cost-effectiveness of RBC care as compared 
to CAU, we conducted before-after analyses. For these analyses, we used data of two 
successive multicenter prospective cohorts: Expect Study I (CAU group) and Expect Study 
II (RBC group). In total 3,425 women were included; 2590 women received CAU and 835 
women received RBC. 
After adjusting for health utility at baseline, we observed no differences in maternal quality 
of life between both groups. Overall, in RBC as compared to CAU, the risk of an adverse 
perinatal outcome did not decrease statistically significant (aOR 0.76; 95%CI 0.51-1.11). 
However, a statistically significant reduction was found among nulliparous women (aOR 
0.56; 95%CI 0.32-0.94), whereas in multiparous women no clear difference was observed 
(aOR 1.15; 95%CI 0.64-1.97). Using a healthcare perspective, RBC was cost-effective and 
mean costs per woman were significantly lower for RBC compared to CAU (mean difference 
-€2,766, 95% CI -€3,700 – -€1,825). 
Methodological considerations
In this paragraph, the most important methodological considerations of the research 
described in this thesis are discussed alongside with their potential influence upon the 
results.
Study population and data collection
Data of both the validation study (Expect Study I) as well as the impact study (Expect 
Study II) were used for the research described in this thesis. The diversity of participating 
midwifery centers, as well as hospitals, combined with the broad inclusion criteria should 
have ensured a population as unselected as possible. Nevertheless, women of Caucasian 
origin were overrepresented and the majority of women are well educated. Since impaired 
health literacy is correlated with non-adherence and impaired health outcomes 9,10, results 
in our study with respect to these outcomes may be somewhat overestimated. The use of 
multiple web-based surveys, a user-friendly method of data collection in today’s digital era, 
provided high data quality by reducing potential recall biases and the numbers of missing 
data 11-13. 
Recruitment of women was similar for both cohorts. However, to assure women 
participating in the impact study received RBC, only women for whom the Expect Calculator 
was used were eligible for inclusion. The Expect Calculator was developed for usage in the 
general population and was promoted as such. Still, this may have introduced a selection 
bias, since pro-active healthcare professionals may have been over-represented among 
the professionals who used our prediction tool. The intensive usage of the prediction tool 
throughout the region and the multitude of collaborating centers diminishes the potential 
influence of selection bias. Additionally, inclusion criteria for both cohorts were identical. 
Nevertheless, subtle differences were apparent at baseline between both cohorts. Per 
characteristic, differences were small, but together they yielded a less favorable risk profile 
among women in RBC as compared to CAU (e.g. lower health utility at baseline, a higher 
proportion recruited in secondary care, and a more often complicated obstetric history). 
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Although we adjusted for prognostic important baseline characteristics, residual confounding 
remains possible. Residual confounding may still result in women having a more untoward 
risk profile in the RBC group compared to the CAU group. However, this would rather result 
in an underestimation than an overestimation of the positive effects correlated with RBC. 
External validation of sPTB prediction models
To our knowledge, this is the first systematic review of studies reporting non-invasive 
prediction models for the risk of sPTB. For the validation study, we enrolled 2,614 women 
receiving care-as-usual, of which 2,540 women were available for the external validation 
of sPTB. Although there is no golden rule available for the required sample size of external 
validations studies, a general rule of thumb is a minimum of 100 events (i.e. spontaneous 
preterm birth) 14,15. An inadequate sample size decreases the precision of external validation 
measures 14,15. Our sample included 118 women with a sPTB <37 weeks of gestation. 
Furthermore, the data were very complete with a maximum of only 1.2% of missing values.
Our cohort might suffer from treatment bias to a small extent since we did not exclude 
women who had received treatment such as a cerclage or tocolysis. This may have resulted 
into the prevention of sPTB and thus an underestimation of model discrimination and 
calibration 16.
The outcome sPTB was obtained from a combination of the medical record and the 
postpartum survey. Combination of these two data sources, ensured for a reliable evaluation 
of the cause of preterm birth. In case of discrepancies, healthcare professionals were 
contacted.
Pregnancy and childbirth satisfaction
The usage of a multicenter prospective study design improved the probability of collecting 
a representative sample. Furthermore, it enabled optimal measurement of outcomes by 
minimizing recall bias and recording of all independent variables before completion of the 
patient satisfaction questionnaire. 
To obtain a sufficient number of women in our analysis, we focused on women who 
experienced less than perfect healthcare. Our study does not have qualitative data regarding 
the level of satisfaction or dissatisfaction related to the obstetric healthcare services. 
However, the amount of studies using the validated pregnancy and childbirth questionnaire 
is limited and none of these used dissatisfaction as outcome 17,18. Focusing on the less 
satisfied women may result into renewed insights that could improve obstetric care.
Assessing the usage of risk-based interventions
In this study usage of the risk-based interventions recommended by the Expect Calculator 
are mainly based on self-report. Women may have answered in a socially acceptable manner 
resulting in an overestimation of the usage rate 19. However, women reporting non-use are 
likely to be telling the truth 19. The potential overestimation of usage rates due to self-report 
is probably limited since all risk-based recommendations were subject to a shared decisional 
process. 
Besides socially acceptable answers, self-report is also prone to recall problems. By using 
multiple surveys, strategically timed (e.g. shortly after the antenatal intake) and with 
relatively short intervals, the influence of recall problems was minimized. 
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With respect to the LDA recommendations, we were unable to reliably verify LDA usage 
with medical records or pharmacy registries since LDA is available over-the-counter in the 
Netherlands. Regarding the recommendations of an oral glucose tolerance test (OGTT), 
OGTT dates were retrieved from the medical record if women did not complete the 
postpartum survey, or when they did not recall the gestational age at the time of the OGTT. 
Given the nature of the OGTT (i.e. a specific appointment at a diagnostic center, for which 
women need to fast and drink a concentrated glucose solution), it is unlikely women would 
incorrectly recall whether they had undergone an OGTT.
We deliberately chose not to examine other interventions recommended to women with an 
increased PE or GDM risk (e.g. extra fetal biometry, extra blood pressure measurements). 
Women are possibly unable to distinguish between additional risk-based care and general 
basic care. With respect to the medical record, provided all interventions are registered 
reliably, it would be hard to determine whether the additional interventions were initiated 
as part of additional risk-dependent care, or due to other reasons (i.e. initiated due to 
clinical symptoms arisen during pregnancy). Therefore, we concluded usage rates of these 
interventions could not be determined reliably. 
Evaluating impact and cost-effectiveness of risk-based care
In essence, our study design used to assess the impact of RBC compared to CAU, is a ‘before 
after comparison’. Theoretically, despite both cohorts succeeding each other in a relatively 
short time-span (~1.5 years), outcomes may be affected by external trends over time (e.g. 
reduction of neonatal deaths due to improved obstetric care, or a reduction in healthcare 
expenditures). To detect such trends, we performed analyses taking into account the study 
period regarding healthcare related costs and perinatal health outcomes in the CAU cohort. 
These analyses did not point to a decreasing trend regarding the perinatal composite 
outcome. With respect to the costs, we did not find a trend over the study period. Moreover, 
nationwide statistics of Dutch health expenditures per capita suggest an increase rather 
than a decrease over time 20. As a result, we conclude that the cost reduction and improved 
perinatal outcomes in the RBC group are unlikely to be attributable to trends over time. 
Despite the fact that all healthcare professionals of the region committed themselves to 
RBC, it could have been the case that for the RBC cohort women in particular were recruited 
by enthusiastic, above-averagely adherent healthcare professionals. The widespread use 
of the Expect Calculator, on the other hand, as well as the fact that most women receive 
obstetric care from multiple professionals during their pregnancy, limit the possibility of 
this effect. Moreover, results did not essentially differ after restriction of the analysis to 
women enrolled by obstetric centres that recruited women for both cohorts. This reduces 
the likelihood of our results being influenced by a difference in healthcare professionals 
involved. 
Clinical implications and future directions
The studies covered in this thesis provide useful insights into the clinical utility of a prediction 
tool in obstetric care ‘outside the realm of research’. Prediction model development studies 
can provide us with potentially useful models and validation studies may improve our 
confidence in model’s estimated discriminative performance. Nevertheless, an adequate 
discriminate performance does not guarantee a prediction model has a positive clinical 
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impact in daily practice. This could be due to several reasons, for example differences in 
application (e.g. using the model in a specific subgroup of women opposed to the general 
population), or due to an interplay of both healthcare professionals’ and women’s adherence 
to the recommendations provided 21. The results described in this thesis may act as a starting 
point to improve the utilisation of the prediction tool and its recommendations, as well as 
implementation in other regions.
Spontaneous preterm birth and risk-based care
Unfortunately, our external validation of sPTB prediction models indicated that these models 
are unable to reliably predict the occurrence of sPTB. For this reason, assessing sPTB risk is 
still performed with the aid of lists of single risk factors. Currently, a large meta-analysis 
using individual patient data (IPD) from a large number of studies is being performed (using 
Expect Study data as well). Such a study has the advantage that results are more robust and 
that relevant subgroup analyses can be carried out such as preterm births in nulliparous 
women. Hopefully, the IPD study can help improve the prediction of sPTB risks and pave the 
way for better RBC with respect to preterm birth.
Pregnancy and childbirth satisfaction
In general, women were highly satisfied with the healthcare received during their pregnancy 
and childbirth period. Referral during antepartum care, which results in transfer from 
primary care to secondary care, was associated with suboptimal satisfaction. Furthermore, 
antenatal anxiety was experienced by 25% of all women and was associated with decreased 
satisfaction scores. Screening and treatment of women suffering from anxiety might improve 
pregnancy and childbirth satisfaction, but further research is necessary. Women’s birthing 
experience may improve by reducing unnecessary secondary obstetric healthcare.
Utilization of risk-based recommendations
Despite the vast increase of preventive measurements used by women identified with in an 
increased risk, the potential clinical benefit of RBC is currently not fully utilized. The majority 
of women with an increased PE risk estimation reported their healthcare professional 
discussed the option of LDA. Yet, most women opted not to use LDA during their pregnancy 
due to concerns regarding the effectiveness or possible adverse effects. However, no serious 
adverse effects of LDA have been reported and it appears to be safe for the neonate, thus 
the risks of adverse effects likely outweigh the risks of harmful effects caused by PE 22-26. 
Future qualitative research, for example with the aid of focus groups, is warranted to further 
explore women’s decisional process and attitude regarding LDA usage. This will increase 
our insight how women weigh competing risks (i.e. PE-risk vs. risks upon adverse effects), 
whether the information currently offered is clear and sufficient, and how the shared 
decisional process may be improved. Such studies may provide us with suggestions how to 
increase the LDA usage rate among high-risk women.
There is also room for improvement regarding the utilisation of RBC in women with respect 
to GDM. The majority of women with an increased GDM risk stated their healthcare 
professional offered the option of an OGTT, and most women eventually had an OGTT in the 
recommended gestational window. Still, 58% of the women who did not had an OGTT within 
the recommend gestational window, reported the option of an OGTT was not discussed 
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with them. This indicates healthcare professionals likely fulfil a key role. Future qualitative 
research, exploring the reasons why healthcare professionals not always offer an OGTT in 
women with an increased GDM risk estimate, is therefore necessary. Moreover, the possible 
barriers responsible for a less than optimal adherence rate are likely to be of interest as well 
if a universal screening approach is considered. 
Universal versus risk-based recommendations
For both the OGTT as well as LDA usage, recommendation of these preventive measurements 
to all women has been advocated as well 27,28. A universal approach has the advantage that it 
simplifies the guidelines for healthcare professionals and the options for pregnant women. 
Moreover, such an approach would yield the highest clinical benefit at population level, 
because every prediction tool or guideline that targets specific risk groups will inevitably 
result in cases being missed (false-negatives), since they generally do not have a 100% 
sensitivity rate. 
On the other hand, a universal approach may have several disadvantages. The results in this 
thesis indicate that both performance of an OGTT and LDA-usage were strongly correlated 
with the predicted risks of GDM and PE, respectively. This may suggest that in case of lower 
risk estimates, healthcare professionals and pregnant women deliberately chose not to 
use these preventive measurements. It is questionable, whether these women and their 
healthcare professionals would feel comfortable with a universal recommendation and 
would adhere to it. 
A universal approach will increase the number women being recommended an OGTT or LDA 
enormously, especially low-risk women. At the same time, low-risk women are least likely 
to benefit from these preventive measurements. Additionally, a universal approach does 
not provide a specific argument for an individual woman. High-risk women may remain 
unaware of their risk, which deprives them of an extra argument compared to average-risk 
women. As a result, even though a universal approach may enhance the average adherence 
rate, it may result in reduced adherence rates among high-risk women when compared to 
a selective approach.
Another disadvantage, perhaps the most important one, is that universal recommendations 
bypass women’s feelings and thoughts regarding these decisions. By using a prediction tool, 
absolute risks can be calculated which empowers women to make an informed decision 
together with their healthcare professional. It enables women to weigh the possible 
advantages and disadvantages for their individual situation. Moreover, previous reports 
indicated that decision tools and a shared decisional approach are likely to reduce women’s 
anxiety 29, which, according to the research in this thesis, is correlated with patient 
satisfaction scores.
In general, universal approaches have been compared with a selective approach relying 
on an ‘opt-in’ strategy. For example, in case of the existence of any listed risk factors (e.g. 
BMI ≥30) an OGTT or LDA-usage is recommended 30,31. This usually results in much more 
stringent strategies with a remarkably lower detection rate 32. When a universal approach 
is considered, it should also be compared with a selective approach relying on an ‘opt-
out’ strategy. Taking GDM as an example, this could mean recommending an OGTT to all 
pregnant women unless she meets specific exclusion criteria (i.e. multiparous women 
with an uncomplicated obstetric history). The likelihood these women develop GDM in a 
subsequent pregnancy is minimal 33, while such a strategy would reduce the amount of 
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OGTT’s substantially. We suggest an alternative: to exclude women identified as low-risk by 
a prediction model with a high detection rate.
The trade-off between a universal approach (more true-positives, but also more false-
negatives) versus a selective approach (more true-negatives, but also more false-positives), 
differs per topic (GDM risk and performing an OGTT vs. PE risk and using LDA) due to 
differences in advantages and disadvantages. Furthermore, it differs per country due to 
differences in the organization of obstetric care, but also because the trade-off depends on 
the incidence rate and thus a populations’ a priori risk. Countries with an a priori high-risk 
population (e.g. due to a high obesity prevalence), potentially have more to gain with a 
universal approach. Eventually, the choice between a universal versus a selective approach 
is one that needs to be made by all stakeholders together (policymakers, obstetricians, 
midwives, and pregnant women).
Impact of risk-based care
Regardless of the approach preferred, it is important to utilize the full potential clinical 
benefit of the chosen approach. Our impact analysis indicated that RBC, being a more 
pro-active form of obstetric care, as compared to CAU may improve Dutch obstetric care. 
Although RBC did not lead to any clinically relevant difference in maternal quality of life or a 
statistically significant decrease in adverse perinatal outcomes, sub group analysis showed 
a clinically relevant and statistically significant reduction of the adverse perinatal composite 
outcome in nulliparous women (reduction: 44%; 95%CI 6%-68%).
The interpretation of the nature of the reduction of adverse perinatal outcomes is 
somewhat complicated since we used a composite outcome. Still, the clinical significance 
of this reduction is clear since all components of the composite outcome are important 
determinants of child mortality and morbidity. In the Netherlands, 44% of singletons are 
born to nulliparous women. Together, they give birth to roughly 71,000 children 34. Assuming 
a 6% prevalence rate of the perinatal composite outcome, equal to the observed rate 
among nulliparous women in Expect Study I, a 44% reduction would mean that nationwide 
implementation of RBC in the Netherlands would prevent 1,874 newborns having an 
adverse perinatal composite outcome annually. Moreover, our cost-effectiveness analysis 
showed that RBC, as compared to CAU, is cost-effective and correlated with a substantial 
cost reduction. This, taken together with the improved perinatal outcomes in nulliparous 
women, implies that nationwide implementation of RBC is likely to make Dutch obstetric 
care cheaper and more effective.
Conclusions
In conclusion, the research presented in this thesis provide useful insights into the 
implementation and impact of a prediction-based first trimester decision tool in daily 
obstetric practice in the Netherlands. Soon after its introduction, obstetric care providers 
started using the tool and discussed estimated risks with a large majority of pregnant 
women, indicating adequate adherence. Furthermore, usage of preventive measurements 
strongly increased in comparison to previous care as usual, particularly in high-risk women. 
In comparison to CAU, RBC resulted in a significant reduction of perinatal adverse outcomes 
in nulliparous women, but not in multiparous women. Possibly, in nulliparous women, 
transparent personalized risk estimations followed by tailored care increased awareness 
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amongst all involved, resulting in better outcomes. Moreover, RBC was cost-effective and 
resulted in lower costs without a negative impact on maternal health outcomes when 
adjusted for baseline health utility. Besides, women’s birthing experience may improve 
when risk-based care reduces unnecessary secondary obstetric healthcare.
Nevertheless, the potential clinical benefit of RBC is currently not fully utilized. Both 
LDA-usage as well as the performance of OGTTs remained suboptimal. Future qualitative 
research is necessary to identify factors that positively or negatively influence healthcare 
professionals’ adherence and women’s decisions regarding risk-based recommendations.
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Summary
Dutch obstetric care is divided into primary care provided by autonomous midwives and 
secondary care provided by obstetricians. In this system, risk selection plays a pivotal role. 
Nevertheless, the obstetric guideline used for the risk assessment, and thus the assignment 
of healthcare level, is merely a checklist of several single risk factors. This list does not assess 
women’s absolute risk nor does it take a combination of multiple factors into account. 
Furthermore, Dutch obstetric care typically involves reacting to complications when they 
already exist or are imminent. Especially in obstetrics, prevention is better than cure, 
since therapeutic options are often limited due to the relatively short time window and 
sometimes potentially adverse effects for the foetus. A number of interventions has been 
shown to reduce the risk of adverse pregnancy outcomes, but most of these interventions 
are not suitable for all pregnant women. 
In the past years, a number of prediction models have been developed that estimate the 
risk of pregnancy related complications including pre-eclampsia, gestational diabetes, 
preterm birth, and foetal growth deviations. Prediction models weigh several risk factors 
simultaneously and consider their possible interrelations, thereby potentially improving risk 
assessment. During Expect Study I, published prediction models relying on predictors readily 
available in Dutch obstetric care were externally validated. At the same time, the Limburg 
obstetric consortium focused at standardizing obstetric care by developing healthcare 
pathways tailored to individual risk assessments. Risk-based care (RBC) was designed by 
combining the results of the external validation study with the obstetric care pathways. 
Subsequently, the Expect Study II was performed, focusing on implementation and impact 
of RBC. The preparations and framework conditions necessary for the implementation of 
RBC are covered in the first part of this thesis. The second part of this thesis reports on the 
implementation and impact of RBC as compared to care-as-usual (CAU).
For Expect Study I, from 2013 to 2015, 2,614 pregnant women were enrolled in a multicenter 
prospective cohort in the Southeastern part of the Netherlands. These women received 
CAU, completed multiple web-based surveys, and allowed collection of their medical record. 
Of these women, 884 participated in a sub cohort by completing additional surveys. This sub 
cohort was used to evaluate healthcare related costs and patient satisfaction associated 
with CAU.
Results of the external validation of models predicting spontaneous preterm birth (sPTB) 
are covered in chapter 2 of this thesis. Five models were retrieved from the literature. Most 
studies suffered from a moderate to high risk of bias. Models’ discriminative performance 
ranged from 0.54 to 0.70 in the general population, but was poor in a subgroup composed 
of nulliparous women (0.51-0.56). Decision curve analyses indicated low clinical benefit, 
even for the best performing model.
Chapter 3 evaluates women’s satisfaction regarding the obstetric care services they received 
in the CAU situation. In general, women were highly satisfied. However, satisfaction 
questionnaires often result in high scores. For this reason, determinants related to sub 
optimal satisfaction scores were analyzed. Antenatal anxiety and antenatal transferal from 
healthcare level were both significantly related to reduced satisfaction scores. Moreover, 
antenatal anxiety was experienced by 25% of the pregnant women.
Chapter 4 covers the strategy used to implement RBC as well as the methods used to 
evaluate its impact as compared to CAU. Chapter 5 describes the methods used to decide 
163  
Summary
Add.
on the risk-threshold to discriminate between low and increased risk of PE. Participants in 
the decision process stressed that the threshold to be selected should be a starting point 
for a shared-decisional process regarding management of PE risk, rather than a compulsory 
ground for advising low-dose aspirin (LDA). As a result, an above-population-average PE risk 
was selected as threshold (>3.0%; sensitivity 75%, specificity 64%) to start discussing the 
option of using LDA with the pregnant woman. General adherence of care professionals to 
this recommendation was high: 81% of women identified with a PE risk >3.0% reported that 
the option of LDA usage was discussed with them. 
Chapter 6 evaluates LDA usage-rates of pregnant women receiving RBC and compares it 
to the usage rates reported by women whom received CAU. LDA usage by women with 
an elevated risk increased strongly as compared to CAU (29.4% vs. 1.5%, RR 19.1; 95%CI 
11.2-32.5). However, the general per protocol usage rate of LDA in RBC, 25%, remained 
moderate. In RBC, daily LDA usage was positively associated with both predicted PE risk and 
women’s concerns regarding PE. Most reported reasons for non- or incomplete use were 
unawareness of LDA as a preventive intervention, concerns for potential adverse effects, 
and doubts regarding the benefits.
The consortium achieved consensus regarding a suitable GDM risk-threshold using a similar 
procedure as for the selection of a PE risk threshold. A predicted risk ≥3.5% was used as 
cut-off value to identify women at increased risk of GDM (sensitivity 80%, specificity 51%) 
and to discuss the option of an oral glucose tolerance test (OGTT) with these women. The 
adherence rate to risk-based GDM care is covered in chapter 7. Of all women, 78% reported 
their healthcare professional discussed their GDM-risk with them. In case of an increased 
risk, 59% of women received an OGTT within the recommended gestational window. 
Predicted GDM risks were positively correlated with the performance of an OGTT. The 
OGTT was experienced as uncomfortable by 25% of women who had an OGTT. Therefore, a 
selective screening strategy based on a prediction model with a high detection rate may be 
an interesting alternative to universal screening. Furthermore, a selective screening strategy 
relying on a prediction model enables women to make an informed decision together with 
their healthcare professional.
The impact of RBC on perinatal outcomes and healthcare related costs are described in 
chapter 8. Data of 3,425 women were available for the analysis of the adverse neonatal 
outcome; 2,590 women received CAU and 835 received RBC. No statistically significant 
difference was observed regarding the adverse neonatal composite outcome between 
the RBC and CAU group. However, subgroup analysis regarding parity showed a significant 
reduction of neonatal adverse outcomes among the RBC group in nulliparous women 
(aOR 0.56; 95%CI 0.32-0.94). We think that the differences between RBC and CAU mostly 
affect obstetric care for nulliparous women. For multiparous women, irrespective of care 
being RBC or CAU, health care professionals’ judgment of risk is strongly influenced by the 
available information on obstetric history. For nulliparous women, the risk assessment may 
be less straightforward, as less information is available. As a result, improvement of the risk 
assessment would mainly effect these nulliparous women.
For the economic evaluation, data of 1,693 women were available: 884 and 809 women 
receiving CAU and RBC, respectively. Healthcare related costs per pregnant women were 
statistically significantly lower for RBC (mean difference -€2,766, 95%CI -€3,700 – -€1,825). 
Moreover, the incremental cost effectiveness ratios (ICERs) indicated RBC was highly cost-
effective), while no differences in maternal quality of life, adjusted for baseline health, were 
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Chapter 9 discusses the evidence presented in this thesis. We conclude that RBC, as developed 
and implemented in our region, increases the usage of preventive measurements, but also 
that there remains room for improvement. We also conclude that RBC results in lower costs 
and, in nulliparous women, improves neonatal outcomes. Nationwide implementation 
of RBC is likely to have a positive impact on the obstetric care in the Netherlands. Future 
qualitative research is necessary to improve our insights regarding the shared decisional 
process between pregnant women and healthcare professionals, in order to improve usage 
rates of preventive measurements.
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Samenvatting
Het Nederlandse verloskundige zorgsysteem is onderverdeeld in 1e lijns zorg (verloskundigen 
in zelfstandige praktijken) en 2e lijns zorg (gynaecologen in het ziekenhuis). In dit systeem 
speelt risicoselectie, het beoordelen van de zwangerschapsrisico’s, een belangrijke rol. 
Immers, aan de hand van de verloskundige indicatielijst, de richtlijn die doorgaans wordt 
gebruikt voor de risicoselectie, wordt een zwangere vrouw al dan niet doorverwezen naar 
de 2e lijn. De verloskundige indicatielijst is echter slechts een checklist van losstaande 
risicofactoren. Middels deze lijst kan niet het absolute risico van een vrouw worden bepaald 
en ook is het niet mogelijk om een combinatie van factoren gelijktijdig te wegen in de 
daadwerkelijke risicoselectie.
De Nederlandse verloskundige zorg worden medische interventies doorgaans toegepast 
op het moment dat er complicaties (dreigen te) ontstaan. Juist in de verloskunde geldt 
echter het adagium van ‘voorkomen is beter dan genezen’. In een zwangerschap worden de 
therapeutische mogelijkheden beperkt door mogelijke foetale bijwerkingen en het relatief 
korte tijdsbestek waarin een effect zou moeten optreden. Van een aantal interventies en 
maatregelen is bekend dat zij complicaties voorkomen of het risico daarop verkleinen. Het 
merendeel van deze interventies is echter niet geschikt om aan alle vrouwen aan te bieden. 
In de afgelopen jaren zijn diverse predictiemodellen ontwikkeld die het risico op 
zwangerschapscomplicaties voorspellen, bijvoorbeeld: pre-eclampsie, diabetes gravidarum, 
vroeggeboorte en afwijkende foetale groei. Predictiemodellen zijn in staat om meerdere 
risicofactoren simultaan te wegen en nemen daarbij ook eventuele onderlinge verbanden 
mee in de voorspelling. In de Expect Studie I zijn gepubliceerde predictiemodellen die gebruik 
maken van voorspellers die eenvoudig beschikbaar zijn in de Nederlandse verloskunde, 
extern gevalideerd. Tegelijkertijd heeft het Limburgs obstetrisch consortium zich gericht op 
het standaardiseren van de obstetrische zorg middels het ontwikkelen van risico zorgpaden.
Door de resultaten van de externe validatie studie te combineren met de ontwikkelde 
zorgpaden ontstaat risico-gebaseerde zorg. Middels risico-gebaseerde zorg is het mogelijk 
om vrouwen met een verhoogd risico te counselen omtrent preventieve maatregelen die het 
risico verkleinen. De Expect Studie II richtte zich op de implementatie van risico-gebaseerde 
zorg en het meten van de impact daarvan.
De voorbereidende werkzaamheden alsmede de basiscondities die nodig waren voor het 
slagen van de implementatie zijn beschreven in het eerste deel van dit proefschrift. Het 
tweede deel van dit proefschrift beschrijft de implementatie en impact van risico-gebaseerde 
zorg ten opzichte van het voormalige verloskundige systeem (standaardzorg).
Gedurende 2013-2015 is ten behoeve van Expect Studie I in Limburg een multicenter 
prospectief cohort gevormd bestaande uit totaal 2.614 vrouwen. Deze vrouwen hebben allen 
de standaardzorg ontvangen tijdens hun zwangerschap. Verder hebben zij meerdere online 
vragenlijsten beantwoord en toegang tot hun medisch dossier verleend. Van deze groep heeft 
884 vrouwen deelgenomen aan een subcohort door extra vragenlijsten te beantwoorden. 
Dit subcohort is gebruikt voor de evaluatie van zorgkosten en patiënttevredenheid voor de 
standaardzorg. 
De resultaten van de externe validatie van modellen die spontane vroeggeboorte 
voorspellen staan beschreven in hoofdstuk 2 van dit proefschrift. In totaal werden vijf 
modellen geselecteerd uit de literatuur. De meeste studies van deze modellen hadden een 
redelijk tot hoog risico op vertekende resultaten. Het onderscheidende vermogen van de 
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modellen in de algemene populatie was matig tot redelijk (0,54-0,70), echter in nulliparae 
was dit vermogen lager (0,51-0,56). Decision curve analysis toonde aan dat de modellen 
waarschijnlijk niet in staat zijn de huidige klinische praktijk te verbeteren.
Hoofdstuk 3 evalueert de tevredenheid van zwangere vrouwen over de medische 
hulpverlening die zij tijdens de zwangerschap en de geboorte hebben mogen ontvangen. 
Over het algemeen waren vrouwen erg tevreden, maar tevredenheidsvragenlijsten binnen 
het verloskundige domein resulteren vaak in hoge scores. Om deze reden zijn de analyses 
gericht geweest op factoren die bijdragen tot een suboptimale tevredenheid. Antenatale 
angst alsook een antenatale overname van de zorg waren significant geassocieerd met 
verminderde tevredenheid. Antenatale angst werd door 25% van de zwangere vrouwen 
ervaren.
De strategie en methoden toegepast om risico-gebaseerde zorg te implementeren en de 
impact ten opzichte van de standaardzorg te evalueren zijn beschreven in hoofdstuk 4. In 
hoofdstuk 5 wordt beschreven welke methode is gehanteerd om een geschikt afkappunt 
te selecteren. Op basis van dit afkappunt wordt de mogelijkheid tot preventieve aspirine-
inname besproken met de zwangere vrouw om zo het risico op pre-eclampsie te reduceren. 
Zorgverleners kwamen overeen om een afkappunt te kiezen waarbij laagdrempelig het 
gebruik van aspirine besproken zou worden. Er werd echter benadrukt dat dit afkappunt als 
startpunt dient voor de gezamenlijke besluitvorming omtrent preventief aspirine gebruik. Dit 
resulteerde in het feit dat het risico van de algemene populatie als grenswaarde is gekozen 
(grenswaarde >3,0%; sensitiviteit 75%, specificiteit 64%). De naleving van deze aanbeveling 
was over het algemeen hoog: 81% van de vrouwen met een pre-eclampsie risico >3,0% gaf 
aan dat de optie om aspirine in te nemen met hen besproken was.
In hoofdstuk 6 wordt geëvalueerd hoeveel vrouwen aspirine hebben gebruikt gedurende 
hun zwanger, daarbij wordt de risico-gebaseerde zorg met de standaardzorg vergeleken. 
Het aspirine gebruik nam tijdens de risico-gebaseerde zorg sterk toe in vergelijking tot de 
standaardzorg (29.4% vs. 1.5%, RR 19.1; 95%BI 11.2-32.5). Desondanks was ook gedurende 
de risico-gebaseerde zorg het percentage vrouwen dat conform de aanbevelingen aspirine 
gebruikte, met 25%, relatief laag. Het aspirine gebruik in de risico-gebaseerde zorg 
was positief gecorreleerd met het voorspelde pre-eclampsie risico als ook de mate van 
bezorgdheid van de vrouw omtrent pre-eclampsie. De meest genoemde redenen voor het 
niet innemen van aspirine waren onwetendheid over het preventieve effect, zorgen omtrent 
mogelijke bijwerkingen en twijfels over de voordelen.
Middels een vergelijkbare strategie als toegepast bij het pre-eclampsie model, bereikte 
het consortium ook consensus omtrent een afkappunt voor het diabetes gravidarum 
predictiemodel. Een geschat risico ≥3,5% (sensitiviteit 80%, specificiteit 51%) werd 
geselecteerd als drempelwaarde om vrouwen met een verhoogd diabetes gravidarum-risico 
op te sporen. Bij een risico ≥3,5% wordt middels gezamenlijke besluitvorming een keuze 
gemaakt om gedurende de zwangerschap een orale glucosetolerantie test (OGTT) uit te 
voeren. De naleving van deze aanbevelingen staan verslagen in hoofdstuk 7. Van alle vrouwen 
gaf 78% aan dat de zorgverlener het diabetes gravidarum-risico met hen had besproken, 
in geval van een verhoogd risico was bij 58% van de vrouwen de OGTT tijdig uitgevoerd. 
Het voorspelde diabetes gravidarum-risico was daarbij positief gecorreleerd met het tijdig 
uitvoeren van een OGTT. De OGTT werd door 25 van de vrouwen als een erg onaangename 
test ervaren. Mede om die reden is een selectieve screeningsprocedure gebaseerd op een 
predictiemodel met een hoge detectiegraad wellicht een interessant alternatief vergeleken 
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met een universele screeningsprocedure. Daarnaast biedt selectieve screening middels een 
predictiemodel zwangere vrouwen de mogelijkheid om samen met hun zorgverlener een 
weloverwogen besluit te nemen (zgn. shared decision making). 
De impact van risico-gebaseerde zorg met betrekking tot perinatale uitkomsten en 
zorgkosten staat beschreven in hoofdstuk 8. Voor deze analyse werden gegevens van 
in totaal 3.425 vrouwen gebruikt, daarvan hebben 2.590 vrouwen de standaardzorg 
ontvangen en 835 risico-gebaseerde zorg. Er was geen statistisch significant verschil 
tussen beide groepen met betrekking tot de neonatale uitkomstmaat. Subgroepanalyses 
lieten echter een statistisch significante reductie van negatieve neonatale uitkomsten zien 
onder nulliparae (gecorrigeerde OR 0.56; 95%BI 0.32-0.94). Mogelijk hebben de verschillen 
tussen risico-gebaseerde zorg en standaardzorg met name een effect hebben op nulliparae. 
Bij multiparae wordt de boordeling van risico’s sterk bepaald door informatie over de 
obstetrische voorgeschiedenis, ongeacht de methode van risicoselectie die men toepast. 
Voor nulliparae is de risicoselectie wellicht minder eenduidig, omdat er minder informatie 
beschikbaar is. Om die reden zal een mogelijke verbetering van de risicoselectie met name 
de zorg voor nulliparae beïnvloeden.
Voor de economische evaluatie waren de gegevens van 1.693 vrouwen beschikbaar: 884 
vrouwen die standaardzorg ontvingen en 809 vrouwen die risico-gebaseerde zorg kregen. 
Zorgkosten per zwangere vrouw waren statistisch significant lager bij risico-gebaseerde 
zorg (gemiddelde verschil -€2.766, 95%BI -€3.700 – -€1.825). Na correctie voor de 
gezondheidsscore bij aanvang van de zwangerschap werd er geen verschil met betrekking tot 
maternale kwaliteit van leven waargenomen tussen beide groepen. Bovendien impliceerde 
de incrementele kosteneffectiviteit ratio’s (ICERs) dat risico-gebaseerde zorg overduidelijk 
kosteneffectief was.
In hoofdstuk 9 wordt de onderzoeksresultaten gepresenteerd in dit proefschrift 
bediscussieerd. Wij concluderen dat risico-gebaseerde zorg, zoals ontwikkeld en 
geïmplementeerd in onze regio, leidt tot een toename in het toepassen van preventieve 
maatregelen. Er blijft echter ruimte voor verbetering. Verder concluderen wij dat risico-
gebaseerde zorg leidt tot lagere zorgkosten en kosteneffectief is. Bovendien verbeteren de 
neonatale uitkomsten bij nulliparae. Landelijke implementatie van risico-gebaseerde zorg 
zal daarom zeer waarschijnlijk een positieve impact hebben op de Nederlandse obstetrische 
zorg. Toekomstig kwalitatief onderzoek is noodzakelijk om ons inzicht met betrekking tot het 
proces van gezamenlijke besluitvorming tussen de zwangere vrouw en haar zorgverlener te 
verbeteren. Op die manier worden mogelijk handvatten aangedragen om het gebruik van 
preventieve maatregelen verder te laten toenemen.
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Valorisation
This chapter discusses the societal and economic relevance of this thesis. Valorisation has 
been defined by the Dutch National valorisation committee as ‘the process of value creation 
from knowledge by making knowledge suitable for either economical or societal utilization 
and by translating knowledge into new products, services, processes, or business’ 1.
Relevance
The unique Dutch system with autonomous midwives providing primary care for pregnant 
women and obstetricians providing secondary, used to be an example of well-organized 
maternity care with low rates of medical intervantions 2. However, this conservative approach 
underlying the Dutch system became subject of debate due to high perinatal mortality rates 
in the Netherlands as reported by two successive European perinatal health reports 3-5. 
A system strictly divided into two separate levels of care, such as Dutch obstetric care, may 
suffer from disadvantages such as insufficient risk awareness and selection, discontinuity of 
care, and an increased risk of inaccurate communication 6. Due to the European perinatal 
health reports, there was an increasing call for a reform of obstetric care into a system of 
integrated client-centered care with a more proactive approach 3,6. In Limburg, the obstetric 
consortium, consisting of obstetric healthcare professionals representing the region, chose 
to achieve this by designing and implementing a risk-based care (RBC) approach: an obstetric 
healthcare system relying on an individual risk assessment with basic care pathways for low-
risk women and additional recommendations for women identified with an increased risk 
for pregnancy related complications. Furthermore, RBC pathways might stimulate integrated 
care by intensifying the collaboration between autonomous midwives and gynecologists.
The majority of perinatal deaths in the Netherlands are related to either asphyxia, preterm 
birth (PTB), small-for-gestational-age infancy (SGA), or congenital anomalies 7. Hypertensive 
disorders in pregnancy, such as pre-eclampsia (PE), are strongly associated with SGA and PTB 
8. Gestational diabetes mellitus (GDM) increases the risk of with birth injuries and asphyxia
9,10. Therefore, preventing these adverse outcomes could eventually lead to a reduction of
perinatal mortality.
A number of interventions have shown to be effective in the prevention of adverse pregnancy
outcomes, such as low-dose aspirin treatment in case of PE 11-13, adequate management of
GDM 14,15, and progesterone administration in women at risk of spontaneous PTB 16. Most
of the interventions, however, are not suitable for all pregnant women, because of either
possible adverse effects, patient burden, or costs. Consequently, healthcare professionals
need a risk assessment in order to decide which women may, on average, benefit most from
such preventive measurements.
In care-as-usual (CAU), the Dutch obstetric indication list is used to check whether there is
a predefined risk factor present, or a complication during pregnancy that warrants transfer
from primary to secondary care 17. However, this list does not assess an individual woman’s
absolute risk and is unable to take a combination of factors into account simultaneously.
Furthermore, it does not describe the contents of obstetric care that should be offered.
The Expect Study was designed to improve the risk selection of pregnant women and consists
of two parts 11,18. Expect Study I was aimed at the external validation of in total 39 non-
invasive prediction models predicting important pregnancy related complications. Expect
Study II, which is reported on in this thesis, focused on the implementation and evaluation
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of RBC using prediction models, combined with obstetric healthcare paths tailored to the 
individual risk assessments 18.
Expect Calculator
To implement RBC we designed an online prediction tool, the Expect Calculator. This tool 
combines the selected prediction models, risk-thresholds, and care paths to enable RBC. 
Risk assessment of pre-eclampsia and gestational diabetes mellitus is performed with 
the aid of externally validated prediction models. Risks of spontaneous preterm birth and 
fetal growth deviations are assessed with regional guidelines which were provided by the 
Limburg obstetric consortium. 
To facilitate the shared decisional approach, the results of the risk assessment are visualized 
at a linear scale. Moreover, the tool automatically provides patient information brochures 
tailored to the results of the individual risk assessment. As shown in Figure Add.1, displaying 
the number of risk assessments made per month, the Expect Calculator was increasingly and 
intensively used. Although the Expect Calculator was specifically developed for healthcare 
professionals of Limburg, it can be easily used by any obstetric healthcare professional.
Figure Add.1 Number of risk assessments performed by the Expect Calculator per month
Societal impact
Merely explaining the societal relevance of improving obstetric healthcare would quickly 
result in stating the obvious. However, when accompanied with some statistics it may be 
easier to realize the potential societal impact of it. RBC focuses on early detection and 
prevention of pregnancy related complications with the aid of prediction models. The 
studies in this thesis indicate that implementation of RBC resulted in an increased usage 
of preventive measurements and a reduction of neonatal adverse outcomes. The following 
paragraphs discuss the potential societal impact of these improvements in Dutch obstetric 
care.
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Roughly 8,500 women give birth in Limburg annually 19. Applying the incidence rate of PE, 
approximately 3% 8, to this number, means that every year 255 women in Limburg suffer 
from PE. Fortunately, the majority of the women PE will be manifest term or near-term. In 
these cases labor will be induced and often further adverse events are either prevented or 
remain manageable. However, for a minority PE truly becomes a life threatening disease, 
either for the mother or for the neonate 20. Preterm PE, especially extremely preterm 
PE, frequently results in preterm birth and is often combined with low birthweight and 
prolonged hospitalization of the mother and the neonate. Although the management of 
PE has improved, a cure that would preserve the pregnancy and thereby diminishing the 
sequelea accompanied with preterm birth remains unavailable. Therefore, preventive 
measures play a pivotal role in decreasing the burden of PE 8. The absolute reduction of PE 
depends upon the combined effectiveness of low-dose aspirin prophylaxis and adequate 
calcium intake. A recent meta-analysis examining the effectivity of aspirin solely, indicated a 
relative risk of 0.56 (95% confidence interval, 0.43-0.75) if aspirin was initiated at ≤ 16 weeks 
of gestation 21. This would mean that, if all women at risk were identified and used low-dose-
aspirin as recommended, 112 of the 255 annual cases could be prevented.
In this thesis, a composite outcome was used for the evaluation of the neonatal outcome. 
Interpreting a composite outcome may be somewhat complicated. Still, the relevance of 
the reduction of this outcome is clear since all components of the composite outcome 
are important determinants of child mortality and morbidity. The results of chapter 8 in 
this thesis indicate that RBC was associated with a 44% reduction of the adverse neonatal 
composite outcome in nulliparous women. In the Netherlands, excluding multiple 
pregnancies, roughly 161,000 children are born annually. Of these children, 71,000 (44%) 
are born to nulliparous women 19. Assuming a 6% prevalence rate of the adverse neonatal 
composite outcome, the observed prevalence rate observed in nulliparous women receiving 
CAU, means 4.260 neonates in the Netherlands suffer from such an adverse outcome. 
Applying the 44% reduction rate as indicated by the analyses of chapter 8, would mean 
nationwide implementation of RBC in the Netherlands could prevent 1,874 new-borns 
having an adverse outcome. This number is equal to the number of children of roughly 
seven averagely sized elementary schools.
Economic impact
Ideally, decisions regarding recommendations and preferred follow-up in general are 
primarily based on clinical arguments. However, the potential costs associated with provided 
healthcare services cannot be neglected as resources, be it healthcare costs or trained staff, 
are not infinite. The Dutch government, as most governments of developed countries, 
struggles with increasing healthcare expenditures that threaten the sustainability of the 
healthcare system. When healthcare expenditure remains to increase at the same speed as 
it did during 2006-2016, a household would spent half of its income on healthcare by 2040 
22. As a result, reformation of a healthcare system should be accompanied with an economic 
evaluation. This evaluation should firstly answer whether the reform results into increased 
healthcare costs. If so, the next question is whether the reform is cost-effective, or in other 
words, whether the degree of improved outcomes justify the increased costs. Chapter 8 of 
this thesis describes the economic evaluation of RBC in detail. The results indicate that RBC 
is cost-effective and result in a substantial direct cost reduction of approximately €2,700 per 
pregnant woman. This would mean that nationwide implementation, taking into account 
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163.826 pregnant women 19, may result in a cost saving of 442 million euro per year.
Future implications
The studies in this thesis provide useful insights regarding the potential impact of RBC 
relying on a prediction tool that enables an individual risk assessment. Before a prediction 
model can be put to practice thresholds should be selected that indicate which risks are 
considered as increased 23. This thesis covers how the obstetric consortium of Limburg 
handled this process and tried to incorporate all stakeholders. Although there are many 
different strategies imaginable to accomplish the implementation of a prediction model into 
daily practice, our study design may serve as an example for others.
Dissemination of guidelines or stating recommendations does not automatically result in 
adherence by healthcare professionals. Implementation of effective preventive interventions 
often suffers from low adherence rates 24-26. The research in this thesis gives a first glance of 
the uptake of recommendations that emerged from an individual risk assessment provided 
by a prediction tool. Furthermore, a first insight of potential barriers that may hamper the 
uptake is provided.
By using a qualitative study design, the potential barriers and opportunities involved in this 
process could be evaluated in depth. Such a study, with the aid of focus groups, is currently 
performed regarding the recommendations of adequate calcium intake during pregnancy. 
Further research like this, will be necessary to improve the utilization of recommended 
preventive measures. This would increase our insight how to optimize the implementation 
of RBC, increase the uptake of preventive interventions, and how RBC could be implemented 
best in other regions.
172  
Addendum
References
1. Drooge, L.v., Vandeberg, R., et al., Waardevol: Indicatoren voor Valorisatie, 2011, Rathenau
Instituut: Den Haag.
2. De Vries, R., Nieuwenhuijze, M., et al., What does it take to have a strong and independent
profession of midwifery? Lessons from the Netherlands. Midwifery, 2013. 29(10): p. 1122-1128.
3. Visser, G.H.A., Obstetric care in the Netherlands: relic or example? J Obstet Gynaecol Can, 2012.
34(10): p. 971-975.
4. Euro-Peristat Project with SCPE and EUROCAT, European Perinatal Health Report. The Health and
care of pregnant women and babies in Europe in 2010. 2013: p. 113.
5. Euro-Peristat project with SCPE EUROCAT EURONEOSTAT. European Perinatal Health Report 2004.
2008.
6. Perdok, H., Jans, S., et al., Opinions of maternity care professionals and other stakeholders
about integration of maternity care: a qualitative study in the Netherlands. BMC Pregnancy and
Childbirth, 2016. 16(1): p. 188.
7. Bonsel, G., Birnie, E., et al., Lijnen in de perinatale sterfte, Signalementstudie Zwangerschap en
Geboorte 2010. 2010, Rotterdam: Erasmus MC.
8. Koullali, B., Oudijk, M.A., et al., Risk assessment and management to prevent preterm birth.
Semin Fetal Neonatal Med, 2016. 21(2): p. 80-8.
9. Meertens, L., Smits, L., et al., External validation and clinical usefulness of first-trimester prediction
models for small- and large-for-gestational-age infants: a prospective cohort study. Bjog, 2019.
126(4): p. 472-484.
10. Henriksen, T., The macrosomic fetus: a challenge in current obstetrics. Acta Obstet Gynecol Scand,
2008. 87(2): p. 134-45.
11. Meertens, L.J.E., Scheepers, H.C.J., et al., Should women be advised to use calcium supplements
during pregnancy? A decision analysis. Matern Child Nutr, 2017.
12. Roberge, S., Nicolaides, K., et al., The role of aspirin dose on the prevention of preeclampsia and
fetal growth restriction: systematic review and meta-analysis. American journal of obstetrics and
gynecology, 2017. 216(2): p. 110-120. e6.
13. Rolnik, D.L., Wright, D., et al., Aspirin versus Placebo in Pregnancies at High Risk for Preterm
Preeclampsia. N Engl J Med, 2017.
14. HAPO Study Cooperative Research Group, Hyperglycemia and adverse pregnancy outcomes. N
Engl j Med, 2008. 2008(358): p. 1991-2002.
15. Poolsup, N., Suksomboon, N., et al., Effect of treatment of gestational diabetes mellitus: a
systematic review and meta-analysis. PLoS One, 2014. 9(3): p. e92485.
16. Dodd, J.M., Jones, L., et al., Prenatal administration of progesterone for preventing preterm birth
in women considered to be at risk of preterm birth. Cochrane Database Syst Rev, 2013(7): p.
Cd004947.
17. Commissie Verloskunde van het College voor zorgverzekeringen, verloskundig vademecum -
Verloskundige indicatielijst (VIL), 2003.
18. van Montfort, P., Willemse, J.P., et al., Implementation and Effects of Risk-Dependent Obstetric
Care in the Netherlands (Expect Study II): Protocol for an Impact Study. JMIR Res Protoc, 2018.
7(5): p. e10066.
19. Perined, Perinatale Zorg in Nederland 2017, 2019: Utrecht.
20. Mol, B.W.J., Roberts, C.T., et al., Pre-eclampsia. Lancet, 2016. 387(10022): p. 999-1011.
21. Roberge, S., Nicolaides, K., et al., The role of aspirin dose on the prevention of preeclampsia and
fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol, 2017. 216(2):
p. 110-120.e6.
22. Rapport ‘De zorg: hoeveel extra is het ons waard?’ (Healthcare: how much extra it is worth to
us?). 2016, The Dutch Ministry of Health, Welfare, and Sport.
23. Reilly, B.M. and Evans, A.T., Translating clinical research into clinical practice: impact of using
173  
Valorisation
Add.
prediction rules to make decisions. Annals of internal medicine, 2006. 144(3): p. 201-209.
24. Segaar, D., Bolman, C., et al., Identifying determinants of protocol adoption by midwives: a
comprehensive approach. Health Educ Res, 2007. 22(1): p. 14-26.
25. Offerhaus, P., Fleuren, M., et al., Guidelines on anaemia: effect on primary-care midwives in The
Netherlands. Midwifery, 2005. 21(3): p. 204-11.
26. Zeitlin, J., Manktelow, B.N., et al., Use of evidence based practices to improve survival without
severe morbidity for very preterm infants: results from the EPICE population based cohort. Bmj,
2016. 354: p. i2976.
174  
Addendum
Dankwoord
Allereerst wil ik alle zwangere vrouwen die mee hebben gedaan aan de Expect studie 
hartelijk danken voor hun moeite om de vragenlijsten in te vullen en voor het delen van 
hun medische dossier. Zonder jullie bereidheid om deel te nemen had dit proefschrift niet 
kunnen bestaan.
Dan nu een officieel woord van dank aan mijn voltallige promotieteam, prof. dr. L.J.M. Smits, 
dr. H.C.J. Scheepers en prof. dr. M.E.A. Spaanderman. 
Luc, of beter gezegd, professor Smits; gedurende mijn promotie behaalde ook jij een mijlpaal 
in je carrière met jouw benoeming tot hoogleraar. Erg bijzonder en leuk voor mij om dat 
proces van dichtbij te mogen meemaken. Allereerst denk ik dat ik je vrouw mijn excuses 
aan moet bieden, aangezien ik waarschijnlijk medeverantwoordelijk ben voor een paar 
zilveren wijsheids-haren. Weet je nog die keer dat ik even was vergeten om het copyright te 
checken? …oeps… 
Waarschijnlijk heb ik je ook menig keer het vuur aan de schenen gelegd tijdens onze 
frequente bijeenkomsten. Gelukkig waren we het nog veel vaker volledig met elkaar eens. 
Onze discussies hebben daarbij niet alleen inhoudelijk bij gedragen aan de kwaliteit van 
het proefschrift, maar ook mij als persoon en wetenschapper verder gevormd. Voor mij 
ben je een hele fijne begeleider geweest, waarvan ik enorm veel heb kunnen leren. We 
hebben samen een leuke tijd gehad op Deb., maar ook daarbuiten met onze Expect-etentjes 
en congressen. Zoals dat buitenkansje in Sint-Petersburg, waar wij niet alleen de laatste 
ontwikkelingen van de perinatologische wetenschap hebben mogen ontdekken, maar ook 
de Hermitage en lekkere restaurants. Luc, bedankt voor al je inspanningen!
Liesbeth, het is inmiddels zes jaar geleden dat wij elkaar leerde kennen. Ik had eigenlijk al 
een stageplek geregeld en de deadline was al verstreken toen ik mij realiseerde dat ik toch 
veel liever mijn combistage bij de gyn wilde lopen. Gelukkig had jij meteen alle vertrouwen 
in mij. Inmiddels heb ik geleerd dat deze situatie voor jou geen uitzondering was, jouw 
enthousiasme laat het nooit afweten! Het enthousiasme spat daarbij soms letterlijk van het 
scherm met zinnen die geen einde... 
Je passie voor het vak en de wetenschap werken voor mij aanstekelijk. Juist op momenten 
van tegenslag, wist jij er vaak weer een positieve impuls aan te geven. Verder kon ik rekenen 
op je scherpe klinische blik bij de interpretatie van de resultaten en de translatie daarvan 
naar de dagelijkse praktijk. Daarmee heb je mij enorm geholpen bij het vormgeven van de 
discussies in dit proefschrift. Je doorgaans nuchtere en relativerende houding hebben mij 
tevens geholpen menig knoop door te hakken. Ik hoop dat ik ook in de toekomst daarvoor 
bij je mag blijven binnen lopen. Enorm bedankt voor je inzet en betrokkenheid!
Marc, altijd een bomvolle agenda, maar ook altijd een begripvol oor. Regelmatig was 
een herinneringsmailtje, of twee, en misschien nog een keertje langslopen, noodzakelijk. 
Bewonderenswaardig vond ik het dat, wanneer we dan om tafel zaten, die drukte als vanzelf 
naar de achtergrond verdween en jij alle tijd nam voor mij. Jouw rustige, wel overdenkende 
houding hebben zeker hun positieve invloed gehad. Vaak was jij een van de eerste coauteurs 
die mijn manuscripten las, zonder er vanaf de eerste letter bij betrokken te zijn. Voor mij 
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vormde jouw kritische blik dan ook de vuurdoop en met je constructieve feedback kon 
ik mijn manuscripten verder verbeteren. Op deze manier kon ik mijn manuscripten met 
vertrouwen indienen voor publicatie.
De leden van de beoordelingscommissie, prof. dr. I.C.W. Arts, prof. dr. R.F.P.M. Kruitwagen, 
dr. R. Hermens, dr. M. Nieuwenhuijze en prof. dr. M.A. Joore, wil ik bedanken voor de 
beoordeling van dit proefschrift.
De leden van de Expect projectgroep wil ik eveneens graag bedanken: prof. dr. M.E.A. 
Spaanderman, prof. dr. R.G. de Vries, prof. dr. C.D. Dirksen, dr. I. Korstjens, prof. dr. A.L.M. 
Mulder, dr. M.J. Nieuwenhuijze, prof. dr. J.G. Nijhuis en prof dr. O.C.P. van Schayk. 
Zonder de medewerking van alle betrokken verloskundigenpraktijken en ziekenhuizen was 
de Expect Studie niet tot stand gekomen. In het bijzonder wil ik een woord van dank richten 
aan de LOQS-projectgroep en werkgroepleden:
De gynaecologen Annemieke van Wijck, Ella Wijnen-Duvekot, Iris Zwaan, Ivo van Dooren, 
Josje Langenveld, Martine Wassen, Robert Aardenburg, Maartje Zelis, Liesbeth Scheepers, 
Marc Spaanderman, maar ook niet-werkgroepleden Salwan Al-Nasiry en Stijn van Teeffelen. 
Jullie hebben elk een sleutelrol gespeeld bij de implementatie en het overwinnen van 
diverse uitdagingen. Bedankt voor jullie inzet! 
Uiteraard wil ik ook benadrukken dat de verloskundigen Lilian Custers, Badia El Haddad, 
Cindy Bastings, Claudia Brouwers, Jose ten Thije, Nicky Maassen, Wendy Gijsen, Desiree 
Greven en Hilde Coolen met hun inzet om de ‘massa’ in beweging te krijgen een belangrijke 
rol hebben gespeeld. 
Verder ben ik er vrijwel zeker van dat ik nu een aantal namen niet heb genoemd van mensen, 
die buiten mijn zicht, zich hard hebben gemaakt voor de Expect en ervoor zorgden dat er 
genoeg vrouwen deelnamen aan de studie. Zo ook de kraamcentra, met in het bijzonder, 
Babette Peeters en Marie-Louise Verstappen-Wouters, hebben hierin ook een belangrijke 
rol gespeeld. Ik ben jullie allen zeer dankbaar.
Ten slotte verdiend ook Jolanda Willems-Roberts, research nurse van het Zuyderland, het 
om hier genoemd te worden. Jolanda enorm bedankt jouw inzet en betrokkenheid bij het 
werven van deelneemsters voor de Expect Studie.
Yvonne, toen we eenmaal op elkaar ingespeeld waren wisten wij perfect wat we aan 
elkaar hadden. Jouw inzicht, ervaringen en advies zijn zeer waardevol geweest bij de 
totstandkoming van de implementatie.
Marianne en Lonneke, ik heb maar korte tijd met jullie samengewerkt, maar jullie zijn een 
echte aanwinst voor de LOQS. 
Bij deze wil ik alle coauteurs hartelijk danken voor alle feedback en jullie kritische blik op mijn 
manuscripten. Stéphanie, we hebben intensief samengewerkt aan een gedegen manuscript. 
Het is mooi om te zien dat al onze inspanningen inmiddels beloond worden en hun vruchten 
beginnen af te werpen. Veel succes bij de verdere afronding van je proefschrift!
Sander, in het begin was jij voor mij de rots in de branding toen ik nog pas startte met R. Later 
in het promotietraject bleef je bereikbaar voor goed advies en nuttige tips met betrekking 
tot de analyses. Daarmee was je voor mij een zeer gewaardeerde coauteur. Bedankt voor 
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je tijd en inzet. 
Carmen, bedankt voor alle hulp, wijsheid en bevestiging omtrent het 
kosteneffectiviteitsonderzoek. Dit hoofdstuk was niet tot stand gekomen zonder jouw 
bijdrage en inzet, waarvoor dank!
Laure, nadat Luc eerst een paar maanden naast zijn schoenen liep vanwege de goede 
kandidate die bij hem had gesolliciteerd, was ik toch erg nieuwsgierig geworden. Al gauw 
kwam ik erachter dat hij niet overdreven had. In de korte tijd die we samen hebben gewerkt 
heb ik veel geleerd van jouw statistisch inzicht, wat nog op het laatste moment een stempel 
heeft gedrukt op mijn proefschrift, bedankt.
Stagiaires Pia, Mandy, Babette, en Clémence, ik ben jullie dankbaar voor jullie inzet voor de 
Expect Studie en prettige samenwerking.
Ik wil MEMIC centrum voor data en informatie management bedanken voor de fijne 
samenwerking. Dirk en Luc, jullie hebben een belangrijke bijdrage geleverd aan de uitvoering 
van onze studie opzet, de Expect calculator en de benodigde datakoppelingen. Luc, vaak had 
jij meteen tijd voor mij wanneer dat nodig was. Dirks enthousiasme is zelfs overgeslagen op 
zijn vrouw die vervolgens heeft deelgenomen aan de Expect ;-) 
De heren van Sience Vision, Ger en Jule, wil ik bedanken voor hun bijdrage en inspanningen 
om de Expect Studie alsook de nieuwe geboortezorg met beeldmateriaal te promoten. 
Pieter Kubben, we hebben elkaar leren kennen toen ik nog als coassistent deelnam aan de 
eerste Hackathon Dutch Hacking Health te Maastricht, luchtig borrelend met een lekker 
wijntje bij de vooraankondiging. Als neurochirurg had je inhoudelijk geen enkele relatie met 
mijn project, maar we deelde samen een duidelijk enthousiasme en passie voor (digitale) 
innovaties in de zorg. Je advies en nuchtere vrolijkheid hebben mij geholpen de Expect 
Calculator vorm te geven, en hebben mij gestimuleerd mijn R-skills verder te ontwikkelen 
wat zeer van pas is gekomen gedurende het promotietraject.
Cyriel Heuts, bedankt dat je voor ons een netelige kwestie goed hebt weten op te lossen.
De dames van het secretariaat op Deb., Yvonne, Mariëlle, Petra en Irma, wil ik bedanken 
voor alle hulp en ondersteuning op de afdeling. 
Monique Janssen, Manon Gordijn en Conny de Zwart wil ik in het bijzonder bedanken voor 
hun inspanningen. Het plannen van onmogelijke afspraken is toch echt jullie specialiteit! 
Gelukkig mocht ik altijd een beroep op jullie doen om een overleg in te plannen, uiteraard 
meestal op korte termijn. 
Ella wil ik bedanken voor het feit dat de logistiek van mijn onderwijstaken tiptop 
georganiseerd was. 
Harry en Jos bedankt voor jullie technische ondersteuning. Jos, als behulpzame aanpakker 
sta je voor anderen klaar. Of ik nu problemen had met mijn bureau, beeldscherm, of 
(meermaals) met een compleet gecrashte pc, jij dacht met mij mee en wist het snel op 
te lossen. Harry, bedankt voor alle vernuftige oplossingen waarmee menig tijdrovend ICT-
karweitje ‘on the fly’ werd uitgevoerd. Daarmee was jij, een niet te onderschatten stille 
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kracht van ons project, wat kan een aio zich nog meer wensen?
Ilse Mesters, jouw expertise op het gebied van gezondheidsvoorlichting heeft duidelijk 
bijgedragen aan onze patiëntfolders afgestemd op onze doelgroep. Ik kan het wellicht niet 
evidence-based staven met mijn data, maar ik ben ervan overtuigd dat dit een positieve 
invloed heeft gehad op de mate waarin vrouwen de nieuwe adviezen opgevolgd hebben.
Mijn kantoormaatjes Jessica, Linda, Louise, Karlijn en Vivianne wil ik bedanken voor de vele 
gezellige uurtjes op A2.049.
Karlijn, wij hebben samen het langste de kamer gedeeld tijdens mijn promotietraject. Ik 
hoop dat jij ook een nieuwe werkplek vindt waar je je als een vis in het water voelt. Waar 
je ook terecht komt, jouw doorzettingsvermogen en harde inzet zal overal gewaardeerd 
worden!
Mijn Expect-buddies Jessica en Linda! Wat hebben we het naar onze zin (gehad) met zijn 
drietjes. 
Linda, als stagiaire startte ik op ‘jouw’ project. Een beter voorbeeld als promovendus had 
ik mij niet kunnen wensen. De lat ligt bij jou zo hoog, dat ik soms twijfel of er überhaupt 
wel ergens een lat ligt. Jouw precisie en grondigheid hebben voor mij de toon gezet als 
wetenschapper. Verder vulden wij elkaar, juist door onze verschillen, denk ik perfect aan en 
hebben we elkaar regelmatig gesteund bij de tegenslagen die iedere onderzoeker op zijn 
bordje krijgt. Het was dan ook erg wennen toen ik ineens zonder jou verder moest met de 
Expect studie. Gelukkig zien we elkaar nog steeds regelmatig. Ik wens je heel veel succes bij 
de huisartsgeneeskunde!
Jessica, onze enthousiaste turbo van het team. Ik kan mij niet herinneren dat ik jou eens 
niet vrolijk heb meegemaakt. De positieve energie straalt als een aura om je heen en heeft 
zelfs via de telefoon een effect. Je bent dan ook de perfecte kandidaat voor het kwalitatieve 
onderzoek van de Expect. Het is noemenswaardig hoe je dit weet te combineren met je 
klinische werkzaamheden. Heel veel succes met de afronding van het onderzoek en de 
huisartsgeneeskunde!
Ik wil alle overige collega’s en aiossen van de afdeling bedanken voor de fijne werksfeer en 
gezelligheid tijdens de koffiemomentjes en teamuitjes. De verrassingslunch die jullie voor 
mij hadden georganiseerd was ook echt heel leuk, bedankt daarvoor.
In het bijzonder wil ik Sophie en Jacqueline nog bedanken, we liepen regelmatig bij elkaar 
de kamer binnen en hebben menig lunch samen genuttigd. Vooral in de tijd dat ik alleen 
zat op mijn kantoortje en de muren soms op mij afkwamen was ik daar zeer dankbaar voor. 
Mijn buurman, Adrie, altijd in voor een praatje en geïnteresseerd in mijn onderzoek wil ik 
eveneens in het bijzonder benoemen.
Vrienden en vriendinnen, ik verheug mij enorm op de momenten die wij samen doorbrengen 
en heb altijd wel iets om naar uit te kijken. 
Allon, Joost, Laurens, Luuk en Rob, de mannenavond, inmiddels mannenweekend, is toch 
echt een begrip en vast ritueel geworden! Inmiddels is de groep bijna verdubbeld met Jill, 
Judith, Lieke, Stephanie en Zoë. Het is hartstikke leuk dat we samen zoveel plezier hebben – 
ultimate kaos! ;-) – en lief en leed met elkaar kunnen delen. 
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Laurens, wij hebben elkaar ‘echt’ leren kennen op weg naar de open dag van Universiteit 
Utrecht. Het is zeker niet bij die ene dag in trein gebleven en ben je naast een goede vriend 
ook schoonbroer geworden. Inmiddels hebben we niet meer de luxe om op doordeweekse 
middagen urenlang op het water door te brengen. Gelukkig zien we elkaar nog regelmatig. 
Minimaal één keer per jaar omslaan met de boot lukt ons trouwens nog steeds. Bedankt 
voor alle steun en gezellige momenten.
Lennart, ons promotietraject verliep de laatste jaren grotendeels parallel aan elkaar. De vele 
cappuccino’s, het hardlopen, of het fietsen door het heuvellandschap waarbij we ons hoofd 
konden leegmaken zijn erg gezellig. Dat we nog flink wat kilometers samen mogen maken!
Etiënne, we kennen elkaar al sinds de A-KO en ook na het behalen van ons artsendiploma 
zien we elkaar geregeld, zo niet wekelijks. We hebben al menig serie samen versleten en ’s 
zomers steken we de BBQ graag aan, op naar een nieuw seizoen!
Mijn familie en schoonfamilie wil ik bedanken voor de warme momenten samen en hun 
interesse in mijn onderzoek. De prijs van vrolijkste Expectbaby gaat zonder meer naar Nore.
Pap en mam, toen ik eenmaal vertrok naar Utrecht om diergeneeskunde te studeren was 
volgens mij inmiddels alle hoop dat ik nog enigszins in de buurt zou blijven wonen inmiddels 
vervlogen. Hoe anders is die situatie nu, wonend in heuvelland, bij de vierde (soort van) 
diploma-uitreiking. Jullie hebben mij door dik en dun gesteund en staan altijd voor mij klaar. 
Heel veel dank voor de support die jullie mij hebben gegeven en nog steeds geven! 
Dorien, wie had dat gedacht; dat we nog een tijdje zouden samenwonen nadat we het 
ouderlijk huis hadden verlaten. Inmiddels zijn we allebei weer diverse malen verhuisd, ik 
heb nog steeds rugpijn van die @#$* wasmachine op zolder..., en zien we elkaar door de 
afstand minder vaak. Desondanks kunnen we nog steeds op elkaar rekenen. 
Lieke, mijn zusje, collega, vriendin, onze wegen kruisen elkaar overal en daar ben ik dankbaar 
voor. Ik schiet nog steeds in de lach als ik die verwarde blik van de verpleging herinner 
toen we als semi-arts voor patiëntinformatie ons naar elkaar lieten doorverbinden. Wie 
weet staan we in de toekomst nog eens samen op dezelfde verloskamer, team dokter van 
Montfort, dat is pas continuïteit van zorg!
Lieve Judith, mijn onderzoek was vaak voor jou, net zoals voor de rest van mijn familie en 
vrienden, een ver-van-mijn-bed show. Desondanks steun(de) jij mij door dik en dun. Gelukkig 
komen mijn opgedane vaardigheden nog goed van pas bij de planning van de achtertuin. 
Wat hebben we het toch goed samen!
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